LGND-USA,PGNX-USA,ILMN-USA,SPPI-USA,ENDP-USA,ARWR-USA,BDSI-USA,TECH-USA,REGN-USA,SIGA-USA
 1/09/2020 LGND-US   BW   Ligand to Report 2019 Fourth Quarter and Full Year Financial Results on February 6th," 1/06/2020 PGNX-US     BW   INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Progenics Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm", 9:00a     0KYC2K-E    BW   Illumina Files Patent Infringement Suits Against BGI in Sweden and the United Kingdom,12/26/2019 84763A10  BW   Spectrum Pharmaceuticals Provides Pipeline Update on Late Stage Programs," 1/12/2018 ENDP-US  BW   Glancy Prongay & Murray LLP Reminds Investors of the January 16, 2018 Deadline in the Class Action Lawsuit Against Endo International, PLC (ENDP)", 1/06/2020 ARWR-US  BW   Arrowhead Pharmaceuticals Appoints James Hassard as Chief Commercial Officer,10/09/2019 BDSI-US  BW   Calidi Biotherapeutics Announces Appointment of Seasoned Biotech Executive George Ng to Board of Directors,#N/A," 4/08/2019 ALNY-US  BW   Alnylam and Regeneron Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases",11/16/2016 SIGA-US  BW   SIGA Announces Successful Completion of Rights Offering; Funding of Loan; Completion of Payment of PharmAthene Obligation
12/23/2019 LGND-US   BW   Two Ligand Pharmaceuticals Board Members Recognized as 2019 Most Influential Corporate Directors by WomenInc. Magazine,"12/20/2019 PGNX-US     BW   INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Progenics Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm"," 1/06/2020 0JGNNP-E    BW   NuProbe Global and CarrierGene Biotech Co. Ltd. Announced Completion of Merger, Appointed Yingshuang Chai as CEO, and Established Collaboration with Illumina",11/14/2019 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2019 London Healthcare Conference on November 21st," 1/08/2018 ENDP-US  BW   ENDP INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Endo International, PLC Investors",12/20/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Doses First Patient in AROAAT2002 Open Label Phase 2 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease,"11/02/2017 0BGL4K-E BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by BioDelivery Sciences International, Inc.",#N/A, 8/16/2018 REGN-US  BW   Teva and Regeneron Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip,10/21/2016 SIGA-US  BW   SIGA Announces Commencement of Rights Offering
12/02/2019 LGND-US   BW   Ligand Enters into Worldwide OmniAb® Platform License Agreement with Sanofi,11/08/2019 0LDDK2-E    BW   Velan Receives Requisite Number of Written Consents to Reconstitute Majority of Progenics Board, 1/02/2020 45232710    BW   Illumina and Pacific Biosciences Announce Termination of Merger Agreement,11/07/2019 84763A10  BW   Spectrum Pharmaceuticals Reports Third Quarter 2019 Financial Results and Pipeline Update," 1/05/2018 ENDP-US  BW   ENDO INTERNATIONAL LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Endo International, PLC. To Contact The Firm",12/16/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)," 2/28/2013 09060J10 BW   INVESTOR ALERT: Former Attorney General of Louisiana and Kahn Swick & Foti, LLC Investigate BioDelivery Sciences International, Inc., Following Notice of Non-Reliance of Financial Statements and Restatement",#N/A," 8/06/2018 BLUE-US  BW   bluebird bio and Regeneron Announce Collaboration to Discover, Develop and Commercialize New Cell Therapies for Cancer","10/13/2016 003Q3K-E BW   SIGA Announces Dr. Phil Gomez Joins Company as New CEO, Dr. Eric Rose to Serve as Executive Chairman of the Board"
11/12/2019 05MFY1-E  BW   Ligand Pharmaceuticals Ranked in Deloitte’s 2019 Technology Fast 500™,11/07/2019 LNTH-US     BW   Lantheus Releases Comprehensive Strategic Plan for Progenics,12/23/2019 45232710    BW   Illumina to Webcast Upcoming Investor Conference Presentation,10/31/2019 84763A10  BW   Spectrum Pharmaceuticals Announces Third Quarter 2019 Financial Results Conference Call," 1/03/2018 ENDP-US  BW   Glancy Prongay & Murray Announces Filing of a Securities Class Action on Behalf of Endo International, PLC Investors and Encourages Investors to Contact the Firm",12/16/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-HSD for Treatment of Alcohol and Nonalcohol Related Liver Disease," 1/17/2013 09565S-E BW   Research and Markets: Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2012",#N/A,10/16/2017 AIMT-US  BW   Aimmune Therapeutics Announces Clinical Collaboration to Study AR101 with Regeneron and Sanofi’s Dupilumab for Peanut Allergy,10/10/2016 SIGA-US  BW   SIGA Announces Oct. 12 Record Date for Rights Offering
11/08/2019 LGND-US   BW   Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol,11/04/2019 PGNX-US     BW   Glass Lewis Recommends Stockholders Vote on GREEN Consent Card for Velan Nominees to Constitute Majority of Progenics Board,12/19/2019 000KYD-E    BW   Denodo Announces Winners of Second Annual Data Innovation Award During Datafest 2019,10/24/2019 84763A10  BW   Spectrum Pharmaceuticals Announces Submission to the U.S. Food and Drug Administration of Updated Biologics License Application for ROLONTIS®,12/23/2017 ENDP-US  BW   SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Endo International plc of Class Action Lawsuit and Upcoming Deadline – ENDP,12/13/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Appoints Marianne De Backer to Board of Directors, 2/08/2011 09060J10 BW   BioDelivery Sciences to Present at the 13th Annual BIO CEO & Investor Conference,#N/A, 6/19/2017 VEEV-US  BW   Standardizing on Veeva Vault Enhances Regeneron’s Clinical and Regulatory Operations Processes, 9/21/2016 06ZQG4-E BW   SIGA Announces Bankruptcy Court Approval of Transaction Under Which SIGA Will Pay PharmAthene Claim in Full
11/07/2019 LGND-US   BW   Ligand to Participate in the Stephens 2019 Nashville Investment Conference,10/28/2019 0LDDK2-E    BW   ISS Recommends Shareholders Vote on the GREEN Consent Card for Election of Velan Nominees and Removal of Progenics CEO,11/20/2019 45232710    BW   Illumina to Webcast Upcoming Investor Conference Presentations,10/09/2019 BDSI-US   BW   Calidi Biotherapeutics Announces Appointment of Seasoned Biotech Executive George Ng to Board of Directors,12/05/2017 ENDP-US  BW   Robbins Arroyo LLP: Endo International plc (ENDP) Misled Shareholders According to a Recently Filed Class Action,12/11/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Files IND for Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma, 1/21/2011 008SRQ-E BW   BioDelivery Sciences Refutes Patent Claim,#N/A," 1/23/2017 UGNEQ-US BW   Aerie Pharmaceuticals Announces Appointment of Kristine Erickson, O.D., Ph.D., as Vice President Clinical Research", 8/29/2016 SIGA-US  BW   SIGA Announces Completion of Enrollment and Dosing in the Final Cohort of Phase III Study of TPOXX™ (tecovirimat)
11/05/2019 LGND-US   BW   Ligand Reports Third Quarter 2019 Financial Results,10/24/2019 0LDDK2-E    BW   Independent Director Candidates Nominated by Velan Issue Letter to Progenics Shareholders,10/24/2019 45232710    BW   Illumina Reports Financial Results for Third Quarter of Fiscal Year 2019,10/04/2019 84763A10  BW   Spectrum Pharmaceuticals Announces Publication of Positive Poziotinib Data in Cancer Cell,"11/15/2017 ENDP-US  BW   ENDO INTERNATIONAL INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing in Endo International, Plc to Contact the Firm",12/06/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $266.8 Million, 1/06/2011 05WV00-E BW   BioDelivery Sciences Hires Head of Manufacturing Operations,#N/A,10/17/2016 06CR5C-E BW   Regeneron and Teva Provide Update on Fasinumab Clinical Development Programs, 8/08/2016 SIGA-US  BW   SIGA Announces Data Safety Monitoring Board (DSMB) Approval to Complete Subject Enrollment in the Final Cohort of Phase III Study of TPOXX™ (tecovirimat)
10/22/2019 LGND-US   BW   Ligand to Report Third Quarter 2019 Results on November 5th,10/23/2019 PGNX-US     BW   Velan Responds to Misleading Communications from Progenics,"10/08/2019 45232710    BW   Illumina to Announce Third Quarter 2019 Financial Results on Thursday, October 24, 2019", 9/25/2019 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the 2019 Cantor Global Healthcare Conference on October 2nd," 9/25/2017 ENDP-US  BW   The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Endo International plc Shareholders and a Lead Plaintiff Deadline of October 17, 2017",12/04/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock,12/09/2010 09060J10 BW   BioDelivery Sciences Announces Enrollment of the First Patient in the Phase 3 BEMA Buprenorphine Clinical Program,#N/A,10/13/2016 06CR5C-E BW   Ocular Therapeutix™ and Regeneron Enter Into Strategic Collaboration to Develop Sustained Release Formulation of Aflibercept for the Treatment of Wet AMD and Other Serious Retinal Diseases, 4/25/2016 SIGA-US  BW   SIGA Announces Enrollment of First Patients in the Final Cohort of Phase III Study of Tecovirimat
10/15/2019 LGND-US   BW   Ligand Appoints Pharmaceutical Executive Sarah Boyce to its Board of Directors,10/22/2019 PGNX-US     BW   Velan Sends Letter to Progenics Stockholders,10/07/2019 ILMN-US     BW   QIAGEN and Illumina Partner to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests, 9/06/2019 84763A10  BW   Spectrum Announces Poziotinib Data Being Presented at the IASLC 2019 World Conference on Lung Cancer," 9/20/2017 ENDP-US  BW   ENDP INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Endo International plc and a Lead Plaintiff Deadline of October 17, 2017",12/02/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock,11/23/2010 09060J10 BW   BioDelivery Sciences Announces Resumption of ONSOLIS Manufacturing,#N/A," 9/20/2016 REGN-US  BW   Teva and Regeneron Announce Global Collaboration to Develop and Commercialize Fasinumab, an Investigational NGF Antibody for Chronic Pain", 4/12/2016 SIGA-US  BW   SIGA Emerges from Chapter 11 Bankruptcy Protection
 8/29/2019 LGND-US   BW   Ligand to Participate in the H. C. Wainwright 21st Annual Global Investment Conference,10/21/2019 PGNX-US     BW   Velan Issues Presentation Outlining Nominees’ Comprehensive Strategic Plan to Save Progenics,10/07/2019 ILMN-US     BW   QIAGEN und Illumina gehen Partnerschaft zur Einführung sequenzierungsbasierter In-vitro-Diagnostik-Tests ein, 9/03/2019 84763A10  BW   Spectrum Pharmaceuticals to Present at Two Upcoming Investor Conferences in September," 9/18/2017 ENDP-US  BW   EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Endo International plc and Set a Lead Plaintiff Deadline of October 17, 2017",11/26/2019 ARWR-US  BW   Arrowhead Pharmaceuticals to Participate in Upcoming December 2019 Conferences,"11/12/2010 09060J10 BW   BioDelivery Sciences to Hold Investor Conference Call on Monday, November 15, 2010",#N/A,11/24/2015 REGN-US  BW   ERS Genomics Licenses Genome-Editing Patents to Regeneron Pharmaceuticals, 3/17/2016 SIGA-US  BW   SIGA Commences Clinical Study for Intravenous (IV) Formulation of TPOXX
 8/12/2019 LGND-US   BW   Ligand Partner CASI Pharmaceuticals Launches EVOMELA® in China,10/08/2019 PGNX-US     BW   Velan Sends Letter to Progenics Pharmaceuticals Stockholders and Files Definitive Consent Statement,10/07/2019 45232710    BW   Illumina and QIAGEN Partner to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests, 8/08/2019 84763A10  BW   Spectrum Pharmaceuticals Reports Second Quarter 2019 Financial Results and Pipeline Update, 9/18/2017 ENDP-US  BW   IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm,11/25/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Fiscal Year 2019 Results,11/10/2010 09060J10 BW   BioDelivery Sciences to Present at Lazard and Piper Jaffray Investor Conferences,#N/A,11/20/2015 06NNTP-E BW   Regeneron’s Dr. George D. Yancopoulos Elected to Cold Spring Harbor Laboratory Board of Trustees, 3/15/2016 SIGA-US  BW   SIGA Technologies Engages PiperJaffray as Financial Advisor
 7/30/2019 LGND-US   BW   Ligand Reports Second Quarter 2019 Financial Results,"10/03/2019 PGNX-US     BW   PROGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Progenics Pharmaceuticals, Inc. - PGNX", 9/30/2019 45232710    BW   Illumina and Broad Institute Announce Agreement to Co-Develop Genomic Secondary Analysis Tools, 8/01/2019 84763A10  BW   Spectrum Pharmaceuticals Announces Second Quarter 2019 Financial Results Conference Call, 9/15/2017 ENDP-US  BW   ENDO LOSS NOTICE: Rosen Law Firm Reminds Endo International plc Investors of Important Deadline in Class Action – ENDP,11/18/2019 ARWR-US  BW   Arrowhead Presents New Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at AHA Scientific Sessions 2019,10/27/2010 09060J10 BW   BioDelivery Sciences Announces Positive End-of-Phase 2 Meeting with FDA for BEMA Buprenorphine in Chronic Pain,#N/A," 7/08/2015 0B17BB-E BW   Kendall Law Group Investigating Potential Breaches of Fiduciary Duties By Regeneron Pharmaceuticals, Inc. (REGN) Officials on Behalf of Shareholders", 2/24/2016 06CR5C-E BW   FDA Concurs on Clinical Dose for SIGA’s Tecovirimat Antiviral
" 7/23/2019 LGND-US   BW   Ligand Acquires Ab Initio Biotherapeutics, an Antigen-Discovery Company",10/02/2019 PGNX-US     BW   Velan Comments on Announced Sale of Progenics to Lantheus, 9/23/2019 45232710    BW   Illumina Names Joydeep Goswami Senior Vice President of Corporate Development and Strategic Planning, 7/22/2019 84763A10  BW   Spectrum Announces Expansion of the Poziotinib Clinical Program, 9/15/2017 ENDP-US  BW   IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm,11/15/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Announces Planned Management Transition,10/20/2010 09060J10 BW   BioDelivery Sciences and Meda Announce European Approval of BEMA Fentanyl (BREAKYL),#N/A, 5/21/2013 ALCLS-FR BW   Cellectis : Compact TALENTM : La nouvelle génération de nucléases effectrices TAL,12/23/2015 SIGA-US  BW   SIGA Announces That Delaware Supreme Court Affirms Court of Chancery Opinion
 7/15/2019 LGND-US   BW   Ligand to Report Second Quarter 2019 Results on July 30th,10/02/2019 LNTH-US     BW   Lantheus to Acquire Progenics to Form a Leading Precision Diagnostics Imaging and Therapeutics Company, 9/12/2019 45232710    BW   Illumina Recommends Stockholders Reject Mini-Tender Offer by TRC Capital Corporation, 6/20/2019 84763A10  BW   Spectrum Pharmaceuticals Appoints Elizabeth Czerepak to its Board of Directors, 9/15/2017 ENDP-US  BW   SHAREHOLDER ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against Endo International plc,11/11/2019 ARWR-US  BW   Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Year End Results,10/07/2010 09060J10 BW   BioDelivery Sciences Announces Commercial Partnership for BEMA Fentanyl in Taiwan,#N/A,"10/17/2012 000KXY-E BW   Genentech’s Lucentis 0.3mg for Diabetic Macular Edema Has Experienced Robust Trial and Uptake During the First Month of Commercial Availability, According to a Recent BioTrends Report",12/15/2015 SIGA-US  BW   SIGA Files Consensual Plan of Reorganization
 7/10/2019 LGND-US   BW   Ligand Announces Positive Top Line Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol," 9/18/2019 0LDDK2-E    BW   Velan Launches Consent Solicitation to Reconstitute the Progenics Board With Its Five Highly-Qualified, Independent Director Nominees", 7/29/2019 45232710    BW   Illumina Reports Financial Results for Second Quarter of Fiscal Year 2019, 6/02/2019 84763A10  BW   Spectrum Pharmaceuticals Announces Integrated Results from Two Phase 3 ROLONTIS® (eflapegrastim) Trials Being Presented at the ASCO Annual Meeting," 9/15/2017 ENDP-US  BW   The Klein Law Firm Notifies Investors of Commencement of a Class Action Filed on Behalf of Endo International plc Shareholders and a Lead Plaintiff Deadline of October 17, 2017",11/08/2019 ARWR-US  BW   Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data for Investigational Hepatitis B Regimens at The Liver Meeting® 2019," 9/08/2010 09060J10 BW   BioDelivery Sciences to Present at Rodman & Renshaw, Baird, and Stifel Nicolaus Investor Conferences",#N/A," 7/04/2012 REGN-US  BW   Research and Markets: Regeneron Pharmaceuticals, Inc.: Pharmavitae 2012 Report - Approval for Eylea Is Expected In the EU in Late 2012 or Early 2013", 3/18/2015 82691710 BW   SIGA Technologies Receives NASDAQ Delisting Notification
 7/08/2019 LGND-US   BW   Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation," 6/21/2016 07J4DM-E    BW   Progenics Pharmaceuticals, Inc. Signs Commercial License Agreement with Selexis SA for Use of Proprietary Cell Line and SUREtechnology Platform"," 7/16/2019 45232710    BW   Illumina Expands Genomics Accelerator to Cambridge, UK", 5/29/2019 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2019 Global Healthcare Conference on June 5th, 9/14/2017 ENDP-US  BW   IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm,10/31/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ENaC at the North American Cystic Fibrosis Conference, 9/07/2010 09060J10 BW   BioDelivery Sciences Adds New Executive to Lead Business and Strategic Development,#N/A, 6/25/2012 063WMX-E BW   NextBio and Cancer Care Institute Form Strategic Partnership Focused on Clinical Use of Genomics," 1/16/2015 82691710 BW   SIGA Technologies, Inc. Appeals Judgment of Delaware Court of Chancery"
" 7/01/2019 LGND-US   BW   ZULRESSO™ (brexanolone) CIV, a Product for Treating Postpartum Depression Using Ligand’s Captisol® in its Formulation, Launched by Sage Therapeutics", 9/29/2014 74318710    BW   FDA Approves RELISTOR® Subcutaneous Injection for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-cancer Pain, 7/11/2019 45232710    BW   Illumina Reports Preliminary Revenue for Second Quarter of Fiscal Year 2019, 5/28/2019 84763A10  BW   Spectrum Announces Poziotinib ZENITH20 Trial HER2 Cohort (Cohort 2) Has Reached Enrollment Target, 9/13/2017 ENDP-US  BW   IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm,10/18/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of RNAi Therapeutics, 9/02/2010 09060J10 BW   BioDelivery Sciences Announces Positive Meeting with FDA on a Streamlined ONSOLIS REMS with Broadened Distribution,#N/A, 6/22/2012 07G69B-E BW   Research and Markets: Gout Therapeutics - Pipeline Assessment and Market Forecasts to 2019," 1/07/2015 82691710 BW   Delaware Court Decision Regarding SIGA Technologies, Inc."
 6/12/2019 LGND-US   BW   Ligand Subsidiary Vernalis and PhoreMost Limited Announce Drug Discovery Collaboration for Novel Oncology Target," 8/11/2014 74318710    BW   FDA Assigns September 29, 2014 Prescription Drug User Fee Act Goal Date for RELISTOR® Subcutaneous Injection sNDA for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain"," 6/28/2019 GNOM.XX2-US BW   Illumina Files Patent Infringement Suits Related to BGI in Switzerland, Turkey and the US", 5/16/2019 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the 20th Annual B. Riley FBR Investor Conference on May 23rd," 9/13/2017 ENDP-US  BW   ENDP EQUITY ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Endo International plc and a Lead Plaintiff Deadline of October 17, 2017",10/02/2019 ARWR-US  BW   Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics, 8/30/2010 09060J10 BW   BEMA Buprenorphine Phase 2 Study Results Selected for Presentation at Pain Week 2010,#N/A, 5/31/2012 07GVF3-E BW   Research and Markets: Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019," 9/17/2014 82691710 BW   SIGA Technologies, Inc. Receives Bankruptcy Court Approval for First-Day Motions in Connection with Chapter 11 Case"
 5/17/2019 LGND-US   BW   Ligand Licenses VER250840 to Cumulus Oncology, 7/14/2014 74318710    BW   FDA Office of Drug Evaluation III Approves Salix’s Request that the FDA Approve the RELISTOR® Subcutaneous Injection sNDA for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain," 6/17/2019 45232710    BW   Illumina Wins Infringement Suit Against Ariosa Diagnostics, Inc.", 5/09/2019 84763A10  BW   Spectrum Pharmaceuticals Reports First Quarter 2019 Financial Results and Pipeline Update, 9/12/2017 ENDP-US  BW   INVESTOR ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against Endo International plc, 9/30/2019 ARWR-US  BW   Arrowhead Pharmaceuticals to Participate in Upcoming October 2019 Conferences, 8/10/2010 09060J10 BW   BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference,#N/A, 5/30/2012 060RWY-E BW   Russia’s Colorectal Cancer Drug Market Projected to Grow to More Than $480 Million in 2016," 9/16/2014 82691710 BW   SIGA Technologies, Inc. Files for Chapter 11 Reorganization"
" 5/06/2019 LGND-US   BW   Ligand Acquires Milestone and Royalty Rights to SB206 from Novan, Inc.", 6/12/2014 PGNX-US     BW   FDA Ad Comm Provides Recommendations Regarding the Potential Cardiovascular Risk Associated with the Class of Peripherally-active Opioid Receptor Antagonists and the Trials to Support Approval of Products for OIC," 6/04/2019 45232710    BW   Illumina Introduces Expanded Version of VeriSeq™ NIPT Solution, Offering More Comprehensive Detection of Rare Chromosomal Conditions", 5/09/2019 0GHV9Q-E  BW   Spectrum Announces Asset Purchase and License for a Novel Immuno-Oncology Platform including Two Early Stage Assets, 9/08/2017 ENDP-US  BW   EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Endo International plc – ENDP, 9/20/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4), 5/27/2010 09060J10 BW   BioDelivery Sciences Announces Commercial Partnership for BEMA Fentanyl in South Korea,#N/A, 9/26/2011 09W3PW-E BW   Impact of CATT Study Findings Evident in Significant Reported Changes in Prescribing of Genentech’s Avastin and Lucentis for the Treatment of Wet AMD According to a BioTrends Report, 4/23/2014 0CFKXC-E BW   BioSurplus To Auction Lab Equipment from SIGA Technologies
 5/02/2019 LGND-US   BW   Ligand Reports First Quarter 2019 Financial Results, 4/22/2014 74318710    BW   Salix Pharmaceuticals and Progenics Pharmaceuticals Announce the Acceptance of Submission to Expand the Use of RELISTOR in Chronic Non-Cancer Pain by the European Medicines Agency, 5/29/2019 45232710    BW   Illumina to Webcast Upcoming Investor Conference Presentation, 5/02/2019 84763A10  BW   Spectrum Pharmaceuticals Announces First Quarter 2019 Financial Results Conference Call, 9/05/2017 ENDP-US  BW   The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Endo International plc, 9/16/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Presents Initial Top-Line Clinical Data and Preclinical Data on RNAi Candidates ARO-APOC3 and ARO-ANG3, 5/26/2010 09060J10 BW   BioDelivery Sciences to Host Analyst & Investor Day June 3rd in New York City,#N/A, 9/23/2011 07GVF3-E BW   Research and Markets: Macular Degeneration Therapeutics - Pipeline Assessment and Market Forecasts to 2018,11/08/2011 09ZX1M-E BW
 5/02/2019 LGND-US   BW   Ligand Completes Enrollment of Phase 1 Clinical Trial of Captisol-enabled Iohexol,10/01/2013 74318710    BW   Salix and Progenics Announce FDA Advisory Committee Scheduled to Review Relistor sNDA for Opioid-Induced Constipation in Patients with Chronic Pain, 5/15/2019 45232710    BW   Illumina Files Patent Infringement Suit Against BGI in Denmark, 4/02/2019 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the H.C. Wainwright Global Life Sciences Conference on April 9, 8/31/2017 ENDP-US  BW   The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Endo International plc, 8/30/2019 ARWR-US  BW   Arrowhead Pharmaceuticals to Participate in Upcoming September 2019 Conferences, 5/10/2010 09060J10 BW   BioDelivery Sciences and Meda Announce the Approval of ONSOLIS in Canada,#N/A, 1/25/2011 SGEN-US  BW   Maven Semantic: Age-Related Macular Degeneration Research Database, 2/03/2011 SIGA-US  BW
 4/18/2019 LGND-US   BW   Ligand to Report First Quarter 2019 Results on May 2nd, 6/11/2013 74318710    BW   Salix and Progenics Announce FDA Advisory Committee to Review Relistor sNDA for Opioid-Induced Constipation in Patients with Chronic Pain, 5/01/2019 45232710    BW   Illumina to Webcast Upcoming Investor Conference Presentation, 3/15/2019 84763A10  BW   Spectrum Pharmaceuticals Provides BLA Filing Update for ROLONTIS® (eflapegrastim)," 8/18/2017 ENDP-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Endo International plc and Set a Lead Plaintiff Deadline of October 17, 2017", 8/28/2019 005Y9C-E BW   Arrowhead Collaborator Janssen Begins REEF-1 Phase 2b Combination Study in Patients with Chronic Hepatitis B Infection, 4/20/2010 09060J10 BW   BioDelivery Sciences to Raise $10 Million in Registered Direct Offering From Institutional Investors,#N/A, 1/19/2011 REGN-US  BW   Maven Semantic: Immunohistochemistry Research Database, 1/10/2011 SIGA-US  BW
 3/21/2019 LGND-US   BW   Ligand to Receive Milestone and Royalties as Result of FDA Approval of Sage Therapeutics’ ZULRESSO™ (brexanolone) Injection," 5/10/2013 74318710    BW   Faruqi & Faruqi, LLP Launches An Investigation Against Progenics Pharmaceuticals, Inc. (PGNX) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors", 4/25/2019 45232710    BW   Illumina Reports Financial Results for First Quarter of Fiscal Year 2019, 3/13/2019 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Oppenheimer 29th Annual Healthcare Conference on March 20, 7/12/2017 ENDP-US  BW   ENDP SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Endo International plc, 8/08/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Doses First Patient in SEQUOIA Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease, 3/22/2010 09060J10 BW   BioDelivery Sciences Announces Positive Pre-IND Meeting on BEMA Granisetron Development Program,#N/A, 1/18/2011 TLRK-US  BW   Maven Semantic: Signal Transduction Database,#N/A
 3/12/2019 LGND-US   BW   Ligand to Participate in Four Upcoming Investor Conferences,12/07/2012 0C7XF4-E    BW   CytoDyn Expands Outreach Through Increased Online Presence," 4/09/2019 45232710    BW   Illumina to Announce First Quarter 2019 Financial Results on Thursday, April 25, 2019", 3/01/2019 84763A10  BW   Spectrum Pharmaceuticals Announces the Completion of the Sale of its Marketed Portfolio, 7/07/2017 ENDP-US  BW   SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Endo International plc - ENDP, 8/05/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Fiscal 2019 Third Quarter Results, 3/19/2010 09060J10 BW   BioDelivery Sciences Files Annual Report 10-K and Complies with Nasdaq Marketplace Rule 5250(b)(2),#N/A," 1/06/2011 05WSX6-E BW   Eleven Biotherapeutics Appoints Eric Furfine, Ph.D., to President of Research and Development",#N/A
 3/12/2019 LGND-US   BW   Ligand Provides Highlights from Today’s Analyst Day Event,10/26/2012 CYDY-US     BW   CytoDyn Moves Corporate Headquarters to Oregon, 3/29/2019 45232710    BW   Illumina Files Patent Infringement Suit Against BGI in Germany, 2/28/2019 84763A10  BW   Spectrum Pharmaceuticals Reports Fourth Quarter 2018 and Full Year 2018 Financial Results and Pipeline Update, 7/06/2017 ENDP-US  BW   ENDP INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Endo International plc, 7/24/2019 ARWR-US  BW   Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Third Quarter Results, 3/09/2010 09060J10 BW   BioDelivery Sciences to Present at the 22nd Annual ROTH OC Growth Stock Conference,#N/A,12/21/2010 TGEN-US  BW,#N/A
 3/05/2019 LGND-US   BW   Ligand Sells Promacta Assets and Royalty for $827 Million, 9/05/2012 SLXP-US     BW   Salix Pharmaceuticals Outlines Data Presentations at PAINWeek, 3/27/2019 45232710    BW   Illumina et le Centre de géogénétique de la Fondation Lundbeck collaborent pour générer l’un des plus grands ensembles de données sur le génome ancien afin de décoder les origines génétiques et l’évolution des problèmes de santé mentale, 2/21/2019 84763A10  BW   Spectrum Pharmaceuticals Announces Fourth Quarter and Full Year 2018 Financial Results Conference Call, 7/03/2017 ENDP-US  BW   IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Endo International plc and Encourages Investors with Losses to Contact the Firm, 7/16/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-ANG3, 3/03/2010 09060J10 BW   BioDelivery Sciences to Present at the Cowen and Company 30th Annual Health Care Conference,#N/A," 5/05/2010 TRI-CA   BW   Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals Inc., Sanofi-Aventis, AstraZeneca, Interactive Data Corp. and Thompson Reuters",#N/A
 2/21/2019 LGND-US   BW   Reminder: Ligand to Host Analyst Day on March 12th in New York City," 7/30/2012 PGNX-US     BW   CytoDyn Announces Entry into Agreement with Progenics Pharmaceuticals, Inc. to Acquire PRO 140", 3/26/2019 45232710    BW   Illumina und Lundbeck Foundation GeoGenetics Centre arbeiten gemeinsam an der Erstellung eines der größten Datensätze historischer Genome zur Entschlüsselung der genetischen Ursachen und Entwicklung von psychischen Gesundheitsproblemen, 2/07/2019 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Guggenheim Healthcare Talks Idea Forum on February 14, 6/28/2017 ENDP-US  BW   IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Endo International plc and Advises Investors with Losses to Contact the Firm, 7/08/2019 ARWR-US  BW   Arrowhead Pharmaceuticals to Participate in Roth RNA Revolution Conference, 2/26/2010 09060J10 BW   BioDelivery Sciences Business Update: Plans for Three Products Entering Phase 3 Next Year,#N/A,#N/A,#N/A
 2/07/2019 LGND-US   BW   Ligand Reports Fourth Quarter and Full Year 2018 Financial Results, 7/27/2012 SLXP-US     BW   Salix and Progenics Receive Complete Response Letter from FDA for RELISTOR® sNDA, 3/26/2019 45232710    BW   Illumina and the Lundbeck Foundation GeoGenetics Centre Collaborate to Generate One of the Largest Ancient Genome Datasets to Decode the Genetic Origins and Evolution of Mental Health Issues, 1/17/2019 068W2B-E  BW   Spectrum Pharmaceuticals Sells Marketed Portfolio to Acrotech Biopharma L.L.C. to Focus on New and Innovative Therapies for Cancer Patients," 6/13/2017 ADGO-GB  BW   Albert Identified as One of Gartner’s “Cool Vendors in Advertising, 2017”", 6/27/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Receives Fast Track Designation for ARO-AAT for Treatment of Alpha-1 Liver Disease, 2/18/2010 09060J10 BW   BioDelivery Sciences to Host Business Update Conference Call and Webcast on February 25,#N/A,#N/A,#N/A
 2/07/2019 0G2BGD-E  BW   Ligand Announces OmniAb® Partnership with Genagon Therapeutics, 5/11/2012 SGEN-US     BW   Seattle Genetics to Present at Bank of America Merrill Lynch Health Care Conference, 2/28/2019 45232710    BW   Illumina to Webcast Upcoming Investor Conference Presentation, 1/02/2019 84763A10  BW   Spectrum Pharmaceuticals Announces Full Enrollment of the Poziotinib EGFR Cohort for Previously Treated Non-Small Cell Lung Cancer Patients with Exon 20 Insertion Mutations, 6/12/2017 ENDP-US  BW   SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Endo International plc, 6/21/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4), 1/12/2010 09060J10 BW   BioDelivery Sciences Granted a Meeting with FDA to Discuss the Clinical Development of BEMA Granisetron,#N/A,#N/A,#N/A
 2/04/2019 LGND-US   BW   Ligand Announces Investment in Dianomi Therapeutics," 4/25/2012 SLXP-US     BW   Salix and Progenics Announce FDA Extension of RELISTOR® sNDA Goal Date to July 27, 2012", 2/06/2019 45232710    BW   Illumina Names Susan E. Siegel to Its Board of Directors,12/27/2018 84763A10  BW   Spectrum Pharmaceuticals Announces Submission of Biologics License Application to the FDA for ROLONTIS® (eflapegrastim) as a Treatment for Chemotherapy-Induced Neutropenia, 6/12/2017 ENDP-US  BW   IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Endo International plc and Advises Investors with Losses to Contact the Firm, 6/21/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-APOC3,#N/A,#N/A,#N/A,#N/A
 1/25/2019 LGND-US   BW   Ligand Partner Seelos Therapeutics Becomes a Public Company,"12/20/2011 74318710    BW   Salix and Progenics Announce Positive Highly Statistically Significant Results of Oral Methylnaltrexone for Phase 3 Trial in Chronic, Non-Cancer Pain Subjects with Opioid-Induced Constipation", 1/29/2019 45232710    BW   Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2018,12/19/2018 84763A10  BW   Spectrum Pharmaceuticals Provides Poziotinib Update," 6/12/2017 ENDP-US  BW   INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Endo International plc -- ENDP", 5/31/2019 ARWR-US  BW   Arrowhead Pharmaceuticals to Present at Upcoming June 2019 Conferences,#N/A,#N/A,#N/A,#N/A
 1/17/2019 LGND-US   BW   INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Ligand Pharmaceuticals Incorporated,"10/26/2011 SGEN-US     BW   Seattle Genetics Appoints Vice President, Medical Affairs and Announces Vice President, Quality Management Promotion"," 1/15/2019 45232710    BW   Illumina to Announce Fourth Quarter and Fiscal Year 2018 Financial Results on Tuesday, January 29, 2019",12/06/2018 84763A10  BW   Spectrum Pharmaceuticals Announces Results from the RECOVER Phase 3 Study of ROLONTIS® (eflapegrastim) at the 2018 SABCS Annual Meeting, 6/09/2017 ENDP-US  BW   IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of Endo International plc and Encourages Investors with Losses to Contact the Firm, 5/08/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Fiscal 2019 Second Quarter Results,#N/A,#N/A,#N/A,#N/A
 1/15/2019 LGND-US   BW   Ligand to Report Fourth Quarter and Full Year 2018 Results on February 7th, 8/30/2011 74318710    BW   Progenics and Salix Announce FDA Acceptance of sNDA Filing for RELISTOR® in Patients with Non-Cancer Pain,12/20/2018 45232710    BW   Illumina to Webcast Upcoming Investor Conference Presentations,12/03/2018 84763A10  BW   Spectrum Pharmaceuticals Announces Positive Results from Phase 2 Trial Evaluating Use of Oral Leucovorin to Potentially Mitigate Mucositis in Patients Treated with FOLOTYN® (pralatrexate)," 6/09/2017 ENDP-US  BW   Arons & Arons, LLC. Announces Investigation on Behalf of Endo International plc Investors", 5/02/2019 ARWR-US  BW   Arrowhead Pharmaceuticals to Present at Upcoming May 2019 Conferences,#N/A,#N/A,#N/A,#N/A
12/18/2018 LGND-US   BW   Ligand Introduces 2019 Financial Outlook and Raises 2018 Financial Guidance, 4/04/2011 74318710    BW   Progenics Pharmaceuticals to Webcast Upcoming Presentations,12/06/2018 45232710    BW   Illumina Announces a New Genotyping Array and Scientific Contribution to Three Genome Centers to Support the All of Us Research Program,11/30/2018 84763A10  BW   Spectrum Pharmaceuticals Highlights Three Posters at the 60th Annual Meeting of the American Society of Hematology, 6/09/2017 ENDP-US  BW   INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Endo International plc, 4/24/2019 ARWR-US  BW   Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Second Quarter Results,#N/A,#N/A,#N/A,#N/A
12/17/2018 0HBC56-E  BW   Ligand Acquires Milestone and Royalty Rights to PTX-022 from Palvella Therapeutics, 3/15/2011 74318710    BW   Progenics Pharmaceuticals Announces Fourth Quarter and Year-End 2010 Financial Results,11/13/2018 45232710    BW   Illumina to Webcast Upcoming Investor Conference Presentations,11/13/2018 84763A10  BW   Spectrum Pharmaceuticals Appoints Dr. Jeffrey Vacirca to its Board of Directors," 6/09/2017 ENDP-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Endo International plc", 4/24/2019 ARWR-US  BW   Arrowhead Begins Triple Combination Cohort in Chronic HBV Patients and Earns $25 Million Milestone Payment from Janssen,#N/A,#N/A,#N/A,#N/A
"12/17/2018 LGND-US   BW   Vernalis Research, a Ligand Company, Achieves Success Milestone in Collaboration with Asahi Kasei Pharma", 3/09/2011 74318710    BW   Progenics Pharmaceuticals Announces Changes in Executive Responsibilities,"11/01/2018 45232710    BW   Illumina to Acquire Pacific Biosciences for Approximately $1.2 Billion, Broadening Access to Long-Read Sequencing and Accelerating Scientific Discovery",11/08/2018 84763A10  BW   Spectrum Pharmaceuticals Reports Third Quarter 2018 Pipeline Update and Financial Results, 6/09/2017 ENDP-US  BW   Glancy Prongay & Murray LLP Commences Investigation on Behalf of Endo International plc Investors, 4/15/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease,#N/A,#N/A,#N/A,#N/A
11/21/2018 LGND-US   BW   Ligand Announces OmniAb® Partnership with iMetabolic Biopharma Corporation, 2/17/2011 74318710    BW   Progenics Reports Positive Preliminary Data from Ongoing Phase 1 Clinical Study of PSMA ADC,"10/30/2018 45232710    BW   Illumina Launches TruSight Oncology 500 to Power Comprehensive, Accurate, Pan-Cancer Tumor Profiling",11/07/2018 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2018 London Healthcare Conference on November 14,"12/07/2016 ENDP-US  BW   DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Endo International plc To Contact The Firm", 4/12/2019 ARWR-US  BW   Arrowhead Presents Clinical Data on JNJ-3989 (ARO-HBV) at The International Liver Congress™,#N/A,#N/A,#N/A,#N/A
"11/13/2018 LGND-US   BW   Vernalis Research, a Ligand Company, Achieves Success Milestones in Collaboration with Daiichi Sankyo", 2/07/2011 SLXP-US     BW   Salix Pharmaceuticals and Progenics Pharmaceuticals Announce Worldwide License Agreement for RELISTOR®,10/23/2018 45232710    BW   Illumina Reports Financial Results for Third Quarter of Fiscal Year 2018,11/01/2018 84763A10  BW   Spectrum Pharmaceuticals Announces Third Quarter 2018 Financial Results Teleconference and Webcast,"11/18/2016 ENDP-US  BW   INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Endo International plc To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit", 4/12/2019 ARWR-US  BW   Arrowhead Preclinical Data Demonstrates RNAi Therapy Prevents and Reverses Alpha-1 Liver Disease at The International Liver Congress™,#N/A,#N/A,#N/A,#N/A
11/08/2018 LGND-US   BW   Ligand Reports Third Quarter 2018 Financial Results, 2/07/2011 74318710    BW   Progenics Pharmaceuticals and Salix Pharmaceuticals Announce Worldwide License Agreement for RELISTOR®,"10/09/2018 45232710    BW   Illumina to Announce Third Quarter 2018 Financial Results on Tuesday, October 23, 2018",10/23/2018 84763A10  BW   Spectrum Pharmaceuticals Receives FDA Approval of KHAPZORY™ (levoleucovorin) for injection,11/10/2016 ENDP-US  BW   INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm, 3/29/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A
11/02/2018 LGND-US   BW   Ligand to Participate in Stephens NY Investment Conference, 1/25/2011 74318710    BW   Pfizer Inc and Progenics Alert Physicians and Patients to Information Related to Triad Group Alcohol Prep Products Included In U.S. RELISTOR Kit Packaging, 9/28/2018 45232710    BW   Illumina Announces Conversion Period for 0% Convertible Senior Notes due 2019 and 0.5% Convertible Senior Notes due 2021,10/18/2018 84763A10  BW   Spectrum Pharmaceuticals Announces Dr. Francois Lebel as Chief Medical Officer,11/09/2016 ENDP-US  BW   IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm, 3/18/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Files IND for Pivotal Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease,#N/A,#N/A,#N/A,#N/A
10/15/2018 LGND-US   BW   Ligand to Report Third Quarter 2018 Results on November 8th, 1/18/2011 PGNX-US     BW   Maven Semantic: Protein Structure and Function Research Database, 8/30/2018 45232710    BW   Illumina to Webcast Upcoming Investor Conference Presentation, 9/27/2018 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the 2018 Cantor Global Healthcare Conference on October 2,11/07/2016 ENDP-US  BW   IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm, 3/11/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia,#N/A,#N/A,#N/A,#N/A
10/10/2018 LGND-US   BW   Ligand Announces the Close of its Acquisition of Vernalis, 1/10/2011 XGEN.XX1-US BW   Maven Semantic: Prostate Cancer Research Database, 8/27/2018 45232710    BW   Illumina Receives Approval of MiSeq™Dx System in China, 9/24/2018 84763A10  BW   Spectrum Pharmaceuticals Announces Release of Updated Poziotinib Data From MD Anderson Phase 2 Study in Non-Small Cell Lung Cancer Patients,11/03/2016 ENDP-US  BW   IMPORTANT SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Endo International plc and Advises Investors with Losses to Contact the Firm, 3/01/2019 ARWR-US  BW   Arrowhead Pharmaceuticals to Present at Upcoming March 2019 Conferences,#N/A,#N/A,#N/A,#N/A
 8/29/2018 LGND-US   BW   Ligand to Participate in H.C. Wainwright 20th Annual Global Investment Conference, 1/10/2011 SIGA-US     BW, 8/16/2018 45232710    BW   Illumina Announces Pricing of Convertible Senior Notes, 9/12/2018 84763A10  BW   Spectrum Pharmaceuticals Expands Poziotinib Clinical Trial Into First-Line Therapy and Doses First Patient,11/03/2016 ENDP-US  BW   Glancy Prongay & Murray LLP Commences Investigation on Behalf of Endo International PLC Investors Concerning Recent Revelations Regarding an Alleged Illegal Conspiracy to Fix Drug Prices, 2/07/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Fiscal 2019 First Quarter Results,#N/A,#N/A,#N/A,#N/A
" 8/09/2018 LGND-US   BW   Ligand Makes Offer to Acquire Vernalis, a Leader in Structure-Based Drug Discovery, For Approximately $43 Million in Cash",11/16/2010 74318710    BW   Progenics Pharmaceuticals Announces Phase 2 Clinical Trial of Subcutaneous Methylnaltrexone in Japan by Ono Pharmaceutical, 8/15/2018 45232710    BW   Illumina to Offer $650 Million Convertible Senior Notes, 9/05/2018 84763A10  BW   Spectrum Pharmaceuticals Announces Release of Poziotinib Abstract as Part of the IASLC 19th World Conference on Lung Cancer," 7/12/2016 ENDP-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Endo International plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 25, 2016 – ENDP", 1/24/2019 ARWR-US  BW   Arrowhead Pharmaceuticals to Webcast Fiscal 2019 First Quarter Results,#N/A,#N/A,#N/A,#N/A
 8/06/2018 LGND-US   BW   Ligand Reports Second Quarter 2018 Financial Results,11/08/2010 74318710    BW   Progenics Pharmaceuticals Announces Third Quarter 2010 Financial Results, 7/30/2018 45232710    BW   Illumina Reports Financial Results for Second Quarter of Fiscal Year 2018, 8/30/2018 84763A10  BW   Spectrum Pharmaceuticals to Present at Two Upcoming Investor Conferences in September," 7/08/2016 00FV7G-E BW   ENDP INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Endo International plc and a Lead Plaintiff Deadline of July 25, 2016", 1/07/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-ANG3 for Treatment of Dyslipidemias and Metabolic Diseases,#N/A,#N/A,#N/A,#N/A
 7/09/2018 LGND-US   BW   Ligand to Report Second Quarter 2018 Results on August 6th,10/19/2010 PGNX-US     BW   Medidata Solutions Selected by Progenics Pharmaceuticals for Seamless Integration of EDC and IVRS," 7/10/2018 45232710    BW   Illumina to Announce Second Quarter 2018 Financial Results on Monday, July 30, 2018", 8/09/2018 84763A10  BW   Spectrum Pharmaceuticals Reports Second Quarter 2018 Financial Results and Pipeline Update," 7/07/2016 ENDP-US  BW   JULY 25, 2016 DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Endo International plc and Reminds Investors with Losses to Contact the Firm", 1/07/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia,#N/A,#N/A,#N/A,#N/A
 6/27/2018 0H50DZ-E  BW   Ligand Receives $47 Million from WuXi Biologics for Expansion of Worldwide OmniAb® Platform License Agreement,10/06/2010 74318710    BW   Progenics Awarded $4.1 Million NIH Grant to Advance Novel C. Difficile Antibody Therapy, 5/29/2018 45232710    BW   Illumina to Webcast Upcoming Investor Conference Presentations, 8/02/2018 84763A10  BW   Spectrum Pharmaceuticals Announces Second Quarter 2018 Financial Results Teleconference and Webcast, 7/06/2016 AYTU-US  BW   Acerus Completes NATESTO® U.S. Transition,12/17/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A
 5/18/2018 LGND-US   BW   Ligand Prices Offering of $650 Million of Convertible Senior Notes," 9/29/2010 74318710    BW   Progenics Announces Approvals of New Ready-to-Use Pre-Filled Syringes for RELISTOR in U.S., E.U. and Canada"," 5/24/2018 ILMN-US     BW   Kaskela Law LLC Announces Investigation of Illumina, Inc. on Behalf of Stockholders", 6/29/2018 84763A10  BW   Spectrum Pharmaceuticals Presents ADVANCE Phase 3 ROLONTIS® (eflapegrastim) Data at MASCC 2018 and Announces the Phase 3 RECOVER Study Met the Primary Endpoint, 7/01/2016 ENDP-US  BW   IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Endo International plc and Reminds Investors with Losses to Contact the Firm,12/11/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Fiscal 2018 Year End Results,#N/A,#N/A,#N/A,#N/A
 5/16/2018 LGND-US   BW   Ligand Announces Proposed Offering of $650 Million of Convertible Senior Notes, 9/27/2010 74318710    BW   Progenics Extends Agreement with Pfizer for RELISTOR Commercialization, 5/15/2018 45232710    BW   Illumina Acquires Edico Genome to Accelerate Genomic Data Analysis, 6/25/2018 84763A10  BW   Spectrum Pharmaceuticals to Host Conference Call Highlighting ROLONTIS® (eflapegrastim) Phase 3 ADVANCE Study Data Presented at Multinational Association of Supportive Care in Cancer (MASCC)," 6/29/2016 ENDP-US  BW   INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Endo International plc of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 25, 2016",11/27/2018 ARWR-US  BW   Arrowhead Pharmaceuticals to Webcast 2018 Fiscal Year End Results,#N/A,#N/A,#N/A,#N/A
 5/11/2018 LGND-US   BW   Ligand to Participate in Upcoming Investor Conferences, 9/21/2010 74318710    BW   Progenics Announces Clinical Completion of Subcutaneous Methylnaltrexone Safety Study in Chronic Non-Malignant Pain Patients, 5/02/2018 45232710    BW   Illumina to Webcast Upcoming Investor Conference Presentation, 5/30/2018 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2018 Global Healthcare Conference on June 6th," 6/24/2016 00FV7G-E BW   SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Endo International plc and a Lead Plaintiff Deadline of July 25, 2016",11/09/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Presents Late-Breaking Clinical Data on ARO-AAT at Liver Meeting® 2018,#N/A,#N/A,#N/A,#N/A
 5/08/2018 LGND-US   BW   Ligand Reports First Quarter 2018 Financial Results, 9/13/2010 74318710    BW   Progenics’ Humanized Monoclonal Antibodies Significantly Improve Survival in an Animal Model of C. difficile-associated Disease," 4/29/2018 ILMN-US     BW   EQUITY ALERT: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties By Management of Illumina, Inc. – ILMN", 5/16/2018 84763A10  BW   CORRECTING and REPLACING Spectrum Pharmaceuticals Announces Detailed Results from Phase 3 Study of ROLONTIS® (eflapegrastim) Published in an ASCO Abstract," 6/20/2016 ENDP-US  BW   IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit Against Endo International plc and Encourages Investors With Losses in Excess of $100,000 to Contact the Firm",11/09/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Presents Late-Breaking Preliminary Clinical Data on ARO-HBV at Liver Meeting® 2018,#N/A,#N/A,#N/A,#N/A
 4/24/2018 LGND-US   BW   Ligand to Report First Quarter 2018 Results on May 8th, 9/08/2010 74318710    BW   Progenics Pharmaceuticals Initiates Oral Methylnaltrexone Phase 3 Trial in Patients with Chronic Non-Cancer Pain, 4/24/2018 45232710    BW   Illumina Reports Financial Results for First Quarter of Fiscal Year 2018, 5/09/2018 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2018 Health Care Conference on May 16th, 6/16/2016 ENDP-US  BW   SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Endo International plc and Encourages Investors With Losses to Contact the Firm,11/01/2018 ARWR-US  BW   Arrowhead Pharmaceuticals to Present at Upcoming November 2018 Conferences,#N/A,#N/A,#N/A,#N/A
 3/30/2018 07ST71-E  BW   Ligand Enters into Agreement with venBio to Make Worldwide OmniAb® Platform License Accessible to Portfolio Companies, 8/31/2010 74318710    BW   Progenics Pharmaceuticals to Present Preclinical Study of Novel Monoclonal Antibodies Against C. difficile at 2010 ICAAC, 4/13/2018 45232710    BW   Bristol-Myers Squibb and Illumina Announce Strategic Collaboration to Develop and Commercialize Companion Diagnostics for Bristol-Myers Squibb’s Oncology Immunotherapies, 5/03/2018 84763A10  BW   Spectrum Pharmaceuticals Reports First Quarter 2018 Financial Results and Pipeline Update, 6/15/2016 ENDP-US  BW   IMPORTANT INVESTOR NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm,10/31/2018 005Y9C-E BW   Arrowhead Pharmaceuticals Announces Closing of Agreements with Janssen,#N/A,#N/A,#N/A,#N/A
 3/06/2018 LGND-US   BW   Ligand Licenses Glucagon Receptor Antagonist Program to Roivant Sciences, 8/09/2010 74318710    BW   Progenics Pharmaceuticals Announces Second Quarter 2010 Financial Results, 4/10/2018 45232710    BW   Illumina and Loxo Oncology to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics, 5/03/2018 065BPX-E  BW   Spectrum Pharmaceuticals Announces Exclusive Licensing Agreement on Certain Methods of Use of Poziotinib with The University of Texas MD Anderson Cancer Center," 6/10/2016 00FV7G-E BW   ENDO SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Endo International plc",10/16/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Hosts R&D Day on Pipeline of RNAi Therapeutics,#N/A,#N/A,#N/A,#N/A
 3/05/2018 LGND-US   BW   Ligand to Participate in Two Upcoming Investor Conferences, 8/05/2010 74318710    BW   Progenics Announces Positive Opinion Issued by a Committee of the European Medicines Agency for Relistor in Pre-Filled Syringes," 4/10/2018 45232710    BW   Illumina to Announce First Quarter 2018 Financial Results on Tuesday, April 24, 2018", 5/01/2018 TMO-US    BW   Spectrum Pharmaceuticals Enters into a Next-Generation Sequencing Companion Diagnostic Partnership with Thermo Fisher Scientific, 6/06/2016 ENDP-US  BW   SHAREHOLDER ALERT: Lundin Law PC Announces Investigation Of Endo International plc And Advises Investors With Losses to Contact the Firm,10/15/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3,#N/A,#N/A,#N/A,#N/A
 2/21/2018 LGND-US   BW   Ligand Reports Fourth Quarter and Full Year 2017 Financial Results, 6/10/2010 74318710    BW   Peter Crowley Elected Progenics Chairman of the Board," 3/30/2018 ILMN-US     BW   ILLUMINA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Illumina, Inc. - ILMN", 4/30/2018 84763A10  BW   Spectrum Pharmaceuticals Announces Corporate Governance Enhancements and Board Changes, 6/02/2016 ENDP-US  BW   IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Investigation of Endo International plc and Advises Investors with Losses to Contact the Firm,10/11/2018 ARWR-US  BW   Arrowhead to Present Late-Breaking Clinical Data on ARO-AAT and ARO-HBV at AASLD Liver Meeting® 2018,#N/A,#N/A,#N/A,#N/A
 2/05/2018 LGND-US   BW   Ligand to Report Fourth Quarter and Full Year 2017 Results on February 21st, 6/07/2010 74318710    BW   Progenics Phase 1 PSMA ADC Study Presented in New “Trials in Progress” Poster Session at ASCO Annual Meeting," 3/22/2018 ILMN-US     BW   The Shuman Law Firm Investigates Illumina, Inc.", 4/27/2018 SPPI-US   BW   Company Profile for SPECTRUM PHARMACEUTICALS, 6/02/2016 ENDP-US  BW   Robbins Arroyo LLP: Endo International plc (ENDP) Misled Shareholders According to a Recently Filed Class Action,10/04/2018 005Y9C-E BW   Arrowhead Enters $3.7 Billion License and Collaboration Agreements with Janssen,#N/A,#N/A,#N/A,#N/A
 1/22/2018 LGND-US   BW   Ligand Enters into Worldwide OmniAb® Platform License Agreement with Ferring Pharmaceuticals, 5/27/2010 74318710    BW   Progenics Presents Novel Monoclonal Antibodies against Clostridium difficile at the American Society for Microbiology Conference, 3/12/2018 45232710    BW   Illumina Names Dr. Phil Febbo Chief Medical Officer, 4/26/2018 84763A10  BW   Spectrum Pharmaceuticals Announces First Quarter 2018 Financial Results Teleconference and Webcast," 5/16/2016 ENDP-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Endo International plc", 9/25/2018 ARWR-US  BW   Arrowhead Pharmaceuticals to Present at Upcoming October 2018 Conferences,#N/A,#N/A,#N/A,#N/A
" 1/18/2018 LGND-US   BW   Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Contrast Agents for Diagnostic Imaging", 5/10/2010 74318710    BW   Progenics Pharmaceuticals Announces First Quarter 2010 Financial Results, 2/27/2018 45232710    BW   Illumina to Webcast Upcoming Investor Conference Presentation, 4/23/2018 84763A10  BW   Spectrum Pharmaceuticals Announces Publication of Poziotinib Data in Nature Medicine, 5/16/2016 ENDP-US  BW   INVESTOR ALERT: Investigation of Endo International plc Announced by Law Offices of Howard G. Smith, 9/24/2018 ARWR-US  BW   Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics,#N/A,#N/A,#N/A,#N/A
 1/11/2018 073W4T-E  BW   Ligand Enters into Worldwide OmniAb® Platform License Agreement with Glenmark Pharmaceuticals, 3/15/2010 74318710    BW   Progenics Announces Fourth Quarter and Year-End 2009 Financial Results, 1/30/2018 45232710    BW   Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2017, 4/17/2018 84763A10  BW   Spectrum Pharmaceuticals Highlights Data Showing Poziotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other Cancers at the American Association for Cancer Research (AACR) in Chicago, 5/06/2016 ENDP-US  BW   Hagens Berman Investigates Potential Securities Law Violations by Endo International plc, 9/21/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A
 1/03/2018 009420-KR BW   Ligand Earns $6 Million as OmniAb Partner Out-Licenses Antibody Projects, 3/12/2010 74318710    BW   Progenics to Advance Oral Methylnaltrexone into Late Stage Clinical Development," 1/26/2018 45232710    BW   Illumina Awarded $26.7M in Patent Suit Against Ariosa Diagnostics, Inc.", 4/10/2018 84763A10  BW   Spectrum Pharmaceuticals Announces Update of MD Anderson’s Phase 2 Data Studying Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer Patients,12/31/2015 TRL-CA   BW   Acerus Announces Termination of NATESTO™ Agreement with Endo, 9/06/2018 ARWR-US  BW   Arrowhead Presents New ARO-HBV Clinical Data Demonstrating HBsAg Reductions at World Gastroenterologists Summit,#N/A,#N/A,#N/A,#N/A
11/14/2017 LGND-US   BW   Ligand Provides Highlights from Today’s Analyst Day Event, 2/04/2010 74318710    BW   Progenics Presents Novel Multiplex PI3-Kinase Inhibitors at American Association for Cancer Research Conference on Protein Translation and Cancer," 1/16/2018 45232710    BW   Illumina to Announce Fourth Quarter and Fiscal Year 2017 Financial Results on Tuesday, January 30, 2018", 4/03/2018 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the H.C. Wainwright Global Life Sciences Conference on April 10th, 6/10/2015 G3040110 BW   ARIAD Et Laboratoires Paladin Annoncent La Signature D’une Entente De Distribution Commerciale D’iclusig (Ponatinib) Au Canada, 8/31/2018 ARWR-US  BW   Arrowhead Completes Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease,#N/A,#N/A,#N/A,#N/A
11/09/2017 0G9V6N-E  BW   Ligand Reports Third Quarter 2017 Financial Results,#N/A, 1/09/2018 ILMN-US     BW   Helix To Help Expand Healthy Nevada Project, 3/07/2018 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Cowen and Company 38th Annual Health Care Conference on March 13th, 6/10/2015 ARIA-US  BW   ARIAD and Paladin Announce Commercial Distribution Agreement for Iclusig (Ponatinib) in Canada, 8/30/2018 ARWR-US  BW   Arrowhead Pharmaceuticals to Present at Upcoming September 2018 Conferences,#N/A,#N/A,#N/A,#N/A
11/06/2017 LGND-US   BW   Reminder: Ligand to Host Analyst Day on November 14th in New York City,#N/A, 1/08/2018 45232710    BW   Thermo Fisher Scientific and Illumina Sign Agreement to Provide Research Market Broader Access to Ion AmpliSeq Technology, 3/06/2018 84763A10  BW   Spectrum Pharmaceuticals Reports Fourth Quarter 2017 and Full Year 2017 Financial Results and Pipeline Update," 3/11/2015 SLXP-US  BW   Salix Pharmaceuticals, Ltd. Confirms Receipt of an Unsolicited Proposal from Endo International plc", 8/07/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Fiscal 2018 Third Quarter Results,#N/A,#N/A,#N/A,#N/A
11/02/2017 LGND-US   BW   Ligand to Participate in the Stephens Fall Investment Conference,#N/A, 1/08/2018 45232710    BW   Illumina Launches iSeq 100 Sequencing System, 2/27/2018 84763A10  BW   Spectrum Pharmaceuticals Announces Appointment of William L. Ashton to its Board of Directors, 6/18/2014 ENDP-US  BW   Trendlines Acquires Intellectual Property from Collaboration with Endo, 8/01/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Earns $10 Million Milestone Payment from Amgen,#N/A,#N/A,#N/A,#N/A
10/24/2017 LGND-US   BW   Ligand to Report Third Quarter 2017 Results on November 9th,#N/A, 1/04/2018 07MCDV-E    BW   Illumina and KingMed Diagnostics Partner to Develop Next-Generation Sequencing Technology for Chinese FDA Approval, 2/26/2018 84763A10  BW   Spectrum Pharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results Teleconference and Webcast," 5/11/2010 G3040110 BW   Bull & Lifshitz, LLP Announces Investigation of the Acquisition of HealthTronics, Inc. by Endo Pharmaceuticals Holdings Inc.", 7/24/2018 ARWR-US  BW   Arrowhead Pharmaceuticals to Webcast Fiscal 2018 Third Quarter Results,#N/A,#N/A,#N/A,#N/A
"10/04/2017 LGND-US   BW   Ligand to Acquire Crystal Bioscience, the Leader in Chicken-derived Fully-human Antibody Generation, for $25 Million in Cash plus Additional Potential Payments",#N/A,12/19/2017 45232710    BW   Illumina to Webcast Upcoming Investor Conference Presentations, 2/15/2018 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the 2018 RBC Capital Markets Global Healthcare Conference on February 22nd,#N/A, 6/29/2018 ARWR-US  BW   Arrowhead Presents New Clinical Data on ARO-AAT at Alpha-1 National Education Conference,#N/A,#N/A,#N/A,#N/A
 9/25/2017 LGND-US   BW   Ligand to Host Analyst Day on November 14th in New York City,#N/A,"12/11/2017 45232710    BW   Illumina Names Aimee Hoyt Chief People Officer, Bringing 20+ Years of Senior Human Resources Leadership from Global Technology Companies", 2/05/2018 84763A10  BW   Spectrum Pharmaceuticals Announces ROLONTIS™ (eflapegrastim) Met the Primary Endpoint in the Phase 3 ADVANCE Study,#N/A, 6/27/2018 ARWR-US  BW   Arrowhead Receives Positive EMA Opinion on Orphan Designation for ARO-AAT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency,#N/A,#N/A,#N/A,#N/A
 9/05/2017 LGND-US   BW   Ligand Announces Top-Line Results from Phase 2 Study of LGD-6972 in Patients with Type 2 Diabetes,#N/A,12/07/2017 DIS-US      BW   Disney Board Elects Oracle’s Safra Catz and Illumina’s Francis A. deSouza as Directors, 1/23/2018 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Noble Capital Markets' Fourteenth Annual Investor Conference,#N/A, 6/18/2018 ARWR-US  BW   Arrowhead Completes Enrollment in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease,#N/A,#N/A,#N/A,#N/A
 9/01/2017 LGND-US   BW   Ligand to Participate in Two Upcoming Investor Conferences,#N/A,11/29/2017 45232710    BW   Illumina eröffnet in Frankreich erstes Vertriebs- und Kundenschulungszentrum,12/17/2017 SPPI-US   BW   Spectrum Pharmaceuticals Announces Leadership Changes,#N/A, 6/08/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A
 8/21/2017 LGND-US   BW   Ligand Appoints Dr. Nancy Gray to its Board of Directors,#N/A,11/29/2017 45232710    BW   Illumina Opens First Commercial and Customer Training Center in France,12/13/2017 84763A10  BW   Spectrum Pharmaceuticals Highlights Two Oral Presentations on FOLOTYN® (pralatrexate injection) at the 59th Annual Meeting of the American Society of Hematology (ASH),#N/A, 5/30/2018 ARWR-US  BW   Arrowhead Completes Enrollment in Single Dose Portion of Phase 1/2 Study of ARO-HBV,#N/A,#N/A,#N/A,#N/A
 8/18/2017 002437-CN BW   Ligand to Receive $2 Million from WuXi Biologics for Licensing Clinical-Stage anti-PD-1 Antibody Discovered Using the OmniAb® Technology,#N/A,11/29/2017 45232710    BW   Illumina ouvre son premier « Solution Center » en France,"12/04/2017 84763A10  BW   Spectrum Pharmaceuticals Highlights 15 Abstracts at the 59th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia, December 9-12, 2017",#N/A, 5/30/2018 ARWR-US  BW   Arrowhead Pharmaceuticals to Present at Upcoming June 2018 Conferences,#N/A,#N/A,#N/A,#N/A
 8/07/2017 LGND-US   BW   Ligand Reports Second Quarter 2017 Financial Results,#N/A,11/22/2017 45232710    BW   Illumina to Webcast Upcoming Investor Conference Presentation,11/08/2017 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2017 London Healthcare Conference on November 15th,#N/A, 5/21/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Presents New Preclinical Data on ARO-ENaC for Treatment of Cystic Fibrosis,#N/A,#N/A,#N/A,#N/A
 7/20/2017 LGND-US   BW   Ligand to Report Second Quarter 2017 Results on August 7th,#N/A,"11/21/2017 NIPT-GB     BW   Illumina Wins Infringement Suit Against Premaitha Health plc and Ariosa Diagnostics, Inc.",11/02/2017 84763A10  BW   Spectrum Pharmaceuticals Reports Third Quarter 2017 Financial Results and Pipeline Update,#N/A, 5/14/2018 ARWR-US  BW   Arrowhead Doses First Hepatitis B Patients in Multiple Dose Portion of Phase 1/2 Study of ARO-HBV,#N/A,#N/A,#N/A,#N/A
 7/17/2017 LGND-US   BW   Ligand Enters Into Commercial License and Supply Agreement with Amgen for Rights to Use Captisol in the Formulation of AMG 330,#N/A,11/15/2017 45232710    BW   Illumina Grows Clinical IVD Portfolio with Introduction of NextSeq™ 550Dx System and Expanded Use of MiSeq™Dx System,10/30/2017 84763A10  BW   Spectrum Pharmaceuticals Announces Initiation of a Multicenter Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer (NSCLC) Patients with Exon 20 Insertion Mutation in EGFR or HER2,#N/A, 5/11/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Presents Preclinical Data on Expanding Cardiometabolic Pipeline,#N/A,#N/A,#N/A,#N/A
 6/20/2017 RIBX-US   BW   Ligand’s Partner Melinta Therapeutics Announces U.S. FDA Approval of Baxdela™ (Delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI),#N/A,"11/08/2017 45232710    BW   Illumina Names Gary S. Guthart, Ph.D., to its Board of Directors, Adding Decades of Leadership Experience in Healthcare",10/26/2017 84763A10  BW   Spectrum Pharmaceuticals Announces Third Quarter 2017 Financial Results Teleconference and Webcast,#N/A, 5/08/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Fiscal 2018 Second Quarter Results,#N/A,#N/A,#N/A,#N/A
 6/01/2017 LGND-US   BW   Ligand Enters into Worldwide OmniAb® Platform License Agreement with Surface Oncology,#N/A,10/24/2017 45232710    BW   Illumina Reports Financial Results for Third Quarter of Fiscal Year 2017,10/17/2017 84763A10  BW   Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan,#N/A, 5/01/2018 ARWR-US  BW   Arrowhead Pharmaceuticals to Present Preclinical Data on Emerging Pipeline of RNAi Therapeutics,#N/A,#N/A,#N/A,#N/A
 5/31/2017 LGND-US   BW   Ligand Announces Aziyo Biologics Acquires Commercial Products from Partner CorMatrix,#N/A,10/17/2017 0F0WRJ-E    BW   Jay Flatley and John Martin to be Named Recipients of Life Sciences Leadership Award at California Life Sciences Association’s 2017 Pantheon DiNA™ Awards,10/10/2017 84763A10  BW   Spectrum Pharmaceuticals Announces Agreements to Exchange $69.5 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2018 for Common Stock and Cash,#N/A, 4/24/2018 ARWR-US  BW   Arrowhead Pharmaceuticals to Webcast Fiscal 2018 Second Quarter Results,#N/A,#N/A,#N/A,#N/A
 5/30/2017 LGND-US   BW   Ligand Enters Into Worldwide OmniAb® Platform License Agreement With xCella Biosciences,#N/A,10/16/2017 45232710    BW   Illumina Releases NovaSeq S4 Flow Cell and NovaSeq Xp Workflow, 9/29/2017 84763A10  BW   Spectrum Pharmaceuticals Provides Update on At-The-Market Facility,#N/A, 4/11/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Presents ARC-520 Clinical Data at The International Liver Congress™,#N/A,#N/A,#N/A,#N/A
 5/22/2017 LGND-US   BW   Ligand to Participate in Two Upcoming Investor Conferences,#N/A,"10/10/2017 45232710    BW   Illumina to Announce Third Quarter 2017 Financial Results on Tuesday, October 24, 2017"," 9/28/2017 065BPX-E  BW   Spectrum Pharmaceuticals Highlights Poziotinib Data in Lung Cancer to be Presented in an Oral Presentation at the 18th IASLC World Conference on Lung Cancer in Yokohama, Japan, October 15-18, 2017",#N/A, 3/28/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Announces Multiple Presentations at The International Liver Congress™,#N/A,#N/A,#N/A,#N/A
 5/09/2017 LGND-US   BW   Ligand Reports First Quarter 2017 Financial Results,#N/A, 9/07/2017 45232710    BW   Illumina Files New Patent Infringement Suit Against Premaitha Health plc, 9/05/2017 84763A10  BW   Spectrum Pharmaceuticals to Present at Two Upcoming Investor Conferences in September,#N/A, 3/27/2018 ARWR-US  BW   Arrowhead Begins Dosing in Phase 1/2 Study of ARO-HBV for Treatment of Chronic Hepatitis B,#N/A,#N/A,#N/A,#N/A
 4/13/2017 LGND-US   BW   Ligand to Report First Quarter 2017 Results on May 9th,#N/A," 8/24/2017 06QT6N-E    BW   Illumina and Telegraph Hill Partners Launch Verogen, Inc. to Drive Adoption of Next-Generation Sequencing in the Global Forensic Genomics Market"," 8/17/2017 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the 2017 Southern California Investor Conference in Newport Beach on Thursday, August 24th",#N/A, 3/20/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A
 4/05/2017 LGND-US   BW   Ligand Enters Commercial License and Supply Agreements with Marinus Pharmaceuticals for Captisol-Enabled Ganaxolone,#N/A, 8/01/2017 45232710    BW   Illumina Reports Strong Financial Results for Second Quarter of Fiscal Year 2017, 8/14/2017 84763A10  BW   Spectrum Pharmaceuticals Announces Initiation of the Registrational Phase 3 Trial of Qapzola™ (apaziquone) in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC),#N/A, 3/12/2018 ARWR-US  BW   Arrowhead Begins Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease,#N/A,#N/A,#N/A,#N/A
 3/28/2017 LGND-US   BW   Ligand Announces Licensing Partner Janssen Has Filed an IND for an Antibody Discovered Using the OmniAb® Technology,#N/A," 7/11/2017 45232710    BW   Illumina to Announce Second Quarter 2017 Financial Results on Tuesday, August 1, 2017", 8/03/2017 84763A10  BW   Spectrum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Pipeline Update,#N/A, 3/06/2018 ARWR-US  BW   Arrowhead to Present at Barclays Global Healthcare Conference 2018,#N/A,#N/A,#N/A,#N/A
 3/09/2017 LGND-US   BW   Ligand to Participate in Upcoming Investor Conference,#N/A, 6/29/2017 45232710    BW   Illumina Announces FDA-approved Next-Generation Sequencing Cancer Companion Diagnostic Test Kit," 8/01/2017 84763A10  BW   Spectrum Pharmaceuticals Announces Completion of Enrollment in the Phase 3 Pivotal Study (ADVANCE) of ROLONTIS™ (eflapegrastim), a Novel Long-Acting GCSF",#N/A, 2/22/2018 ARWR-US  BW   Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease,#N/A,#N/A,#N/A,#N/A
 2/28/2017 LGND-US   BW   Ligand Provides Highlights from Today’s Analyst Day Event,#N/A, 6/27/2017 45232710    BW   Genomics England adopte le logiciel BaseSpace d’Illumina pour le cancer, 7/27/2017 84763A10  BW   Spectrum Pharmaceuticals Announces Second Quarter 2017 Financial Results Teleconference and Webcast,#N/A, 2/15/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT,#N/A,#N/A,#N/A,#N/A
 2/28/2017 LGND-US   BW   Ligand Expands License with Sermonix to Include Worldwide Rights for Oral Lasofoxifene,#N/A, 6/27/2017 45232710    BW   Genomics England übernimmt BaseSpace Variant Interpreter für Krebs von Illumina, 6/19/2017 84763A10  BW   Spectrum Pharmaceuticals Highlights Results of a Combination Study of FOLOTYN® (pralatrexate injection) Plus Romidepsin Presented at the 14th International Conference on Malignant Lymphoma (14-ICML) Meeting,#N/A, 2/15/2018 ARWR-US  BW   Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B,#N/A,#N/A,#N/A,#N/A
 2/27/2017 LGND-US   BW   Enrollment Completed in Ligand’s Phase 2 Trial of LGD-6972 in Type 2 Diabetes,#N/A, 6/26/2017 45232710    BW   Genomics England Adopts Illumina’s BaseSpace Variant Interpreter for Cancer," 6/02/2017 SPPI-US   BW   Spectrum Pharmaceuticals Highlights Three Abstracts of Clinical Data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, June 2-6, 2017",#N/A, 2/09/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Fiscal 2018 First Quarter Results,#N/A,#N/A,#N/A,#N/A
 2/23/2017 LGND-US   BW   Ligand Reports Fourth Quarter and Full Year 2016 Financial Results,#N/A," 6/08/2017 ILMN-US     BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Files Amended Complaint Against Illumina, Inc. and Senior Officers", 5/30/2017 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2017 Global Healthcare Conference on June 6th,#N/A, 2/02/2018 ARWR-US  BW   Arrowhead Pharmaceuticals to Webcast Fiscal 2018 First Quarter Results,#N/A,#N/A,#N/A,#N/A
" 2/14/2017 LGND-US   BW   Dr. Christel Iffland Joins Ligand as Vice President, Antibody Technologies, Expands Team Focused on OmniAb Drug Discovery Platform",#N/A, 5/31/2017 ILMN-US     BW   FitnessGenes™ Secures $5 Million Series A Funding, 5/16/2017 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2017 Health Care Conference on May 17,#N/A, 1/22/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $60.4 Million,#N/A,#N/A,#N/A,#N/A
 2/13/2017 LGND-US   BW   Reminder: Ligand to Host Analyst Day on February 28th in New York City,#N/A, 5/30/2017 45232710    BW   Illumina to Webcast Live Presentation at the Goldman Sachs Global Healthcare Conference, 5/02/2017 84763A10  BW   Spectrum Pharmaceuticals Reports First Quarter 2017 Financial Results and Pipeline Update,#N/A, 1/18/2018 05NBLJ-E BW   Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A
 1/24/2017 LGND-US   BW   Ligand to Host Analyst Day on February 28th in New York City,#N/A," 5/22/2017 45232710    BW   Illumina Names Mark Van Oene Chief Commercial Officer, Sales Leader Brings Genomics Expertise and Strong Commercial Leadership Experience to the Role", 4/27/2017 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the 42nd Annual Deutsche Bank Health Care Conference on May 4,#N/A, 1/17/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock,#N/A,#N/A,#N/A,#N/A
 1/23/2017 LGND-US   BW   Ligand to Report Fourth Quarter and Full Year 2016 Results on February 23rd,#N/A, 5/04/2017 45232710    BW   Illumina to Webcast Live Presentation at the Bank of America Merrill Lynch Health Care Conference, 4/25/2017 84763A10  BW   Spectrum Pharmaceuticals Announces First Quarter 2017 Financial Results Teleconference and Webcast,#N/A,12/27/2017 ARWR-US  BW   Arrowhead Pharmaceuticals Appoints William Waddill to Board of Directors,#N/A,#N/A,#N/A,#N/A
" 1/13/2017 LGND-US   BW   UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders of Ligand Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017",#N/A, 4/25/2017 45232710    BW   Illumina Reports Financial Results for First Quarter of Fiscal Year 2017, 4/04/2017 84763A10  BW   Spectrum Pharmaceuticals Highlights Preclinical Data of ROLONTIS™ (eflapegrastim) at the American Association for Cancer Research (AACR) Annual Meeting,#N/A,12/22/2017 ARWR-US  BW   Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV,#N/A,#N/A,#N/A,#N/A
" 1/07/2017 LGND-US   BW   DEADLINE ALERT: Brower Piven Reminds Investors Of The January 17, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Ligand Pharmaceuticals Incorporated To Contact The Firm",#N/A," 4/11/2017 45232710    BW   Illumina to Announce First Quarter 2017 Financial Results on Tuesday, April 25, 2017"," 3/31/2017 84763A10  BW   Spectrum Pharmaceuticals Highlights Three Abstracts on ROLONTIS™ (eflapegrastim) and BELEODAQ® (belinostat) for injection at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C., April 1-5, 2017",#N/A,12/20/2017 ARWR-US  BW   Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-AAT,#N/A,#N/A,#N/A,#N/A
" 1/04/2017 LGND-US   BW   Bragar Eagel & Squire, P.C. Reminds Investors of a Class Action Lawsuit Against Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and the Lead Plaintiff Deadline of January 17, 2017",#N/A, 4/10/2017 45232710    BW   Illumina Launches the VeriSeq™ NIPT Solution in Europe, 3/30/2017 84763A10  BW   Spectrum Pharmaceuticals Announces Initiation of a Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations,#N/A,12/18/2017 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(C)(4),#N/A,#N/A,#N/A,#N/A
"12/27/2016 LGND-US   BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Ligand Pharmaceuticals Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017",#N/A, 4/10/2017 45232710    BW   Illumina lance la solution de dépistage anténatal non invasif VeriSeq™ en Europe, 3/08/2017 84763A10  BW   Spectrum Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results and Pipeline Update,#N/A,12/12/2017 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Fiscal 2017 Year End Results,#N/A,#N/A,#N/A,#N/A
12/22/2016 NOVN-CH   BW   Ligand Enters Commercial License and Supply Agreements for Captisol®-enabled trametinib,#N/A, 4/10/2017 45232710    BW   Illumina lanza la solución VeriSeq™ NIPT en Europa, 3/01/2017 84763A10  BW   Spectrum Pharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results Teleconference and Webcast,#N/A,12/06/2017 ARWR-US  BW   Arrowhead Presents New Clinical Data Demonstrating a Sustained Host Response in Hepatitis B Patients Following RNAi Therapy,#N/A,#N/A,#N/A,#N/A
"12/22/2016 4528-JP   BW   Ligand Enters into Worldwide OmniAb® Platform License Agreement with ONO PHARMACEUTICAL CO., LTD.",#N/A, 4/10/2017 45232710    BW   Illumina lancia la soluzione VeriSeq™ NIPT in Europa, 2/16/2017 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the 2017 RBC Capital Markets Global Healthcare Conference on February 23rd,#N/A,12/05/2017 ARWR-US  BW   Arrowhead Pharmaceuticals to Webcast 2017 Fiscal Year End Results,#N/A,#N/A,#N/A,#N/A
12/05/2016 LGND-US   BW   LGND NOTICE: Rosen Law Firm Reminds Ligand Pharmaceuticals Incorporated Investors of Important Deadline in Class Action Filed by Firm - LGND,#N/A, 4/10/2017 45232710    BW   Illumina lanceert de VeriSeq™ NIPT-oplossing in Europa,12/08/2016 07LCB1-E  BW   Spectrum Pharmaceuticals Highlights Promising Preclinical Data Evaluating Poziotinib in Lung Cancer at the 17th IASLC World Conference on Lung Cancer,#N/A,11/14/2017 ARWR-US  BW   Arrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference,#N/A,#N/A,#N/A,#N/A
11/21/2016 06CR5C-E  BW   Ligand Partner Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016,#N/A, 4/10/2017 45232710    BW   Illumina lanciert VeriSeq™ NIPT-Lösung in Europa,12/06/2016 84763A10  BW   Spectrum Pharmaceuticals Highlights Survival Advantage in a Case Match Control Analysis of the PROPEL Study with FOLOTYN® (pralatrexate injection) at the 58th Annual Meeting of the American Society of Hematology (ASH),#N/A,10/23/2017 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A
11/18/2016 LGND-US   BW   INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,#N/A, 4/06/2017 ILMN-US     BW   Lucigen to Distribute Entire Epicentre Product Line,"12/05/2016 84763A10  BW   Spectrum Pharmaceuticals Highlights Five Abstracts on ROLONTIS™ (eflapegrastim) and Poziotinib at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, December 6-10, 2016",#N/A,10/23/2017 ARWR-US  BW   Arrowhead Presents Promising Preclinical Data on Development of ARO-AAT for Treatment of Alpha-1 Liver Disease at Liver Meeting® 2017,#N/A,#N/A,#N/A,#N/A
"11/18/2016 LGND-US   BW   Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Encourages Investors to Contact the Firm",#N/A," 4/03/2017 45232710    BW   Illumina Advances the Use of Genomics in Precision Oncology, Donates Thousands of Somatic Interpretations to CIViC","12/02/2016 06QBQ2-E  BW   Spectrum Pharmaceuticals Highlights Four Abstracts at the 58th Annual Meeting of the American Society of Hematology (ASH) in San Diego, California, December 3-6, 2016",#N/A,10/10/2017 ARWR-US  BW   Arrowhead Pharmaceuticals to Present Preclinical Data on ARO-AAT at The Liver Meeting®,#N/A,#N/A,#N/A,#N/A
11/17/2016 LGND-US   BW   INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,#N/A," 3/21/2017 ILMN-US     BW   Kailos Genetics Announces Co-marketing Agreement with Illumina, Inc. for Pharmacogenetics Solution for Research","11/17/2016 07LCB1-E  BW   Spectrum Pharmaceuticals Announces Poziotinib Data Presentation at the 17th IASLC World Conference on Lung Cancer in Vienna, Austria, December 4-7, 2016",#N/A,10/03/2017 ARWR-US  BW   Arrowhead to Present at Chardan Gene Therapy Conference,#N/A,#N/A,#N/A,#N/A
11/17/2016 LGND-US   BW   EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Ligand Pharmaceuticals Incorporated - LGND,#N/A, 3/08/2017 ILMN-US     BW   MLL Münchner Leukämielabor wählt IBM Watson und Illumina für Forschungszusammenarbeit zur Vervollkommnung der Diagnostik und Entwicklung personalisierter Behandlungsinstrumente bei Leukämie und Lymphomen,"11/14/2016 SPPI-US   BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Spectrum Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 21, 2016",#N/A, 9/27/2017 ARWR-US  BW   Arrowhead Data Reveal Important Considerations for Future Hepatitis B Treatment,#N/A,#N/A,#N/A,#N/A
11/15/2016 LGND-US   BW   SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,#N/A, 3/08/2017 ILMN-US     BW   Le Munich Leukemia Laboratory lance avec IBM Watson et Illumina une recherche collaborative visant à améliorer les diagnostics et à mettre au point des traitements personnalisés contre la leucémie et le lymphome,11/14/2016 84763A10  BW   Spectrum Pharmaceuticals Provides Third Quarter Financial Update,#N/A, 9/14/2017 ARWR-US  BW   Arrowhead Hosts Investor & Analyst R&D Day to Introduce TRiM™ Platform and Lead RNAi-based Drug Candidates,#N/A,#N/A,#N/A,#N/A
"11/15/2016 LGND-US   BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Violations of Federal Securities Laws by Certain Officers and Directors of Ligand Pharmaceuticals, Inc.",#N/A, 3/08/2017 ILMN-US     BW   CORRECTING and REPLACING Munich Leukemia Laboratory Selects IBM Watson and Illumina for Research Collaboration to Advance Diagnostics and Develop Personalized Treatment Tools for Leukemia & Lymphoma,"11/09/2016 SPPI-US   BW   IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Spectrum Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A, 9/11/2017 ARWR-US  BW   Arrowhead to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A
11/15/2016 LGND-US   BW   IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Ligand Pharmaceuticals Incorporated and Advises Investors with Losses to Contact the Firm,#N/A," 2/28/2017 45232710    BW   Illumina Announces the iHope Network, an Expansion of Its iHope Philanthropic Clinical Whole Genome Sequencing Program","11/09/2016 SPPI-US   BW   SPPI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Shareholders of a Class Action Involving Spectrum Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of November 21, 2016",#N/A, 9/01/2017 ARWR-US  BW   Arrowhead Pharmaceuticals to Host R&D Day on RNAi-Based Therapies,#N/A,#N/A,#N/A,#N/A
11/03/2016 LGND-US   BW   Ligand Reports Third Quarter 2016 Financial Results,#N/A, 2/21/2017 ILMN-US     BW   Illumina to Webcast Live Presentation at the Cowen and Company Annual Health Care Conference,11/03/2016 84763A10  BW   Spectrum Pharmaceuticals Provides Third Quarter Financial and Pipeline Update,#N/A, 8/03/2017 ARWR-US  BW   Arrowhead Reports Fiscal 2017 Third Quarter Results,#N/A,#N/A,#N/A,#N/A
10/24/2016 06CR5C-E  BW   Ligand Partner Melinta Therapeutics Submits Baxdela New Drug Application for Hospital-Treated Skin Infections,#N/A," 2/20/2017 UPS-US      BW   Illumina Names John W. Thompson to Its Board of Directors, Bringing More Than 40 Years of Technology Leadership to Illumina","10/31/2016 SPPI-US   BW   INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Spectrum Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A, 7/27/2017 ARWR-US  BW   Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Third Quarter Results,#N/A,#N/A,#N/A,#N/A
10/13/2016 LGND-US   BW   Ligand Announces Third Quarter 2016 Earnings Release Date and Participation in the Stephens Fall Investment Conference,#N/A," 2/03/2017 ILMN-US     BW   ILMN SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Illumina, Inc. and a Lead Plaintiff Deadline of February 14, 2017","10/31/2016 SPPI-US   BW   GPM Reminds Investors of the November 21st Deadline in the Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm",#N/A, 6/09/2017 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A
10/07/2016 LGND-US   BW   Ligand Partner Lundbeck Receives FDA Approval of Carnexiv™ (carbamazepine) Injection as Intravenous Short-Term Replacement Therapy for Certain Seizure Types,#N/A," 2/01/2017 ILMN-US     BW   Investor Alert: GPM Reminds Investors of the February 14 Deadline in the Class Action Lawsuit Against Illumina, Inc.",10/27/2016 84763A10  BW   Spectrum Pharmaceuticals Announces Third Quarter 2016 Financial Results Teleconference and Webcast,#N/A, 5/03/2017 ARWR-US  BW   Arrowhead Reports Fiscal 2017 Second Quarter Results,#N/A,#N/A,#N/A,#N/A
 9/22/2016 LGND-US   BW   Ligand Licenses Four Programs to Seelos Therapeutics,#N/A, 1/31/2017 45232710    BW   Illumina Reports Full Financial Results for Fourth Quarter and Fiscal Year 2016,"10/18/2016 84763A10  BW   Spectrum Pharmaceuticals Announces Appointment of Luigi Lenaz, M.D., as Lead Director",#N/A, 4/26/2017 ARWR-US  BW   Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results,#N/A,#N/A,#N/A,#N/A
" 9/16/2016 LGND-US   BW   Ligand Enters OmniAb® License Agreement with TeneoBio, Inc.",#N/A," 1/30/2017 45232710    BW   Illumina präsentiert Analysesoftware VeriSeq™ (48 Proben), optimierte Datenanalyse für nicht-invasive pränatale Diagnostik","10/11/2016 SPPI-US   BW   SPPI LOSS NOTICE: Rosen Law Firm Reminds Spectrum Pharmaceuticals, Inc. Investors of Important Deadline in Class Action Filed by Firm - SPPI",#N/A, 4/24/2017 ARWR-US  BW   Arrowhead Pharmaceuticals Presents ARC-AAT Clinical Data at The International Liver Congress™,#N/A,#N/A,#N/A,#N/A
 9/13/2016 LGND-US   BW   Ligand Initiates Phase 2 Trial with LGD-6972 in Type 2 Diabetes,#N/A," 1/30/2017 45232710    BW   Illumina Debuts VeriSeq™ Analysis Software (48 Samples), Optimized Data Analysis for Noninvasive Prenatal Testing"," 9/23/2016 SPPI-US   BW   INVESTOR ALERT: Investigation of Spectrum Pharmaceuticals, Inc. Announced by Law Offices of Howard G. Smith",#N/A, 4/20/2017 ARWR-US  BW   Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress™,#N/A,#N/A,#N/A,#N/A
 9/07/2016 LGND-US   BW   Ligand Partner Retrophin Announces Positive Top-Line Results from Phase 2 DUET Study of Sparsentan in Patients with Focal Segmental Glomerulosclerosis,#N/A," 1/30/2017 45232710    BW   Illumina lance le logiciel d'analyse VeriSeq™ (48 échantillons), avec analyse optimisée des données pour tests prénataux non invasifs"," 9/21/2016 SPPI-US   BW   SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Spectrum Pharmaceuticals, Inc. To Contact The Firm",#N/A, 4/05/2017 ARWR-US  BW   Arrowhead Pharmaceuticals Announces Presentations at The International Liver Congress™,#N/A,#N/A,#N/A,#N/A
 9/02/2016 MS-US     BW   Ligand to Participate in Two Upcoming Investor Conferences,#N/A," 1/27/2017 45232710    BW   Illumina Names Caroline Dorsa to Its Board of Directors, Adding Over 30 Years of Leadership Experience in the Healthcare, Telecommunications and Energy Industries"," 9/20/2016 SPPI-US   BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Spectrum Pharmaceuticals, Inc.",#N/A, 3/23/2017 ARWR-US  BW   Arrowhead Pharmaceuticals Adopts Stockholder Rights Agreement,#N/A,#N/A,#N/A,#N/A
 9/01/2016 NTEC-IL   BW   Intec Pharma Reports First Half 2016 Financial Results,#N/A," 1/26/2017 ILMN-US     BW   February 14 Deadline Alert: Law Offices of Howard G. Smith Reminds Illumina, Inc. Investors of Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm"," 9/19/2016 SPPI-US   BW   IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Spectrum Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A, 2/06/2017 ARWR-US  BW   Arrowhead Reports Fiscal 2017 First Quarter Results,#N/A,#N/A,#N/A,#N/A
" 8/15/2016 LGND-US   BW   Results from Phase 1 Trials with Ligand’s LGD-6972 in Type 2 Diabetes Mellitus Published in Diabetes, Obesity and Metabolism",#N/A," 1/23/2017 ILMN-US     BW   INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Illumina, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 14, 2017"," 9/19/2016 SPPI-US   BW   EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Spectrum Pharmaceuticals, Inc.",#N/A, 1/30/2017 ARWR-US  BW   Arrowhead Pharmaceuticals to Webcast Fiscal 2017 First Quarter Results,#N/A,#N/A,#N/A,#N/A
 8/04/2016 LGND-US   BW   Ligand Reports Second Quarter 2016 Financial Results,#N/A," 1/17/2017 45232710    BW   Illumina to Announce Fourth Quarter and Fiscal Year 2016 Financial Results on Tuesday, January 31, 2017"," 9/16/2016 SPPI-US   BW   INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Spectrum Pharmaceuticals, Inc.",#N/A," 1/20/2017 ARWR-US  BW   Robbins Arroyo LLP: Arrowhead Pharmaceuticals, Inc. (ARWR) Misled Shareholders According to a Recently Filed Class Action",#N/A,#N/A,#N/A,#N/A
 7/29/2016 LGND-US   BW   Ligand Announces Multi-Program LTP Technology Licensing Agreement with Nucorion Pharmaceuticals,#N/A," 1/12/2017 08JRVQ-E    BW   Illumina, NRGene Collaborate to Accelerate Development of New Molecular Breeding Tools for Cattle to Support Global Food Production", 9/14/2016 06CR5C-E  BW   FDA Advisory Committee Votes that Qapzola™ (apaziquone) Has Not Shown Substantial Evidence of a Treatment Effect Over Placebo,#N/A," 1/09/2017 ARWR-US  BW   INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Arrowhead Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 – ARWR",#N/A,#N/A,#N/A,#N/A
 7/14/2016 LGND-US   BW   Ligand to Report Second Quarter Results on August 4th,#N/A," 1/09/2017 ILMN-US     BW   IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm", 8/09/2016 84763A10  BW   Spectrum Pharmaceuticals Reports Second Quarter 2016 Financial Results and Pipeline Update,#N/A, 1/09/2017 ARWR-US  BW   Arrowhead Provides Response to New Minority Shareholder Announcement,#N/A,#N/A,#N/A,#N/A
 7/08/2016 LGND-US   BW   Ligand Enters into OmniAb® Platform License Agreement with Gilead Sciences,#N/A, 1/09/2017 45232710    BW   Illumina and Bio-Rad Launch Solution for Single-Cell Genomic Sequencing to Enable Robust Study of Complex Diseases, 8/02/2016 84763A10  BW   Spectrum Pharmaceuticals Announces Second Quarter 2016 Financial Results Teleconference and Webcast,#N/A," 1/07/2017 ARWR-US  BW   DEADLINE ALERT: Brower Piven Reminds Investors Of The January 16, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Arrowhead Pharmaceuticals, Inc. To Contact The Firm",#N/A,#N/A,#N/A,#N/A
 6/30/2016 0DF0L8-E  BW   Ligand Receives $4 Million from Expansion of Two OmniAb® License Agreements,#N/A, 1/09/2017 45232710    BW   Illumina Introduces the NovaSeq Series—a New Architecture Designed to Usher in the $100 Genome, 7/27/2016 SPPI-US   BW   Onxeo signe un accord de licence exclusive avec Pint Pharma pour la commercialisation de Beleodaq® en Amérique du Sud dans le domaine du PTCL,#N/A,"12/21/2016 ARWR-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Arrowhead Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017",#N/A,#N/A,#N/A,#N/A
 5/04/2016 LGND-US   BW   Ligand Reports First Quarter 2016 Financial Results,#N/A, 1/05/2017 45232710    BW   GRAIL Plans to Raise in Excess of $1B in Series B Funding, 7/13/2016 SPPI-US   BW   Spectrum Pharmaceuticals Settles FOLOTYN® (pralatrexate injection) ANDA Patent Litigation,#N/A,12/14/2016 ARWR-US  BW   Arrowhead Reports Fiscal 2016 Year End Results,#N/A,#N/A,#N/A,#N/A
 5/04/2016 00B680-E  BW   Ligand Acquires Portfolio of Synthetic Royalty and Milestone Rights from CorMatrix® Cardiovascular for $17.5 Million,#N/A," 1/03/2017 45232710    BW   Illumina Taps Garret Hampton, One of the World’s Leading Clinical Genomics Experts, to Head its Clinical Genomics Unit", 7/06/2016 SPPI-US   BW   Spectrum Pharmaceuticals to Present Corporate Update at the Cantor Fitzgerald’s 2nd Annual Healthcare Conference on July 13th,#N/A,"12/08/2016 ARWR-US  BW   ARWR NOTICE: Rosen Law Firm Reminds Arrowhead Pharmaceuticals, Inc. Investors of Important Deadline in Class Action - ARWR",#N/A,#N/A,#N/A,#N/A
 4/22/2016 LGND-US   BW   Ligand Announces First Quarter 2016 Earnings Reporting Date and Participation in Four Upcoming Investor Conferences,#N/A,"12/28/2016 ILMN-US     BW   INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Illumina, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit", 6/01/2016 SPPI-US   BW   Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2016 Healthcare Conference on June 8th,#N/A,12/07/2016 ARWR-US  BW   Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results,#N/A,#N/A,#N/A,#N/A
 4/07/2016 071VWR-E  BW   Revolade® Approved in EU as First in Class Therapy for Children Aged 1 Year and Above with Chronic ITP,#N/A,12/27/2016 ILMN-US     BW   Illumina to Webcast Live Presentation at the J.P. Morgan Annual Healthcare Conference  ," 5/06/2016 84763A10  BW   Spectrum Pharmaceuticals Highlights an Oral Presentation on Apaziquone at the 2016 Annual Meeting of the American Urological Association Education and Research Inc. (AUA) in San Diego, California, May 6-10, 2016",#N/A,"11/30/2016 ARWR-US  BW   The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Arrowhead Pharmaceuticals, Inc. Investors and Encourages Investors to Contact the Firm",#N/A,#N/A,#N/A,#N/A
 3/28/2016 LGND-US   BW   Ligand Enters Into OmniAb® Platform License Agreement With ABBA Therapeutics,#N/A,"12/20/2016 45232710    BW   Illumina Names Jonathan Seaton as Senior Vice President for Corporate & Business Development, Adding Further Clinical and Life Sciences Expertise to its Executive Team", 5/05/2016 84763A10  BW   Spectrum Pharmaceuticals Reports First Quarter 2016 Financial Results and Pipeline Update,#N/A,11/29/2016 ARWR-US  BW   Arrowhead Pharmaceuticals Focuses Resources on Subcutaneous and Extra-Hepatic RNAi Therapeutics,#N/A,#N/A,#N/A,#N/A
 3/15/2016 06CR5C-E  BW   Ligand Partner Spectrum Pharmaceuticals Receives FDA Approval of EVOMELA™ (melphalan) for Injection,#N/A,"12/17/2016 ILMN-US     BW   IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm", 5/03/2016 SPPI-US   BW   Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2016 Healthcare Conference on May 10th,#N/A,"11/25/2016 ARWR-US  BW   INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Arrowhead Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit",#N/A,#N/A,#N/A,#N/A
 2/10/2016 LGND-US   BW   Ligand Reports Fourth Quarter and Full Year 2015 Financial Results,#N/A,"12/16/2016 ILMN-US     BW   Glancy Prongay & Murray LLP Files Securities Class Action Lawsuit Against Illumina, Inc.", 4/28/2016 84763A10  BW   Spectrum Pharmaceuticals Announces First Quarter 2016 Financial Results Teleconference and Webcast,#N/A,11/21/2016 ARWR-US  BW   Arrowhead Pharmaceuticals Announces Closing of License and Collaboration Agreement with Amgen,#N/A,#N/A,#N/A,#N/A
 2/02/2016 LGND-US   BW   Ligand Enters Into OmniAb® Platform License Agreement with Tizona Therapeutics,#N/A,"12/07/2016 45232710    BW   Illumina Extends Management Team, Appoints Sam A. Samad as Senior Vice President and Chief Financial Officer"," 4/20/2016 06CR5C-E  BW   FDA Grants Orphan Drug Exclusivity to EVOMELA™ (melphalan) for Injection, Indicated for Multiple Myeloma",#N/A,"11/19/2016 ARWR-US  BW   IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A,#N/A,#N/A,#N/A
 1/22/2016 LGND-US   BW   Ligand to Report Fourth Quarter and Full Year 2015 Results on February 10th,#N/A,12/01/2016 45232710    BW   Illumina Launches iHope Program to Identify Causes of Undiagnosed Genetic Diseases in Children, 3/15/2016 06CR5C-E  BW   Ligand Partner Spectrum Pharmaceuticals Receives FDA Approval of EVOMELA™ (melphalan) for Injection,#N/A,"11/18/2016 ARWR-US  BW   SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A,#N/A,#N/A,#N/A
 1/13/2016 LGND-US   BW   Ligand Enters Into OmniAb® Platform License Agreement with Emergent BioSolutions,#N/A,11/30/2016 YELP-US     BW   Splunk Customers Demonstrate Success on the AWS Cloud, 3/15/2016 06CR5C-E  BW   FDA Grants Spectrum Pharmaceuticals Approval of EVOMELA™ (melphalan) for Injection,#N/A,"11/16/2016 ARWR-US  BW   IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A,#N/A,#N/A,#N/A
"12/17/2015 LGND-US   BW   Ligand to Acquire OMT, Inc., a Leader in Human Antibody Generation, for $178 Million in Cash and Stock",#N/A,11/28/2016 C-US        BW   Illumina to Webcast Live Presentation at the Citi Global Healthcare Conference, 3/09/2016 84763A10  BW   Spectrum Pharmaceuticals Reports Fourth Quarter 2015 and Full Year 2015 Financial Results and Pipeline Update,#N/A,11/14/2016 ARWR-US  BW   Arrowhead Pharmaceuticals Presents New Data on ARC-F12 and ARC-LPA Using DPCsqTM Subcutaneous RNAi Delivery Vehicle,#N/A,#N/A,#N/A,#N/A
12/08/2015 LGND-US   BW   RODES Signs Exclusive Captisol® Licensing Agreement with Ligand Pharmaceuticals for Three Programs,#N/A,11/10/2016 063VST-E    BW   Illumina and Mayo Clinic Form Bioinformatics Relationship to Advance Genetic Disorder Testing," 3/07/2016 84763A10  BW   Spectrum Pharmaceuticals Initiates Phase 2 Breast Cancer Trial for Poziotinib, a Novel Pan-HER Inhibitor",#N/A,11/14/2016 ARWR-US  BW   Arrowhead Pharmaceuticals Presents New Data on ARC-AAT,#N/A,#N/A,#N/A,#N/A
11/18/2015 LGND-US   BW   Ligand Provides Highlights from Today’s Analyst Day Event,#N/A,11/07/2016 45232710    BW   Illumina Launches TruSight Tumor 170, 3/02/2016 84763A10  BW   Spectrum Pharmaceuticals Announces Fourth Quarter and Full Year 2015 Financial Results Teleconference and Webcast,#N/A,"11/09/2016 ARWR-US  BW   SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Arrowhead Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm",#N/A,#N/A,#N/A,#N/A
11/09/2015 LGND-US   BW   Ligand Reports Third Quarter 2015 Financial Results,#N/A,11/01/2016 45232710    BW   Illumina Reports Full Financial Results for Third Quarter of Fiscal Year 2016, 2/22/2016 RY-CA     BW   Spectrum Pharmaceuticals to Present Corporate Update at 2016 RBC Capital Markets' Global Healthcare Conference on February 24,#N/A,"11/09/2016 ARWR-US  BW   INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Arrowhead Pharmaceuticals, Inc. Investors",#N/A,#N/A,#N/A,#N/A
10/20/2015 LGND-US   BW   Ligand to Report Third Quarter Results on November 9th,#N/A,10/28/2016 ILMN-US     BW   INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Illumina Inc. and Advises Investors with Losses to Contact the Firm, 2/19/2016 SPPI-US   BW   Spectrum Pharmaceuticals Announces FDA’s Acceptance of NDA Filing for EOquin® (apaziquone for intravesical instillation),#N/A,"11/09/2016 ARWR-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Arrowhead Pharmaceuticals, Inc. -- ARWR",#N/A,#N/A,#N/A,#N/A
10/12/2015 LGND-US   BW   Ligand to Host Analyst Day on November 18th in New York City,#N/A,10/24/2016 45232710    BW   German Court Issues Preliminary Injunction Against amedes Fetalis® Test for Infringement of Non-Invasive Prenatal Screening Patent, 2/04/2016 EGRX-US   BW   Eagle Pharmaceuticals Announces Appointment of Michael Moran as U.S. Head of Sales,#N/A,11/08/2016 ARWR-US  BW   Arrowhead Pharmaceuticals Provides Update on Heparc-2004 Study,#N/A,#N/A,#N/A,#N/A
 9/29/2015 LGND-US   BW   Ligand Expands Captisol License and Supply Agreements with SAGE Therapeutics to Include SAGE-689,#N/A,10/24/2016 IQV-US      BW   Q2 Solutions Enhances Companion Diagnostics Capabilities in Collaboration with Illumina," 1/29/2016 84763A10  BW   Spectrum Pharmaceuticals Begins Enrolling Patients in Registrational Trial of SPI-2012, a Novel, Long Acting G-CSF in Patients with Breast Cancer",#N/A,11/01/2016 CS-CH    BW   Arrowhead Pharmaceuticals to Present at Upcoming Conferences,#N/A,#N/A,#N/A,#N/A
 9/02/2015 LGND-US   BW   Revolade® Receives EU Approval as First-in-Class Therapy for Patients with Severe Aplastic Anemia,#N/A,10/21/2016 ILMN-US     BW   IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Illumina Inc. and Encourages Investors with Losses to Contact the Firm, 1/11/2016 84763A10  BW   Spectrum Pharmaceuticals Signs a Strategic Partnership With Servier Canada,#N/A,10/20/2016 06VHPT-E BW   Arrowhead Pharmaceuticals to Present Data on ARC-AAT at The Liver Meeting®,#N/A,#N/A,#N/A,#N/A
 8/24/2015 LGND-US   BW   FDA Expands Use of Promacta® to Include Treatment of Children Ages 1 and Older with Chronic Immune Thrombocytopenia,#N/A,"10/21/2016 ILMN-US     BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Illumina Inc.","12/16/2015 SPPI-US   BW   Spectrum Pharmaceuticals Announces Agreement with FDA on the Special Protocol Assessment (SPA) for the Registrational Trial of SPI-2012, a Novel, Long Acting G-CSF in Patients with Breast Cancer",#N/A,10/06/2016 SBPH-US  BW   Arrowhead and Spring Bank Announce Clinical Collaboration for ARC-520 and SB 9200 in Chronic Hepatitis B,#N/A,#N/A,#N/A,#N/A
 8/04/2015 LGND-US   BW   Matthew Korenberg to Join Ligand Pharmaceuticals as Chief Financial Officer,#N/A,10/20/2016 ILMN-US     BW   SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Illumina Inc. and Advises Investors with Losses to Contact the Firm,"12/15/2015 SPPI-US   BW   TheGrantLawFirm, PLLC Withdraws Action on Behalf of Spectrum Pharmaceuticals, Inc. Purchasers",#N/A, 9/07/2016 ARWR-US  BW   Arrowhead Pharmaceuticals Doses First Patient with Hepatitis B in Multiple Ascending Dose Portion of Phase 1/2 Study of ARC-521,#N/A,#N/A,#N/A,#N/A
 8/04/2015 LGND-US   BW   Ligand Reports Second Quarter 2015 Financial Results,#N/A,10/20/2016 09WJ1Y-E    BW   Illumina Contributes to ClinVar Database,"12/09/2015 SPPI-US   BW   Spectrum Pharmaceuticals, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors",#N/A, 9/06/2016 ARWR-US  BW   Arrowhead Pharmaceuticals Initiates Phase 2 Study of ARC-AAT,#N/A,#N/A,#N/A,#N/A
 7/30/2015 LGNZZ-US  BW   Ligand Enters into Commercial License and Supply Agreement with Sanofi for Captisol-enabled SAR-125844,#N/A,10/10/2016 45232710    BW   Illumina Announces Preliminary Revenue for Third Quarter of Fiscal Year 2016,12/08/2015 84763A10  BW   Spectrum Pharmaceuticals Highlights Four Abstracts on SPI-2012 and Poziotinib at the San Antonio Breast Cancer Symposium (SABCS),#N/A, 9/01/2016 ARWR-US  BW   Arrowhead Pharmaceuticals to Present at Upcoming September Conferences,#N/A,#N/A,#N/A,#N/A
" 7/24/2015 LGND-US   BW   Revolade® Recommended by CHMP for EU Approval to Treat Patients with Severe Aplastic Anemia, a Serious Blood Disorder",#N/A, 9/21/2016 009FRV-E    BW   Quanterix and Illumina Founder to Present Novel Approach to Cancer Diagnostics at Powering Precision Health 2016,12/06/2015 SPPI-US   BW   Spectrum Pharmaceuticals and Onxeo Announce Complete Response in 67% of Patients with Peripheral T-Cell Lymphoma in Combination of Belinostat (Beleodaq®) and Standard CHOP,#N/A, 8/12/2016 0677K4-E BW   Arrowhead Pharmaceuticals Closes $45 Million Private Offering,#N/A,#N/A,#N/A,#N/A
 7/16/2015 LGND-US   BW   Ligand to Report Second Quarter Results on August 4th,#N/A, 8/30/2016 MS-US       BW   Illumina to Webcast Live Presentation at the Morgan Stanley Global Healthcare Conference,"12/04/2015 SPPI-US   BW   Spectrum Pharmaceuticals Highlights 18 Abstracts at the 57th Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida, December 5-8, 2015",#N/A, 8/09/2016 ARWR-US  BW   Arrowhead Reports Fiscal 2016 Third Quarter Results,#N/A,#N/A,#N/A,#N/A
 6/17/2015 53220K50  BW   Ligand to Participate in Four Upcoming Investor Conferences,#N/A," 8/10/2016 45232710    BW   Illumina and FlowJo, LLC Partner to Develop and Co-Market a Software Solution for Single Cell Genomics",11/20/2015 SPPI-US   BW   Spectrum Pharmaceuticals Submits Phase 2 Breast Cancer Protocol to FDA as Part of an Investigational New Drug (IND) Application for Poziotinib,#N/A, 8/09/2016 ARWR-US  BW   Arrowhead Pharmaceuticals Prices $45 Million Private Offering,#N/A,#N/A,#N/A,#N/A
 6/12/2015 LGND-US   BW   FDA Approves Promacta® for New Pediatric Chronic Immune Thrombocytopenia (cITP) Indication,#N/A, 7/28/2016 ILMN-US     BW   Illumina Names Philip W. Schiller to its Board of Directors,11/18/2015 84763A10  BW   Spectrum Pharmaceuticals Divests Rights to ZEVALIN® (ibritumomab tiuxetan) in Japan and Select Other Ex-US Countries to Mundipharma,#N/A, 8/01/2016 ARWR-US  BW   Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Third Quarter Results,#N/A,#N/A,#N/A,#N/A
 6/07/2015 LGND-US   BW   Ligand Announces Favorable Results From Phase 1b Trial With LGD-6972 in Type 2 Diabetes and Plans to Initiate a Phase 2 Trial,#N/A, 7/26/2016 45232710    BW   Illumina Reports Financial Results for Second Quarter of Fiscal Year 2016,"11/04/2015 SPPI-US   BW   IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. and Strongly Encourages Shareholders to Contact the Firm",#N/A, 7/06/2016 ARWR-US  BW   Arrowhead Pharmaceuticals to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference,#N/A,#N/A,#N/A,#N/A
 6/05/2015 53220K50  BW   Ligand Announces New Time for June 7th Investor Presentation and Webcast at the American Diabetes Association 75th Scientific Sessions,#N/A," 7/12/2016 45232710    BW   Illumina to Announce Second Quarter 2016 Financial Results on Tuesday, July 26, 2016",11/04/2015 EGRX-US   BW   Eagle Pharmaceuticals and Spectrum Pharmaceuticals Announce Co-Promotion Agreement,#N/A, 6/09/2016 ARWR-US  BW   Arrowhead Pharmaceuticals Initiates Phase 1/2 Single and Multiple Dose Study of Hepatitis B Candidate ARC-521,#N/A,#N/A,#N/A,#N/A
" 6/02/2015 53220K50  BW   Ligand Summarizes the Accounting Impact of the Viking Therapeutics, Inc. IPO and Updates 2015 Financial Guidance",#N/A, 7/07/2016 06CR5C-E    BW   Illumina Applauds FDA’s Issuance of Draft Guidances to Advance Precision Medicine Using Next Generation Sequencing,11/04/2015 84763A10  BW   Spectrum Pharmaceuticals Reports Third Quarter 2015 Financial Results and Pipeline Update,#N/A, 6/03/2016 ARWR-US  BW   Arrowhead Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference,#N/A,#N/A,#N/A,#N/A
 5/11/2015 53220K50  BW   Ligand Reports First Quarter 2015 Financial Results,#N/A," 7/07/2016 ENZ-US      BW   Enzo Biochem’s Life Sciences Unit Reaches $21 Million Patent Infringement Settlement in Delaware With Illumina, Inc.",11/02/2015 84763A10  BW   Spectrum Pharmaceuticals Announces Third Quarter 2015 Financial Results Teleconference and Webcast,#N/A, 5/10/2016 ARWR-US  BW   Arrowhead Reports Fiscal 2016 Second Quarter Results,#N/A,#N/A,#N/A,#N/A
 5/11/2015 LGND-US   BW   Ligand Acquires Rights to More Than 15 Fully-Funded Development Programs from Selexis SA,#N/A, 6/16/2016 07B3VF-E    BW   Illumina Announces Initial Customer Orders for the Global Screening Array,10/26/2015 84763A10  BW   Spectrum Pharmaceuticals Initiates Apaziquone Pivotal Trial for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) Following SPA Agreement,#N/A, 5/06/2016 ARWR-US  BW   Arrowhead Pharmaceuticals’ Preclinical Candidate ARC-LPA Achieves 98% Knockdown and Long Duration of Effect after Subcutaneous Administration,#N/A,#N/A,#N/A,#N/A
 5/07/2015 53220K50  BW   Ligand to Present Results of LGD-6972 Phase 1b Trial at American Diabetes Association 75th Scientific Sessions on June 7th and Host Investor Presentation,#N/A, 6/13/2016 ILMN-US     BW   Xcell Biosciences to Present Data From its Avatar System at ISSCR Annual Meeting,"10/23/2015 SPPI-US   BW   SHAREHOLDER ALERT: L & K Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Spectrum Pharmaceuticals, Inc. and Certain Officers and Directors",#N/A, 5/03/2016 ARWR-US  BW   Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Second Quarter Results,#N/A,#N/A,#N/A,#N/A
 5/05/2015 53220K50  BW   Ligand Partner Viking Therapeutics Announces Closing of Initial Public Offering,#N/A, 6/07/2016 45232710    BW   Illumina Announces Donald Danforth Plant Science Center to Receive Agricultural Greater Good Initiative Grant to Improve Food Security in Sub-Saharan Africa,10/23/2015 84763A10  BW   Spectrum Pharmaceuticals Receives Complete Response Letter (CRL) from U.S. Food and Drug Administration (FDA) for EVOMELA™ (melphalan) for Injection,#N/A, 4/29/2016 ARWR-US  BW   Arrowhead Pharmaceuticals to Present at Upcoming May Conferences,#N/A,#N/A,#N/A,#N/A
 4/29/2015 LGND-US   BW   Ligand Partner Viking Therapeutics Announces Pricing of Initial Public Offering,#N/A, 6/06/2016 0DBFR7-E    BW   ArcherDX Partners with Illumina to Bring Leading Fusion Oncology Assays to Global Markets, 9/03/2015 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Rodman & Renshaw 17th Annual Global Investment Conference on September 10th,#N/A, 4/28/2016 ARWR-US  BW   Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521,#N/A,#N/A,#N/A,#N/A
 4/24/2015 53220K50  BW   Ligand to Participate in Two Upcoming Investor Conferences,#N/A," 6/02/2016 45232710    BW   Illumina Appoints Paula Dowdy Senior Vice President and General Manager of Commercial Operations for Europe, the Middle East and Africa", 9/02/2015 84763A10  BW   Spectrum Pharmaceuticals Announces Publication of Pivotal EVOMELA™ (melphalan hydrochloride) for Injection Data in the Biology of Blood and Marrow Transplantation Journal,#N/A, 4/18/2016 ARWR-US  BW   Arrowhead Pharmaceuticals Presents Preclinical Data on Renal Cell Carcinoma Program at AACR 2016,#N/A,#N/A,#N/A,#N/A
 4/23/2015 53220K50  BW   Ligand to Report First Quarter Results on May 11th,#N/A," 6/02/2016 45232710    BW   Illumina nomme Paula Dowdy au poste de vice-présidente principale et directrice générale des opérations commerciales pour la région Europe, Moyen-Orient et Afrique", 8/17/2015 SPPI-US   BW   Spectrum Pharmaceuticals Announces Agreement with FDA on the Special Protocol Assessment (SPA) for the Upcoming Apaziquone Phase 3 Trial in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC),#N/A, 4/13/2016 ARWR-US  BW   Arrowhead Pharmaceuticals Presents Promising ARC-520 Hepatitis B Data at The International Liver Congress™ 2016,#N/A,#N/A,#N/A,#N/A
 4/23/2015 53220K50  BW   Ligand Names Melanie J. Herman Interim Chief Financial Officer,#N/A," 6/02/2016 45232710    BW   Illumina ernennt Paula Dowdy als Senior Vice President und General Manager of Commercial Operations für Europa, den Nahen Osten und Afrika", 8/06/2015 84763A10  BW   Spectrum Pharmaceuticals Reports Second Quarter 2015 Financial Results and Pipeline Update,#N/A, 4/06/2016 ARWR-US  BW   Arrowhead Research Changes Name to Arrowhead Pharmaceuticals,#N/A,#N/A,#N/A,#N/A
 4/22/2015 LGND-US   BW   Ligand Earns Milestone from SAGE Therapeutics for SAGE-547,#N/A, 5/31/2016 0DBFR7-E    BW   ArcherDX to Collaborate with Illumina on Next-Generation Sequencing-Based In Vitro Diagnostics Development, 7/30/2015 84763A10  BW   Spectrum Pharmaceuticals Announces Second Quarter 2015 Financial Results Teleconference and Webcast,#N/A, 3/30/2016 ARWR-US  BW   Arrowhead to Present at Upcoming April Conferences,#N/A,#N/A,#N/A,#N/A
 4/20/2015 53220K50  BW   Ligand Partner TG Therapeutics Presents Positive Pre-clinical Data on IRAK4 Compounds at the American Association for Cancer Research (AACR) Annual Meeting,#N/A, 5/25/2016 GS-US       BW   Illumina to Webcast Live Presentation at Upcoming Investment Conferences in June, 6/24/2015 SPPI-US   BW   Spectrum Pharmaceuticals Announces Publication of Beleodaq® Data Selected as a Rapid Communication in the Journal of Clinical Oncology,#N/A, 3/07/2016 ARWR-US  BW   Arrowhead Presents Promising New Preclinical Data on ARC-F12 at AAAAI 2016,#N/A,#N/A,#N/A,#N/A
 4/14/2015 LGND-US   BW   Ritter Pharmaceuticals Names Paul V. Maier to its Board of Directors,#N/A, 5/09/2016 45232710    BW   Illumina Registers MiSeqDx System in South Korea," 5/29/2015 84763A10  BW   Spectrum Pharmaceuticals Highlights Five Abstracts of Clinical Data at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, May 29-June 2, 2015",#N/A, 3/01/2016 BCS-GB   BW   Arrowhead to Present at Upcoming March Conferences,#N/A,#N/A,#N/A,#N/A
 3/03/2015 53220K50  BW   Ligand to Present at the 27th Annual Roth Conference on March 9th,#N/A, 5/09/2016 45232710    BW   Collaborative Study of Whole Exome Sequencing Offers New Hope for Children with White Matter Disorders, 5/28/2015 SPPI-US   BW   Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies Global Healthcare Conference in New York City on June 3rd,#N/A, 2/16/2016 ARWR-US  BW   Arrowhead to Present at Upcoming February Conferences,#N/A,#N/A,#N/A,#N/A
 2/09/2015 53220K50  BW   Ligand Reports Fourth Quarter and Full Year 2014 Financial Results,#N/A, 5/03/2016 45232710    BW   Illumina Reports Financial Results for First Quarter of Fiscal Year 2016, 5/14/2015 SPPI-US   BW   Spectrum Pharmaceuticals Commits to Review Shareholder Proposal,#N/A, 2/09/2016 ARWR-US  BW   Arrowhead Reports Fiscal 2016 First Quarter Results,#N/A,#N/A,#N/A,#N/A
 2/06/2015 53220K50  BW   Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission Seeking Additional Indication for Revolade®,#N/A, 4/27/2016 45232710    BW   Illumina to Webcast Live Presentation at the Bank of America Merrill Lynch Health Care Conference," 5/07/2015 84763A10  BW   Spectrum Pharmaceuticals Reports Continued Advancement of Robust, Late-Stage Pipeline and First Quarter 2015 Financial Results",#N/A, 2/02/2016 ARWR-US  BW   Arrowhead to Webcast Fiscal 2016 First Quarter Results,#N/A,#N/A,#N/A,#N/A
 2/03/2015 53220K50  BW   Ligand Signs License Agreement with Sermonix for Lasofoxifene,#N/A, 4/21/2016 06YV06-E    BW   Illumina Files Patent Infringement Suit in Switzerland against Genoma SA for Infringement of NIPT Patents, 4/30/2015 84763A10  BW   Spectrum Pharmaceuticals Announces First Quarter 2015 Financial Results Teleconference and Webcast,#N/A, 1/19/2016 ARWR-US  BW   Arrowhead’s ARC-AAT Granted EMA Orphan Drug Designation,#N/A,#N/A,#N/A,#N/A
 2/02/2015 53220K50  BW   Ligand Promotes Matthew W. Foehr to President,#N/A, 4/18/2016 45232710    BW   Illumina Announces Preliminary Revenue for First Quarter of Fiscal Year 2016, 4/29/2015 SPPI-US   BW   Spectrum Pharmaceuticals Selects DSG for Blended SaaS and Tech Transfer EDC,#N/A, 1/07/2016 ARWR-US  BW   Arrowhead Begins Dosing the Phase 2b MONARCH Combination Study of ARC-520 in Patients with Chronic Hepatitis B Infection,#N/A,#N/A,#N/A,#N/A
 1/28/2015 53220K50  BW   Ligand to Present at BIO CEO and RBC Capital Markets Global Healthcare Conferences in February,#N/A, 4/14/2016 45232710    BW   Illumina Invests In New Venture Fund," 3/30/2015 84763A10  BW   Spectrum Pharmaceuticals Presents New Data on EVOMELATM (CE-Melphalan), at the Annual Meeting of the American Pharmacists Association (APhA) in San Diego, Highlighting Stability",#N/A,12/14/2015 ARWR-US  BW   Arrowhead Reports Fiscal 2015 Year End Results,#N/A,#N/A,#N/A,#N/A
 1/27/2015 53220K50  BW   Ligand to Report Fourth Quarter Results on February 9th,#N/A, 4/05/2016 45232710    BW   Illumina Introduces BaseSpace® Informatics Suite to Accelerate Genomic Data Analysis for Sequence Labs, 3/13/2015 84763A10  BW   Spectrum Pharmaceuticals Reports Robust Clinical Data and Strong 2014 Financial Results,#N/A,12/14/2015 ARWR-US  BW   Arrowhead Added to NASDAQ Biotechnology Index®,#N/A,#N/A,#N/A,#N/A
 1/09/2015 53220K50  BW   Ligand Partner Retrophin Receives Orphan Drug Designation for Sparsentan,#N/A, 3/07/2016 45232710    BW   Jay Flatley to Assume Role of Executive Chairman of the Board of Directors of Illumina; Francis deSouza Appointed President and CEO," 3/11/2015 84763A10  BW   Four Oncology Key Opinion Leaders to Present at Spectrum Pharmaceuticals’ Analyst Day on Friday, March 13th",#N/A,12/07/2015 ARWR-US  BW   Arrowhead to Webcast Fiscal 2015 Year End Results,#N/A,#N/A,#N/A,#N/A
 1/08/2015 53220K50  BW   Ligand Partner Melinta Therapeutics Reports Positive Phase 3 Results for Captisol-enabled™ Delafloxacin IV,#N/A, 2/24/2016 ILMN-US     BW   Illumina Applies CE Mark to VeriSeq™ NIPT Analysis Software, 3/09/2015 84763A10  BW   Spectrum Pharmaceuticals Announces FDA's Acceptance of NDA Filing for Captisol-Enabled™ (Propylene Glycol-Free) Melphalan,#N/A,12/07/2015 ARWR-US  BW   Arrowhead’s ARC-520 Leads to Consistent Immune Reactivation in Chimpanzees with Chronic Hepatitis B Infection,#N/A,#N/A,#N/A,#N/A
12/26/2014 53220K50  BW   Ligand Partner Spectrum Pharmaceuticals Announces Submission of New Drug Application for Captisol-Enabled™ Melphalan,#N/A, 2/23/2016 45232710    BW   Illumina Sues Oxford Nanopore for Patent Infringement," 3/04/2015 84763A10  BW   Spectrum Pharmaceuticals In-Licenses Poziotinib, a Novel pan-HER Inhibitor With Clinical Activity in Several Solid Tumors, From Hanmi Pharmaceuticals",#N/A,11/16/2015 ARWR-US  BW   Arrowhead Late-Breaking Clinical Data Shows that ARC-520 Can Produce Deep and Durable Reductions of Hepatitis B Viral Antigens and DNA,#N/A,#N/A,#N/A,#N/A
12/22/2014 53220K50  BW   Ligand Partner GlaxoSmithKline Announces US Regulatory Submission Seeking Additional Indication for Promacta®,#N/A, 2/23/2016 0024VM-E    BW   Illumina to Webcast Live Presentation at the Cowen and Company Annual Health Care Conference, 2/20/2015 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the 2015 RBC Capital Markets' Global Healthcare Conference on February 24th,#N/A,11/15/2015 ARWR-US  BW   Arrowhead Presents Data Showing Robust Sustained Anti-viral Effects with ARC-520 in Hepatitis B Infected Chimpanzees,#N/A,#N/A,#N/A,#N/A
12/19/2014 53220K50  BW   Ligand Partner Pfizer Receives European Marketing Authorization for DUAVIVE® (Conjugated Estrogens/Bazedoxifene) for Treatment of Estrogen Deficiency Symptoms in Postmenopausal Women with a Uterus,#N/A, 2/11/2016 ILMN-US     BW   Genomics England Enters Bioinformatics Partnership with Illumina, 2/17/2015 84763A10  BW   Spectrum Pharmaceuticals Announces Fourth Quarter 2014 Financial Results and Analyst Day,#N/A,11/11/2015 ARWR-US  BW   Arrowhead to Present at Upcoming Conferences,#N/A,#N/A,#N/A,#N/A
11/18/2014 53220K50  BW   Ligand Provides Highlights from Today’s Analyst Day Event,#N/A, 2/10/2016 0DLLD6-E    BW   GRAIL Hires Google Executive Jeff Huber as CEO to Lead Development for Early Cancer Detection, 2/12/2015 84763A10  BW   Spectrum Pharmaceuticals Highlights Clinical Data for Captisol-Enabled™ (Propylene Glycol-Free) Melphalan at the 2015 BMT Tandem Meeting,#N/A,10/20/2015 ARWR-US  BW   Arrowhead Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2015,#N/A,#N/A,#N/A,#N/A
11/12/2014 53220K50  BW   Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission for Severe Aplastic Anemia Indication for Revolade™ (eltrombopag),#N/A, 2/10/2016 45232710    BW   Illumina Building Long Read Application Partnerships,12/26/2014 LGND-US   BW   Ligand Partner Spectrum Pharmaceuticals Announces Submission of New Drug Application for Captisol-Enabled™ Melphalan,#N/A,10/14/2015 ARWR-US  BW   Arrowhead Presents Overview of Its Broad RNAi Delivery Platform and Introduces New Subcutaneously Administered Format,#N/A,#N/A,#N/A,#N/A
10/27/2014 53220K50  BW   Ligand Reports Third Quarter 2014 Financial Results,#N/A, 2/02/2016 45232710    BW   Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2015,12/26/2014 84763A10  BW   Spectrum Pharmaceuticals Files a New Drug Application with the FDA for Captisol-Enabled™ (Propylene Glycol-Free) Melphalan,#N/A,10/05/2015 ARWR-US  BW   Arrowhead to Present at Upcoming Conferences,#N/A,#N/A,#N/A,#N/A
10/16/2014 53220K50  BW   Ligand to Host Analyst Day on November 18th in New York City,#N/A, 2/01/2016 ILMN-US     BW   Illumina Signs Multiple Biobank Deals,"12/05/2014 84763A10  BW   Spectrum Pharmaceuticals Highlights 11 Abstracts at the 56th Annual Meeting of the American Society of Hematology (ASH) in San Francisco, California, December 6-9, 2014",#N/A, 9/24/2015 ARWR-US  BW   Arrowhead Reports Peak Reduction in HBsAg of Up to 99% (1.9 log) After a Single Dose with Hepatitis B Candidate ARC-520 in Treatment Naïve Cohort of Phase 2a Study,#N/A,#N/A,#N/A,#N/A
10/08/2014 53220K50  BW   Ligand Reports Third Quarter Revenues and Expected Diluted EPS,#N/A, 1/28/2016 45232710    BW   Illumina Appoints Dr. Frances Arnold to Its Board of Directors,11/12/2014 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2014 Global London Healthcare Conference on November 19th,#N/A, 9/11/2015 ARWR-US  BW   Arrowhead Nominates ARC-HIF2 As First RNAi Therapeutic Candidate Using Extrahepatic DPC™ Delivery System,#N/A,#N/A,#N/A,#N/A
 9/26/2014 53220K50  BW   Ligand Earns Milestone Payment Triggered by EU Approval of Merck’s Captisol-enabled NOXAFIL® (posaconazole) Concentrate for Solution for Infusion,#N/A," 1/19/2016 45232710    BW   Illumina to Announce Fourth Quarter and Fiscal Year 2015 Financial Results on Tuesday, February 2, 2016",11/06/2014 84763A10  BW   Spectrum Pharmaceuticals Reports Strong Product Sales for the Third Quarter 2014; Sales of $47.9 Million up 15.6% Over Last Year,#N/A, 9/10/2015 ARWR-US  BW   Arrowhead to Webcast Analyst Day Presentation on Hepatitis B Candidate ARC-520,#N/A,#N/A,#N/A,#N/A
" 9/09/2014 LGND-US   BW   Ligand Licenses Captisol-enabled™ Lamotrigine to CURx Pharmaceuticals, Inc.",#N/A, 1/11/2016 ILMN-US     BW   Bio-Rad and Illumina to Co-Develop Comprehensive Solution for Single-Cell Genomics,10/30/2014 84763A10  BW   Spectrum Pharmaceuticals Announces Third Quarter 2014 Financial Results Teleconference and Webcast,#N/A, 8/05/2015 ARWR-US  BW   Arrowhead to Present at Jefferies 2015 Hepatitis B Summit,#N/A,#N/A,#N/A,#N/A
 8/27/2014 53220K50  BW   Ligand Partner GlaxoSmithKline Receives U.S. FDA Approval for Promacta®/Revolade™ For Use in Patients with Severe Aplastic Anemia,#N/A, 1/11/2016 45232710    BW   Illumina Extends Genomics Portfolio, 9/18/2014 84763A10  BW   Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs,#N/A, 8/04/2015 ARWR-US  BW   Arrowhead Reports Fiscal 2015 Third Quarter Financial Results,#N/A,#N/A,#N/A,#N/A
 8/14/2014 53220K50  BW   Ligand Signs Multi-Program Captisol® License Agreement with Avion Pharmaceuticals,#N/A, 1/10/2016 45232710    BW   Illumina Forms New Company to Enable Early Cancer Detection via Blood-Based Screening, 9/16/2014 84763A10  BW   Spectrum Pharmaceuticals Announces Issue of a New Patent for Beleodaq™ (belinostat) for Injection with Patent Term Adjustment till 2027,#N/A, 7/28/2015 ARWR-US  BW   Arrowhead to Report Fiscal 2015 Third Quarter Financial Results,#N/A,#N/A,#N/A,#N/A
 8/13/2014 53220K50  BW   Ligand Prices Offering of $225 Million of Convertible Senior Notes,#N/A," 1/08/2016 45232710    BW   Illumina to Host Investor Call on Sunday, January 10, 2016"," 9/09/2014 84763A10  BW   Spectrum Pharmaceuticals Makes Decision to Advance SPI-2012, a Novel Long-Acting GCSF, to Phase 3 Due to Positive Phase 2 Results in its Collaboration Program with Hanmi Pharm. Co.",#N/A, 7/08/2015 04280A10 BW   Arrowhead Receives Regulatory Clearance for ARC-AAT Phase 1 in the United Kingdom and New Zealand,#N/A,#N/A,#N/A,#N/A
 8/11/2014 53220K50  BW   Ligand Announces Proposed Offering of $225 Million of Convertible Senior Notes and Announces $200 Million Share Repurchase Program,#N/A, 1/07/2016 ILMN-US     BW   Illumina Files Two Patent Infringement Suits in Europe for Infringement of Patents for NIPT, 9/02/2014 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Morgan Stanley Global Healthcare Conference in New York City on September 9th,#N/A, 7/02/2015 ARWR-US  BW   Arrowhead Initiates Dosing of ARC-AAT in Patients with Alpha-1 Antitrypsin Deficiency,#N/A,#N/A,#N/A,#N/A
 8/04/2014 53220K50  BW   Ligand Reports Second Quarter 2014 Financial Results,#N/A,12/28/2015 ILMN-US     BW   Illumina to Webcast Live Presentation at the J.P. Morgan Annual Healthcare Conference," 8/07/2014 84763A10  BW   Spectrum Pharmaceuticals Reports 45% Sales Growth in the Second Quarter, Launches Fifth Product and Moves Closer to a Decision on a Potential Blockbuster",#N/A, 6/17/2015 ARWR-US  BW   Arrowhead Receives Regulatory Clearance to Begin Additional Phase 2b Studies of Hepatitis B Candidate ARC-520,#N/A,#N/A,#N/A,#N/A
 7/23/2014 GSK-GB    BW   Ligand Partner GSK Announces Record Quarterly Promacta™/Revolade™ Revenue of $92 Million,#N/A,"12/14/2015 ILMN-US     BW   bioMérieux and Illumina Announce the Launch of bioMérieux EpiSeq™, a Revolutionary Next-Generation Sequencing Service for Epidemiological Monitoring of Bacterial Infections", 7/31/2014 84763A10  BW   Spectrum Pharmaceuticals Announces Second Quarter 2014 Financial Results Teleconference and Webcast,#N/A, 6/10/2015 ARWR-US  BW   Arrowhead Receives Orphan Drug Designation for ARC-AAT,#N/A,#N/A,#N/A,#N/A
 7/22/2014 0C58C1-E  BW   Ligand Partner SAGE Therapeutics Receives Fast Track Designation for Captisol-enabled SAGE-547 to Treat Status Epilepticus,#N/A,"12/14/2015 BIM-FR      BW   bioMérieux et Illumina annoncent le lancement de bioMérieux EpiSeq™, un service d’avant-garde en Séquençage Nouvelle Génération pour le suivi épidémiologique des infections bactériennes", 7/07/2014 84763A10  BW   FDA Grants Spectrum Pharmaceuticals Accelerated Approval of Beleodaq™ (belinostat) for Injection,#N/A, 5/27/2015 ARWR-US  BW   Arrowhead to Present at Jefferies 2015 Healthcare Conference,#N/A,#N/A,#N/A,#N/A
 7/17/2014 53220K50  BW   Ligand Reports Second Quarter Revenues and Announces Share Repurchase Program,#N/A,"12/14/2015 BIM-FR      BW   bioMérieux and Illumina announce the launch of bioMérieux EpiSeq™, a revolutionary Next-Generation Sequencing service for epidemiological monitoring of bacterial infections", 5/30/2014 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies Global Healthcare Conference in New York City on June 3rd,#N/A, 5/11/2015 04280A10 BW   Arrowhead Reports Fiscal 2015 Second Quarter Financial Results,#N/A,#N/A,#N/A,#N/A
 6/25/2014 53220K50  BW   Ligand Partner GSK Announces the Start of a Phase 3 Study with Eltrombopag in Patients with Myelodysplastic Syndromes,#N/A,12/14/2015 ILMN-US     BW   Novogene and Illumina to Co-Develop NGS Diagnostic System for Reproductive Health and Oncology Applications, 5/28/2014 84763A10  BW   Spectrum Pharmaceuticals Completes Enrollment in Phase 2 Trial of SPI-2012 - A Novel Long-Acting Granulocyte Colony Stimulating Factor (GCSF) to Treat Chemotherapy-induced Neutropenia,#N/A, 5/06/2015 04280A10 BW   Arrowhead Presents Data on Potential RNAi Candidate Targeting Factor 12 Mediated Angioedemic and Thromboembolic Diseases,#N/A,#N/A,#N/A,#N/A
 6/24/2014 53220K50  BW   Ligand Signs Global License Agreement with TG Therapeutics for IRAK-4 Inhibitor Program,#N/A,12/09/2015 45232710    BW   Illumina Accelerator Announces Third Funding Cycle of Genomics Startups, 5/09/2014 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas on May 13th,#N/A, 5/05/2015 04280A10 BW   Arrowhead Completes Dosing Healthy Volunteers and Initiates Transition to Patients in Phase 1 Study of ARC-AAT,#N/A,#N/A,#N/A,#N/A
 6/23/2014 53220K50  BW   Ligand to Participate in ROTH Capital Partners’ Healthcare Corporate Access Day in London,#N/A,12/09/2015 ILMN-US     BW   Desktop Genetics Receives Strategic Investment from Illumina to Advance Genome Editing Software Platform, 5/08/2014 84763A10  BW   Spectrum Pharmaceuticals Reports Financial Results for First Quarter 2014,#N/A, 5/04/2015 04280A10 BW   Arrowhead to Report Fiscal 2015 Second Quarter Financial Results,#N/A,#N/A,#N/A,#N/A
 6/23/2014 53220K50  BW   Ligand Announces Presentation of Positive Data from a Phase 1 Study on the Effect of the SERM Lasofoxifene to Increase Testosterone Levels in Men,#N/A,11/02/2015 45232710    BW   Illumina Announces New $250 Million Share Repurchase Authorization, 5/01/2014 84763A10  BW   Spectrum Pharmaceuticals Announces First Quarter 2014 Financial Results Teleconference and Webcast,#N/A, 4/30/2015 04280A10 BW   Arrowhead Publishes Data on Advances in Subcutaneous siRNA Delivery,#N/A,#N/A,#N/A,#N/A
 6/16/2014 53220K50  BW   Ligand Announces Successful First-in-Human Trial Results for Glucagon Program,#N/A,10/20/2015 45232710    BW   Illumina Reports Financial Results for Third Quarter of Fiscal Year 2015, 4/23/2014 LGND-US   BW   Ligand’s Partner Spectrum Pharmaceuticals Reports Captisol-Enabled Melphalan Meets Primary Endpoint in Pivotal Trial,#N/A, 4/28/2015 04280A10 BW   Arrowhead to Present at Upcoming Conferences,#N/A,#N/A,#N/A,#N/A
 6/13/2014 53220K50  BW   Ligand Partner GSK Announces Results of Phase 3 PETIT2 Study of Eltrombopag (Promacta™/Revolade™) in Pediatric Patients with Chronic Immune Thrombocytopenia,#N/A,10/07/2015 ILMN-US     BW   Illumina Introduces Genomics Solutions to Advance Clinical Research, 4/23/2014 84763A10  BW   Spectrum Pharmaceuticals’ Pivotal Trial of Captisol-Enabled™ (Propylene Glycol-Free) Melphalan Meets Primary Endpoint,#N/A, 4/13/2015 04280A10 BW   Arrowhead Cleared to Proceed with Multiple Dose Phase 2b Study of ARC-520,#N/A,#N/A,#N/A,#N/A
 5/22/2014 53220K50  BW   Ligand Licenses Five Programs to Viking Therapeutics,#N/A,10/06/2015 45232710    BW   Illumina Expands Use of HiSeq X™ Sequencing System to Include Non-Human Species, 4/21/2014 84763A10  BW   Spectrum Pharmaceuticals Promotes and Appoints Joseph Turgeon as President and Chief Operating Officer,#N/A, 3/05/2015 04280A10 BW   Arrowhead Acquires Novartis’ RNAi Research and Development Portfolio,#N/A,#N/A,#N/A,#N/A
 5/14/2014 53220K50  BW   Ligand Signs Research and Licensing Agreement with Omthera Pharmaceuticals for Dyslipidemia-related Diseases,#N/A,10/05/2015 45232710    BW   Illumina Announces Preliminary Revenue for Third Quarter of Fiscal Year 2015," 4/08/2014 84763A10  BW   SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Spectrum Pharmaceuticals, Inc. Regarding Possible Breaches of Fiduciary Duty",#N/A, 3/04/2015 04280A10 BW   Arrowhead to Present at 2015 Barclays Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A
 5/12/2014 53220K50  BW   Ligand Earns Milestone from SAGE Therapeutics for SAGE-547,#N/A,10/01/2015 45232710    BW   Illumina Expands World’s Largest Genomics Analysis Platform and Adds to Open Source Initiative, 3/07/2014 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the 26th Annual ROTH Conference in Laguna Niguel on March 11th,#N/A, 2/23/2015 04280A10 BW   Arrowhead Begins Phase 1 Trial of ARC-AAT for Treatment of Liver Disease Associated with Alpha-1 Antitrypsin Deficiency,#N/A,#N/A,#N/A,#N/A
 5/07/2014 53220K50  BW   Ligand Reports First Quarter 2014 Financial Results,#N/A, 9/30/2015 ILMN-US     BW   Amoy Diagnostics and Illumina Enter Strategic Collaboration for Next-Generation Sequencing Cancer Diagnostics in China, 3/06/2014 84763A10  BW   Spectrum Pharmaceuticals Reports Fourth and Full Year 2013 Financial Results,#N/A, 2/17/2015 04280A10 BW   Arrowhead to Present at 2015 RBC Capital Markets' Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A
 4/30/2014 53220K50  BW   Ligand Partner GlaxoSmithKline Gains Priority Review Designation for Promacta™/Revolade™ for Severe Aplastic Anemia,#N/A, 9/29/2015 ILMN-US     BW   Illumina Launches TruSight® Tumor OncoPanel, 2/27/2014 84763A10  BW   Spectrum Pharmaceuticals Announces Fourth Quarter 2013 Financial Results Teleconference and Webcast,#N/A, 2/09/2015 04280A10 BW   Arrowhead Reports Fiscal 2015 First Quarter Financial Results,#N/A,#N/A,#N/A,#N/A
 4/23/2014 53220K50  BW   Ligand’s Partner Spectrum Pharmaceuticals Reports Captisol-Enabled Melphalan Meets Primary Endpoint in Pivotal Trial,#N/A, 9/23/2015 45232710    BW   Illumina Joins WIN Consortium in Personalized Cancer Medicine," 2/06/2014 84763A10  BW   Spectrum Pharmaceuticals Announces FDA’s Acceptance of NDA Filing for Beleodaq™ (belinostat) for Injection, a novel pan-HDAC inhibitor",#N/A, 2/02/2015 04280A10 BW   Arrowhead to Report Fiscal 2015 First Quarter Financial Results,#N/A,#N/A,#N/A,#N/A
 4/23/2014 53220K50  BW   Ligand to Participate in Three Upcoming Investor Conferences,#N/A, 9/16/2015 ILMN-US     BW   Memorial Sloan Kettering Cancer Center and Illumina Launch Comprehensive Circulating Tumor DNA Program, 1/09/2014 84763A10  BW   Spectrum Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference in San Francisco on January 16th,#N/A, 1/12/2015 04280A10 BW   Arrowhead Provides Update on IND for ARC-520 Phase 2b Study,#N/A,#N/A,#N/A,#N/A
 4/22/2014 53220K50  BW   Ligand to Report First Quarter Results on May 7th,#N/A, 9/09/2015 008541-E    BW   Asuragen to Collaborate with Illumina on Companion Diagnostics Development,12/18/2013 84763A10  BW   Spectrum Pharmaceuticals Announces Pricing of $100 Million Convertible Notes Offering,#N/A,12/15/2014 04280A10 BW   Arrowhead Files IND for RNAi Therapeutic ARC-520 to Begin Phase 2b Multiple-Dose Studies in Chronic Hepatitis B Patients,#N/A,#N/A,#N/A,#N/A
" 3/17/2014 53220K50  BW   Ligand Earns $1 Million Milestone Payment Triggered by FDA Approval of Merck’s NOXAFIL® (posaconazole) Injection for Intravenous Use, a New Captisol-enabled Formulation",#N/A, 9/03/2015 ILMN-US     BW   Illumina to Webcast Live Presentation at the Morgan Stanley Global Healthcare Conference,12/16/2013 84763A10  BW   Spectrum Pharmaceuticals Announces Offering of $100 Million of Convertible Notes,#N/A,12/04/2014 04280A10 BW   CORRECTING and REPLACING Arrowhead Appoints Patrick O’Brien as General Counsel,#N/A,#N/A,#N/A,#N/A
 3/11/2014 53220K50  BW   Ligand Announces Highlights from Presentation at the 26th Annual Roth Capital Conference,#N/A, 9/01/2015 45232710    BW   Illumina Completes Acquisition of GenoLogics,12/11/2013 84763A10  BW   Spectrum Pharmaceuticals Highlights Encouraging FOLOTYN® and MARQIBO® Clinical Data Presented at the 55th Annual Meeting of the American Society of Hematology (ASH),#N/A,12/01/2014 04280A10 BW   INVESTOR ALERT: Class Action Lawsuit Against Arrowhead Research Corporation Announced by Law Offices of Howard G. Smith,#N/A,#N/A,#N/A,#N/A
 3/10/2014 53220K50  BW   Captisol® Licensee Lundbeck Announces FDA Acceptance of NDA Submission for Carbamazepine IV,#N/A, 8/24/2015 45232710    BW   Burning Rock and Illumina Collaborate on Molecular Diagnostics for Oncology,"12/10/2013 84763A10  BW   Spectrum Pharmaceuticals Announces Submission of New Drug Application for Belinostat, a novel pan-HDAC inhibitor",#N/A,"11/28/2014 04280A10 BW   ARROWHEAD RESEARCH CORP. SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Arrowhead Research Corp.",#N/A,#N/A,#N/A,#N/A
 2/28/2014 53220K50  BW   Ligand Partner GlaxoSmithKline Submits U.S. Regulatory Application for Promacta® (eltrombopag) for Severe Aplastic Anaemia,#N/A," 8/18/2015 ILMN-US     BW   Illumina, Warburg Pincus, and Sutter Hill Ventures Form Helix to Accelerate Consumer Adoption of Genomics","12/06/2013 84763A10  BW   Spectrum Pharmaceuticals Highlights 13 Abstracts at the 55th Annual Meeting of the American Society of Hematology (ASH), New Orleans, Louisiana, December 7-10, 2013",#N/A,11/26/2014 04280A10 BW   INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Arrowhead Research Corporation,#N/A,#N/A,#N/A,#N/A
 2/26/2014 53220K50  BW   Ligand to Present at the 26th Annual Roth Conference on March 11,#N/A, 8/05/2015 45232710    BW   Illumina Accelerator Invests in Second Class of Genomics Startups from US and Europe,11/12/2013 84763A10  BW   Spectrum Pharmaceuticals Reports Financial Results for Third Quarter 2013,#N/A,11/25/2014 04280A10 BW   Arrowhead Reports Fiscal 2014 Year End Financial Results,#N/A,#N/A,#N/A,#N/A
 2/11/2014 53220K50  BW   Ligand Reports Fourth Quarter and Full Year 2013 Financial Results,#N/A," 8/04/2015 ILMN-US     BW   Illumina Signs Agreement to Acquire GenoLogics, Leader in Genomics Laboratory Information Management System Market",11/11/2013 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Credit Suisse 2013 Healthcare Conference in Arizona on November 13th,#N/A,"11/24/2014 04280A10 BW   UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Arrowhead Research Corp. and Its Board of Directors and a Lead Plaintiff Deadline of December 9, 2014",#N/A,#N/A,#N/A,#N/A
 2/10/2014 53220K50  BW   Ligand to Receive $1 Million Kyprolis® Commercial Milestone Payment from Onyx Pharmaceuticals,#N/A, 7/21/2015 45232710    BW   Illumina Reports Financial Results for Second Quarter of Fiscal Year 2015,11/08/2013 84763A10  BW   Spectrum Pharmaceuticals Announces Third Quarter 2013 Financial Results Teleconference and Webcast,#N/A,11/21/2014 04280A10 BW   SHAREHOLDER ALERT: Investigation on Behalf of Arrowhead Research Corporation Investors Announced by Law Offices of Howard G. Smith,#N/A,#N/A,#N/A,#N/A
 2/03/2014 53220K50  BW   Ligand Partner GlaxoSmithKline Gains FDA Breakthrough Therapy Designation for Promacta®/Revolade® for Severe Aplastic Anemia,#N/A, 7/20/2015 45232710    BW   Illumina Names Sanjay Chikarmane as Senior Vice President and General Manager of Enterprise Informatics,"10/30/2013 84763A10  BW   Spectrum Pharmaceuticals Announces Completion of Enrollment, in Pivotal Trial of Captisol-Enabled® (Propylene Glycol-Free) Melphalan",#N/A,"11/19/2014 04280A10 BW   SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Arrowhead Research Corp. To Contact Brower Piven Before The December 9, 2014 Lead Plaintiff Deadline In Class Action Lawsuit",#N/A,#N/A,#N/A,#N/A
 1/29/2014 53220K50  BW   Ligand to Report Fourth Quarter Results on February 11th,#N/A, 7/16/2015 45232710    BW   Illumina Introduces Illumina SeqLab, 9/04/2013 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Morgan Stanley Global Healthcare Conference in New York City on September 11th,#N/A,11/18/2014 04280A10 BW   Arrowhead to Report Fiscal 2014 Fourth Quarter and Year End Financial Results,#N/A,#N/A,#N/A,#N/A
12/09/2013 53220K50  BW   Ligand Announces Positive Preclinical Data on Small-Molecule G-CSF Receptor Agonist at the 55th Annual Meeting of the American Society of Hematology,#N/A," 7/13/2015 45232710    BW   Study of Illumina’s Non-Invasive verifi® Prenatal Test Suggests that Test Results, When Discordant from Fetal Karyotyping, May Reflect Presence of Maternal Cancer", 9/03/2013 84763A10  BW   Spectrum Pharmaceuticals Launches Marqibo® (vinCRIStine sulfate LIPOSOME injection) and Ships First Commercial Orders,#N/A,11/18/2014 04280A10 BW   Arrowhead Files for Regulatory Permission to Begin Phase 1 Trial of RNAi Therapeutic ARC-AAT,#N/A,#N/A,#N/A,#N/A
12/04/2013 53220K50  BW   Ligand Raises Fourth Quarter and Full Year 2013 Financial Forecast,#N/A," 7/07/2015 45232710    BW   Illumina to Announce Second Quarter 2015 Financial Results on Tuesday, July 21, 2015", 8/07/2013 84763A10  BW   Spectrum Pharmaceuticals Reports Financial Results for Second Quarter 2013,#N/A,11/14/2014 04280A10 BW   Arrowhead to Present at Upcoming Conferences,#N/A,#N/A,#N/A,#N/A
11/14/2013 53220K50  BW   Ligand Announces Highlights from Today’s Analyst Day Event,#N/A, 7/01/2015 00F34P-E    BW   908 Devices Accelerates Entry into Life Science Market with Backing from Leading Industry Players, 8/01/2013 84763A10  BW   Spectrum Pharmaceuticals Announces Second Quarter 2013 Financial Results Teleconference and Webcast,#N/A,11/10/2014 04280A10 BW   Arrowhead Presents Data on ARC-520 and ARC-AAT at AASLD The Liver Meeting® 2014,#N/A,#N/A,#N/A,#N/A
11/12/2013 53220K50  BW   Ligand Initiates Phase 1 Trial with Glucagon Receptor Antagonist for Type 2 Diabetes,#N/A, 6/10/2015 45232710    BW   Annoroad and Illumina to Co-Develop NGS Diagnostic System for Reproductive Health," 7/17/2013 84763A10  BW   Spectrum Pharmaceuticals Acquires Talon Therapeutics, Inc.",#N/A,"10/22/2014 04280A10 BW   SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Arrowhead Research Corp. To Contact Brower Piven Before The December 9, 2014 Lead Plaintiff Deadline In Class Action Lawsuit",#N/A,#N/A,#N/A,#N/A
11/07/2013 53220K50  BW   Reminder: Ligand to Host Analyst Day on November 14th in Chicago,#N/A," 6/08/2015 ILMN-US     BW   Illumina, Merck KGaA, Darmstadt, Germany, and Genea Form the Global Fertility Alliance for Excellence in Assisted Reproductive Treatment", 7/02/2013 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the 8th Annual JMP Securities Healthcare Conference in New York City on July 9th,#N/A,10/14/2014 04280A10 BW   SHAREHOLDER ALERT: Class Action Lawsuit Against Arrowhead Research Corporation Filed By Glancy Binkow & Goldberg LLP,#N/A,#N/A,#N/A,#N/A
10/30/2013 53220K50  BW   Ligand Reports Third Quarter Financial Results,#N/A, 5/21/2015 ILMN-US     BW   Illumina to Webcast Live Presentation at Upcoming Investment Conferences in June, 7/01/2013 84763A10  BW   Spectrum Pharmaceuticals Elects Two New Healthcare Industry Veterans to the Board of Directors,#N/A,10/14/2014 04280A10 BW   Arrowhead Research Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors,#N/A,#N/A,#N/A,#N/A
10/14/2013 53220K50  BW   Ligand to Host Analyst Day on November 14th in Chicago,#N/A," 5/18/2015 ILMN-US     BW   Illumina Files New Patent Infringement Suit Against Ariosa Diagnostics, Inc. and Roche Molecular Systems, Inc.", 6/06/2013 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Goldman Sachs 34th Annual Global Healthcare Conference in Rancho Palos Verdes on June 11th,#N/A,"10/13/2014 04280A10 BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against Arrowhead Research Corp. and Its Board of Directors and a Lead Plaintiff Deadline of December 9, 2014",#N/A,#N/A,#N/A,#N/A
10/09/2013 53220K50  BW   Ligand to Report Third Quarter Results on October 30th,#N/A, 4/29/2015 ILMN-US     BW   Illumina to Webcast Live Presentation at the Bank of America Merrill Lynch Health Care Conference," 6/05/2013 84763A10  BW   Spectrum Pharmaceuticals Further Strengthens Management; Announces Appointment of Kurt Gustafson as Executive Vice President, Chief Financial Officer and Principal Accounting Officer",#N/A,10/09/2014 04280A10 BW   Arrowhead Issues Open Letter to Shareholders,#N/A,#N/A,#N/A,#N/A
10/07/2013 53220K50  BW   Ligand Announces FDA Acceptance of Investigational New Drug Application for Glucagon Receptor Antagonist Program,#N/A, 4/21/2015 45232710    BW   Illumina Reports Strong Start to Fiscal Year 2015, 6/03/2013 84763A10  BW   Spectrum Pharmaceuticals Announces Positive Data from the BELIEF Trial Presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting,#N/A,10/09/2014 04280A10 BW   EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Arrowhead Research Corp. - ARWR,#N/A,#N/A,#N/A,#N/A
10/03/2013 LGND-US   BW   Ligand Partner Pfizer Receives FDA Approval for DUAVEETM for the Treatment of Moderate-to-Severe Vasomotor Symptoms (Hot Flashes) Associated with Menopause and the Prevention of Postmenopausal Osteoporosis,#N/A," 4/07/2015 45232710    BW   Illumina to Announce First Quarter 2015 Financial Results on Tuesday, April 21, 2015"," 5/31/2013 84763A10  BW   Spectrum Pharmaceuticals Highlights Six Abstracts of Clinical Data at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, May 31 – June 4, 2013",#N/A,10/08/2014 04280A10 BW   Arrowhead to Present ARC-520 Phase 2a Data in Late-Breaking Session at AASLD Liver Meeting® 2014,#N/A,#N/A,#N/A,#N/A
 9/24/2013 53220K50  BW   Ligand Partner GSK Receives Marketing Authorization from the European Commission for Additional Revolade™ (Eltrombopag) Indication as the First Approved Treatment for Chronic Hepatitis C-Associated Thrombocytopenia,#N/A, 3/31/2015 ILMN-US     BW   Berry Genomics NextSeq CN500 Instrument and Non-Invasive Prenatal Testing Reagent Kit Receives Chinese FDA Premarket Clearance, 5/29/2013 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2013 Global Healthcare Conference in New York City on June 5th,#N/A,10/07/2014 04280A10 BW   Arrowhead to Present at 10th Annual Meeting of the Oligonucleotide Therapeutics Society,#N/A,#N/A,#N/A,#N/A
" 8/14/2013 53220K50  BW   Ligand Enters Global License Agreement with CURx Pharmaceuticals, Inc. for Captisol-EnabledTM Topiramate Injection",#N/A, 3/16/2015 45232710    BW   Illumina Files Patent Infringement Suit in the United Kingdom Against Premaitha Health plc for Infringement of NIPT Patents, 5/23/2013 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Deutsche Bank 38th Annual Health Care Conference in Boston on May 30th,#N/A, 9/30/2014 04280A10 BW   Arrowhead Expands Management Team with Appointment of Susan Boynton as Vice President Global Regulatory Affairs,#N/A,#N/A,#N/A,#N/A
 8/01/2013 53220K50  BW   Ligand Reports Second Quarter Financial Results,#N/A, 3/10/2015 45232710    BW   Illumina Announces Strategic Collaboration with Merck Serono to Expand Companion Diagnostics for Oncology, 5/13/2013 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the UBS Global Healthcare Conference in New York City on May 20th,#N/A, 9/19/2014 04280A10 BW   Arrowhead to Present at BioCentury’s NewsMakers in the Biotech Industry Conference,#N/A,#N/A,#N/A,#N/A
 7/26/2013 080RQG-E  BW   Ligand Partner GlaxoSmithKline Receives Positive CHMP Opinion for REVOLADE™ in Thrombocytopenia Associated with Chronic Hepatitis C Infection,#N/A, 3/04/2015 45232710    BW   Illumina Launches TruSight HLA Solution, 5/10/2013 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas on May 14th,#N/A, 8/12/2014 04280A10 BW   Arrowhead Reports Fiscal 2014 Third Quarter Financial Results and Provides Update on ARC-520,#N/A,#N/A,#N/A,#N/A
 7/26/2013 53220K50  BW   Ligand Receives Orphan Designation for Captisol-EnabledTM Topiramate Injection,#N/A, 2/26/2015 45232710    BW   Illumina Accelerator Secures $40 Million Boost Capital to Back New Graduates, 5/09/2013 84763A10  BW   Spectrum Pharmaceuticals Reports Financial Results for First Quarter 2013,#N/A, 7/31/2014 04280A10 BW   Arrowhead to Report Fiscal 2014 Third Quarter Financial Results,#N/A,#N/A,#N/A,#N/A
 7/24/2013 53220K50  BW   Ligand Signs License Agreement with Ethicor for Oral Lasofoxifene,#N/A, 2/23/2015 45232710    BW   Illumina Launches the NeoPrep Library Prep System, 5/02/2013 84763A10  BW   Spectrum Pharmaceuticals Announces First Quarter 2013 Financial Results Teleconference and Webcast,#N/A, 6/19/2014 04280A10 BW   Arrowhead Announces New Clinical Candidate ARC-AAT for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease,#N/A,#N/A,#N/A,#N/A
 7/22/2013 53220K50  BW   Ligand Signs Global License Agreement with Azure for Lasofoxifene,#N/A, 2/18/2015 45232710    BW   Illumina to Webcast Live Presentation at the Cowen and Company Annual Health Care Conference," 4/30/2013 84763A10  BW   DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders of Spectrum Pharmaceuticals, Inc. of Upcoming Deadline",#N/A, 6/16/2014 04280A10 BW   Arrowhead Research Set to Join Russell 3000 Index,#N/A,#N/A,#N/A,#N/A
 7/16/2013 53220K50  BW   Ligand to Report Second Quarter Results on August 1st,#N/A, 1/27/2015 45232710    BW   Illumina Reports Record Financial Results for Fourth Quarter and Fiscal Year 2014," 4/28/2013 84763A10  BW   Law Offices of Todd M. Garber Announces Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc.",#N/A, 6/13/2014 04280A10 BW   Arrowhead Issues a Statement on Intellectual Property Protection for ARC-520,#N/A,#N/A,#N/A,#N/A
 6/24/2013 53220K50  BW   Ligand Announces Positive Preclinical Data for Glucagon Program in Model of Type 1 Diabetes,#N/A, 1/21/2015 45232710    BW   Illumina Announces First Targeted Next-Generation Sequencing Solution for Forensic Genomics," 4/26/2013 84763A10  BW   SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Spectrum Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of May 13, 2013 to Seek a Lead Plaintiff Position",#N/A, 6/11/2014 04280A10 BW   Arrowhead to Host Analyst Day to Discuss New Rare Liver Disease Candidate,#N/A,#N/A,#N/A,#N/A
 6/20/2013 53220K50  BW   Ligand Raises Ownership Limit for BVF Partners to 25% of Shares Outstanding,#N/A," 1/13/2015 45232710    BW   Illumina to Announce Fourth Quarter and Fiscal Year 2014 Financial Results on Tuesday, January 27, 2015"," 4/23/2013 84763A10  BW   21 Days Remain before May 13, 2013, Lead Plaintiff Deadline in Investor Lawsuit against Spectrum Pharmaceuticals, Inc.",#N/A, 6/10/2014 04280A10 BW   Arrowhead to Present at Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A
 5/29/2013 LGND-US   BW   Ligand Provides New Corporate Presentation at Investor Conference,#N/A, 1/12/2015 ILMN-US     BW   Lockheed Martin and Illumina to Collaborate on Developing Genomics Solutions to Improve Public Health and Wellness," 4/19/2013 0BGL4K-E  BW   SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Spectrum Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of May 13, 2013 to Seek a Lead Plaintiff Position",#N/A, 5/29/2014 04280A10 BW   Arrowhead to Present at the Jefferies 2014 Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A
 5/23/2013 53220K50  BW   Ligand to Present at Upcoming Investor Conferences,#N/A, 1/12/2015 45232710    BW   Illumina Expands World’s Most Comprehensive Next-Generation Sequencing Portfolio," 4/12/2013 84763A10  BW   Law Offices of Todd M. Garber Announces Investigation of Spectrum Pharmaceuticals, Inc.",#N/A, 5/06/2014 04280A10 BW   Arrowhead to Present at Upcoming Scientific Conferences,#N/A,#N/A,#N/A,#N/A
 5/14/2013 53220K50  BW   Ligand Partner Rib-X Initiates Phase 3 Trial of Captisol-enabled™ Delafloxacin IV,#N/A, 1/11/2015 45232710    BW   £15m Initiative Puts Scotland at Forefront of Gene-Led Healthcare," 4/08/2013 84763A10  BW   Spectrum Pharmaceuticals Initiates Phase 2 Study of Long-Acting GCSF Drug Candidate, SPI-2012, for the Treatment of Chemotherapy-Induced Neutropenia",#N/A, 5/06/2014 04280A10 BW   Arrowhead Reports Fiscal 2014 Second Quarter Financial Results,#N/A,#N/A,#N/A,#N/A
 5/08/2013 53220K50  BW   Ligand Reports First Quarter Financial Results,#N/A, 1/08/2015 45232710    BW   Illumina Announces African Orphan Crops Consortium to Receive Agricultural Greater Good Initiative Grant," 4/05/2013 84763A10  BW   Glancy Binkow & Goldberg LLP Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc.",#N/A, 5/01/2014 04280A10 BW   Arrowhead to Present at Deutsche Bank 39th Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A
 4/30/2013 53220K50  BW   Ligand Acquires Financial Rights to More Than 15 Fully-Funded Development Programs from Selexis SA,#N/A,12/22/2014 45232710    BW   Illumina to Webcast Live Presentation at the J.P. Morgan Annual Healthcare Conference," 4/03/2013 84763A10  BW   Hagens Berman Reminds Spectrum Pharmaceuticals Investors of May 13, 2013, Deadline in Securities Lawsuit",#N/A, 4/29/2014 04280A10 BW   Arrowhead to Report Fiscal 2014 Second Quarter Financial Results,#N/A,#N/A,#N/A,#N/A
 4/26/2013 53220K50  BW   Ligand Presents Preclinical Data on HepDirect™ Liver-Targeting Technology Platform at 2013 International Liver Congress (EASL) Annual Meeting,#N/A,12/03/2014 ILMN-US     BW   Illumina and Sequenom Pool Noninvasive Prenatal Testing Intellectual Property and End Outstanding Patent Disputes," 3/29/2013 84763A10  BW   Glancy Binkow & Goldberg LLP Announces Filing of a Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc.",#N/A, 4/01/2014 04280A10 BW   Arrowhead Completes Enrollment of First Cohort in Phase 2a Trial of Chronic Hepatitis B Candidate ARC-520,#N/A,#N/A,#N/A,#N/A
 4/23/2013 53220K50  BW   Ligand to Present at Upcoming Investor Conferences,#N/A,"11/19/2014 45232710    BW   USAID, Broad Institute and Illumina Form a Public-Private Partnership Combating the Ebola Epidemic in West Africa"," 3/26/2013 84763A10  BW   Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline in the Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc.",#N/A, 3/24/2014 04280A10 BW   Arrowhead Begins Dosing in Phase 2a Trial of RNAi Therapeutic ARC-520 in Chronic Hepatitis B Patients,#N/A,#N/A,#N/A,#N/A
 4/22/2013 53220K50  BW   Ligand to Report First Quarter Results on May 8th,#N/A,11/18/2014 45232710    BW   bioMérieux and Illumina Enter Agreement to Co-Develop a Next-Generation Sequencing Solution for Epidemiological Monitoring of Bacterial Infections," 3/22/2013 09Y0ZH-E  BW   CORRECTING and REPLACING Abraham, Fruchter & Twersky, LLP Announces That a Class Action Lawsuit Has Been Filed against Spectrum Pharmaceuticals, Inc.",#N/A, 3/10/2014 04280A10 BW   Arrowhead to Present at Barclays Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A
 3/14/2013 53220K50  BW   Ligand Signs Global License Agreement with Spectrum Pharmaceuticals for Captisol-Enabled® Melphalan,#N/A,11/17/2014 ILMN-US     BW   Sequenta Enters Agreement with Illumina on In Vitro Diagnostic Kit for Sequencing-Based Minimal Residual Disease Testing," 3/22/2013 84763A10  BW   Hagens Berman Notifies Spectrum Pharmaceuticals Investors of Pending Class-Action Lawsuit and May 13, 2013, Lead Plaintiff Deadline",#N/A, 3/03/2014 04280A10 BW   Arrowhead Receives Regulatory Approval to Begin Phase 2a Trial of Chronic Hepatitis B Candidate ARC-520,#N/A,#N/A,#N/A,#N/A
" 2/25/2013 53220K50  BW   Ligand Receives $1.4 Million Milestone Payment from Retrophin, Inc.",#N/A,10/20/2014 45232710    BW   Illumina Reports Record Financial Results for Third Quarter of Fiscal Year 2014, 3/21/2013 84763A10  BW   Spectrum Pharmaceuticals Shareholder Alert: Briscoe Law and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors,#N/A, 2/24/2014 04280A10 BW   Arrowhead Closes Underwritten Offering with Gross Proceeds of $120 Million,#N/A,#N/A,#N/A,#N/A
 2/13/2013 53220K50  BW   Ligand Reports Fourth Quarter and Full Year 2012 Financial Results,#N/A,10/17/2014 45232710    BW   Illumina Launches New Reagent Kits for HiSeq X Ten and HiSeq 2500 Systems," 3/18/2013 84763A10  BW   Spectrum Pharmaceuticals Appoints Lee F. Allen, M.D., Ph.D., Industry Veteran, as Chief Medical Officer",#N/A, 2/21/2014 04280A10 BW   Arrowhead Listing Upgraded to NASDAQ Global Select Market,#N/A,#N/A,#N/A,#N/A
 1/23/2013 LGND-US   BW   Ligand to Report Fourth Quarter Results on February 13th,#N/A,10/15/2014 45232710    BW   Illumina Accelerator Announces Investment in Inaugural Startup Class," 3/16/2013 84763A10  BW   Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc.",#N/A, 2/20/2014 04280A10 BW   Arrowhead to Present at RBC Capital Markets' Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A
 1/09/2013 0BVHZK-E  BW   Ligand Receives Equity Milestone Payment from Retrophin,#N/A,"10/06/2014 45232710    BW   Illumina to Announce Third Quarter 2014 Financial Results on Monday, October 20, 2014"," 3/15/2013 84763A10  BW   Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Spectrum Pharmaceuticals, Inc.",#N/A, 2/19/2014 04280A10 BW   Arrowhead Announces Pricing of Underwritten Offering of Common Stock,#N/A,#N/A,#N/A,#N/A
"12/13/2012 LGND-US   BW   U.S. Food and Drug Administration (FDA) Accepts New Drug Application For Bazedoxifene/Conjugated Estrogens, An Investigational Treatment For Symptoms Associated With Menopause And Prevention of Osteoporosis",#N/A,10/02/2014 09JSSJ-E    BW   AB SCIEX and Illumina Collaborate to Create World’s First Multi-omics Cloud-Computing Environment, 3/15/2013 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the 25th Annual ROTH Conference in Laguna Niguel on March 20th,#N/A, 2/18/2014 04280A10 BW   Arrowhead Announces Proposed Underwritten Offering of Common Stock,#N/A,#N/A,#N/A,#N/A
"12/13/2012 LGND-US   BW   U.S. Food And Drug Administration (FDA) Accepts New Drug Application For Bazedoxifene/Conjugated Estrogens, An Investigational Treatment For Symptoms Associated With Menopause And Prevention Of Osteoporosis",#N/A, 9/08/2014 45232710    BW   Actionable Genome Consortium Forms with Cross Disciplinary Leaders from World-Renowned Cancer Institutions," 3/14/2013 84763A10  BW   Robbins Geller Rudman & Dowd LLP Files Class Action Suit against Spectrum Pharmaceuticals, Inc.",#N/A, 2/04/2014 04280A10 BW   Arrowhead Reports Fiscal 2014 First Quarter Financial Results,#N/A,#N/A,#N/A,#N/A
"12/10/2012 LGND-US   BW   Ligand Initiates Pivotal Trial of Captisol-Enabled®, Propylene Glycol-Free Melphalan in Patients with Multiple Myeloma",#N/A, 8/27/2014 45232710    BW   Illumina to Webcast Live Presentation at the Morgan Stanley Global Healthcare Conference, 3/14/2013 SPPI-US   BW   Ligand Signs Global License Agreement with Spectrum Pharmaceuticals for Captisol-Enabled® Melphalan,#N/A, 2/04/2014 04280A10 BW   Arrowhead to Participate in Panel Discussions at 16th Annual BIO CEO & Investor Conference,#N/A,#N/A,#N/A,#N/A
"12/04/2012 53220K50  BW   Ligand to Present Growth Prospects, Review Key Portfolio Assets and Introduce Financial Guidance at Analyst Day Event",#N/A," 8/21/2014 45232710    BW   Illumina Announces Strategic Partnerships with AstraZeneca, Janssen and Sanofi to Redefine Companion Diagnostics for Oncology", 3/14/2013 84763A10  BW   Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled® Melphalan,#N/A, 1/28/2014 04280A10 BW   Arrowhead to Report Fiscal 2014 First Quarter Financial Results,#N/A,#N/A,#N/A,#N/A
11/27/2012 LGND-US   BW   Reminder: Ligand to Host Analyst Day on December 4th in New York City,#N/A, 7/31/2014 45232710    BW   UK to Become World Number One in DNA Testing with Plan to Revolutionise Fight Against Cancer and Rare Diseases, 3/12/2013 84763A10  BW   Spectrum Pharmaceuticals Provides Corporate Update,#N/A,12/18/2013 04280A10 BW   Arrowhead Reports Fiscal 2013 Fourth Quarter and Year-End Financial Results,#N/A,#N/A,#N/A,#N/A
11/19/2012 53220K50  BW   Ligand Partner GlaxoSmithKline Receives FDA Approval for New Indication for PROMACTA® (eltrombopag),#N/A," 7/31/2014 ILMN-US     BW   Providence Health, NantHealth and The Chan Soon-Shiong Institute of Molecular Medicine Partner to Create the Country’s First Health Network for Clinical Whole Genomic Sequencing"," 2/21/2013 84763A10  BW   Spectrum Pharmaceuticals Reports Record Revenues, Profits, and Cash Generated from Operations for the Twelve-Month Period Ended December 31, 2012",#N/A,12/11/2013 04280A10 BW   Arrowhead to Report Fiscal 2013 Fourth Quarter and Year-End Financial Results,#N/A,#N/A,#N/A,#N/A
11/13/2012 53220K50  BW   Ligand Announces Positive Preclinical Data on HepDirect™ Liver-Targeted Antiviral for the Treatment of Hepatitis C,#N/A, 7/31/2014 45232710    BW   Illumina Appoints Jeff Huber to its Board of Directors, 2/20/2013 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the RBC Capital Markets Healthcare Conference in New York on February 27th,#N/A,12/09/2013 04280A10 BW   Arrowhead Presents Phase 1 Data on ARC-520 at HepDART 2013,#N/A,#N/A,#N/A,#N/A
11/05/2012 LGND-US   BW   Ligand Pharmaceuticals Reports Preliminary Third Quarter 2012 Results,#N/A, 7/23/2014 45232710    BW   Illumina Reports Strong Financial Results for Second Quarter of Fiscal Year 2014, 2/12/2013 84763A10  BW   Spectrum Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2012 Financial Results Teleconference and Webcast,#N/A,11/26/2013 04280A10 BW   Arrowhead to Present at Piper Jaffray Healthcare Conference,#N/A,#N/A,#N/A,#N/A
11/05/2012 LGND-US   BW   Ligand Pharmaceuticals to Restate Previous Financial Statements,#N/A, 7/21/2014 45232710    BW   Berry Genomics and Illumina Co-Develop Integrated Next-Generation Sequencing System for Review and Approval by Chinese Regulatory Agency, 2/07/2013 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Leerink Swann 2013 Global Healthcare Conference in New York on February 14th,#N/A,11/25/2013 04280A10 BW   Arrowhead Submits Application to Begin Phase 2a Trial of ARC-520 for the Treatment of Chronic Hepatitis B Infection,#N/A,#N/A,#N/A,#N/A
11/01/2012 53220K50  BW   Ligand to Host Analyst Day on December 4th in New York City,#N/A," 7/16/2014 00FHB8-E    BW   Illumina Acquires Myraqa, a Leading IVD and Companion Diagnostic Consulting Firm"," 1/31/2013 84763A10  BW   Spectrum Pharmaceuticals Acquires Rights for Apaziquone in the U.S., Europe and Other Territories from Allergan; Expects to File New Drug Application",#N/A,11/07/2013 04280A10 BW   Arrowhead to Present at Upcoming Conferences,#N/A,#N/A,#N/A,#N/A
10/22/2012 53220K50  BW   Ligand to Report Third Quarter Results on November 5th,#N/A, 7/14/2014 45232710    BW   Illumina Names Tina S. Nova as Senior Vice President and General Manager of Oncology, 1/28/2013 SPPI-US   BW   Spectrum Pharmaceuticals Announces Presentation of Belinostat Safety Profile from BELIEF Registrational Phase 2 Trial at the Fifth Annual T-Cell Lymphoma Forum,#N/A,11/04/2013 04280A10 BW   Arrowhead Presents Data Suggesting ARC-520 Induces Therapeutic Flare in Chronic Hepatitis B,#N/A,#N/A,#N/A,#N/A
10/22/2012 LGND-US   BW   Ligand to Receive $2 Million Milestone Payment from Merck Triggered by Initiation of Phase 2b/3 Trial of Dinaciclib,#N/A," 7/09/2014 45232710    BW   Illumina to Announce Second Quarter 2014 Financial Results on Wednesday, July 23, 2014", 1/17/2013 84763A10  BW   Spectrum Pharmaceuticals Announces Extension of FUSILEV® (levoleucovorin) for Injection Patent Until 2022,#N/A,10/25/2013 04280A10 BW   Arrowhead Announces Inducement Grants Under NASDAQ Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A
 8/08/2012 LGND-US   BW   Ligand Pharmaceuticals Announces Second Quarter Results,#N/A," 6/30/2014 45232710    BW   Biomnis, Genoma und das Zentrum für Humangenetik und Laboratoriumsdiagnostik in Martinsried schließen Verträge mit Illumina zwecks Verbreitung von nicht invasiven Pränataltests in ganz Europa", 1/11/2013 SPPI-US   BW   Spectrum Pharmaceuticals Announces Promotion of Joseph Turgeon to Senior Vice President and Chief Commercial Officer as Company Builds on Recent Commercial Reorganization to Advance Growth and Market Penetration over the Next Five Years,#N/A,10/18/2013 04280A10 BW   Arrowhead to Present at Upcoming Conferences,#N/A,#N/A,#N/A,#N/A
 7/25/2012 53220K50  BW   Ligand to Report Second Quarter Results on August 8th,#N/A," 6/30/2014 45232710    BW   Biomnis, Genoma, et le Centre de génétique humaine et de diagnostics de laboratoire Martinsried, signent avec Illumina des accords visant à étendre l'accès au dépistage prénatal non invasif dans toute l’Europe", 1/07/2013 84763A10  BW   Spectrum Pharmaceuticals Announces Positive RenaZorb® Phase 1 Clinical Data Demonstrating Robust Activity in Easy-to-Swallow Pill Formulation,#N/A,10/14/2013 04280A10 BW   Arrowhead Closes Private Offering with Net Proceeds of $60 Million,#N/A,#N/A,#N/A,#N/A
 7/25/2012 53220K50  BW   Ligand Partner GlaxoSmithKline Announces Priority Review for Supplemental New Drug Application for Promacta® for the Treatment of Thrombocytopenia in Adult Patients with Chronic Hepatitis C Infection,#N/A," 6/30/2014 0733MF-E    BW   Biomnis, Genoma, and the Center for Human Genetics and Laboratory Diagnostics Martinsried, Enter Agreements with Illumina to Expand Access for Non-Invasive Prenatal Testing Across Europe", 1/02/2013 SPPI-US   BW   Spectrum Pharmaceuticals to Present Corporate Update at 31st Annual J.P. Morgan Healthcare Conference in San Francisco on January 9th,#N/A,10/08/2013 04280A10 BW   Arrowhead Prices At-Market Private Offering for $60 Million Net Proceeds,#N/A,#N/A,#N/A,#N/A
 7/20/2012 53220K50  BW   Ligand Licensee Onyx Pharmaceuticals Receives FDA Accelerated Approval of Kyprolis™ (carfilzomib) for Injection,#N/A, 6/06/2014 45232710    BW   Illumina Announces Pricing of Convertible Senior Notes,12/21/2012 84763A10  BW   Spectrum Pharmaceuticals Announces Achievement of Primary Endpoint in Belinostat Registrational Trial,#N/A,10/08/2013 04280A10 BW   Arrowhead Completes Enrollment in Phase 1 Study of ARC-520 for the Treatment of Chronic Hepatitis B,#N/A,#N/A,#N/A,#N/A
 7/19/2012 LGND-US   BW   Ligand Partner Pfizer Announces European Medicines Agency Accepts Regulatory Submission for Bazedoxifene/Conjugated Estrogens for the Treatment of Symptoms Associated with Menopause and Osteoporosis,#N/A, 6/04/2014 45232710    BW   Illumina to Offer $900 Million Convertible Senior Notes,"12/13/2012 SPPI-US   BW   Spectrum Pharmaceuticals Highlights Promising ZEVALIN®, FOLOTYN® and Belinostat Clinical Data Presented at the 54th Annual Meeting of the American Society of Hematology",#N/A, 9/19/2013 04280A10 BW   Arrowhead Promotes David Lewis to Chief Scientific Officer,#N/A,#N/A,#N/A,#N/A
 7/09/2012 LGND-US   BW   Ligand Announces New Presentation Time at the JMP Securities 7th Annual Healthcare Conference,#N/A, 5/05/2014 45232710    BW   Illumina to Webcast Live Presentation at Upcoming Investment Conferences in May and June,"12/11/2012 84763A10  BW   Spectrum Pharmaceuticals Announces Year-End, Special Cash Dividend of $0.15 per Share of Common Stock",#N/A, 8/07/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 6/27/2012 LGND-US   BW   Ligand to Present at the JMP Securities 7th Annual Healthcare Conference,#N/A, 4/29/2014 45232710    BW   Illumina Launches VeriSeq PGS,"12/07/2012 SPPI-US   BW   Spectrum Pharmaceuticals Highlights 19 Abstracts at the 54th Annual Meeting of the American Society of Hematology (ASH), Atlanta, Georgia, December 8-11, 2012",#N/A, 7/31/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 6/11/2012 LGND-US   BW   Ligand Announces Positive Preclinical Data on LGD-6972 at the American Diabetes Association’s 72nd Scientific Sessions,#N/A," 4/25/2014 45232710    BW   Illumina Files New Patent Infringement Suit Against Ariosa Diagnostics, Inc.",12/05/2012 SPPI-US   BW   Spectrum Pharmaceuticals to Present Corporate Update at Oppenheimer 23rd Annual Healthcare Conference in New York City on December 12th,#N/A, 7/23/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 5/30/2012 GSK-GB    BW   Ligand Partner GlaxoSmithKline Submits US and European Regulatory Applications for use of PROMACTA/REVOLADE to Increase Platelet Counts in Patients with Hepatitis C,#N/A, 4/22/2014 45232710    BW   Illumina Reports Strong Start to Fiscal Year 2014,11/30/2012 SPPI-US   BW   Spectrum Pharmaceuticals to Present Corporate Update at Deutsche Bank’s 2012 dbAccess BioFEST in Boston on December 4th,#N/A, 6/13/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 5/14/2012 LGND-US   BW   CORRECTING and REPLACING Ligand to Present at the Jefferies 2012 Global Healthcare Conference on June 4,#N/A," 4/07/2014 45232710    BW   Illumina to Announce First Quarter 2014 Financial Results on Tuesday, April 22, 2014",11/27/2012 SPPI-US   BW   Spectrum Pharmaceuticals Expands Manufacturing Capacity to Ensure Long-Term Supply of FUSILEV® to Meet Needs of Patients and Physicians,#N/A, 5/28/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 5/07/2012 LGND-US   BW   Ligand to Present at the Bank of America Merrill Lynch 2012 Health Care Conference on May 17,#N/A, 4/02/2014 45232710    BW   Illumina Expands Product Portfolio to Support Oncology Clinical Research and Discovery,11/26/2012 SPPI-US   BW   Spectrum Pharmaceuticals' Chairman and Chief Executive Officer Named Ernst & Young Entrepreneur of the Year® National Award Finalist,#N/A, 5/13/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 5/02/2012 53220K50  BW   Ligand Pharmaceuticals Reports First Quarter Results,#N/A, 3/10/2014 45232710    BW   WuXi PharmaTech Purchases an Illumina HiSeq X Ten Sequencing System,11/08/2012 SPPI-US   BW   Spectrum Pharmaceuticals to Present Corporate Update at Credit Suisse 2012 Healthcare Conference in Phoenix on November 15th,#N/A, 5/09/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 4/16/2012 LGND-US   BW   Ligand to Report First Quarter Results on May 2nd,#N/A, 2/26/2014 45232710    BW   Illumina’s Non-Invasive verifi® Prenatal Test Using cfDNA Significantly Reduces False Positive Rate of Fetal Aneuploidy Detection Compared to Current Standard Pregnancy Screening Practices,11/07/2012 84763A10  BW   INSERTING and REPLACING Spectrum Pharmaceuticals Reports Strong Revenues and Profits for Third Quarter; Revenues of $69 million up 35% over last year and GAAP Diluted EPS of $0.33 and Non-GAAP Diluted EPS of $0.42,#N/A, 5/07/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 3/05/2012 53220K50  BW   Ligand to Present at the 24th Annual Roth Conference on March 12,#N/A, 2/24/2014 45232710    BW   Science for Life Laboratory Joins the Illumina Genome Network,11/01/2012 84763A10  BW   Spectrum Pharmaceuticals Announces Strategic Expansion and Realignment of Sales Force Post-Allos Therapeutics Acquisition in Order to Enhance Presence in U.S. Market,#N/A, 5/06/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 2/21/2012 53220K50  BW   Ligand to Present at the Citi Global Health Care Conference on February 28th,#N/A, 2/18/2014 45232710    BW   Illumina to Webcast Live Presentations at Upcoming Investment Conferences in March,10/31/2012 84763A10  BW   Spectrum Pharmaceuticals Announces Third Quarter 2012 Financial Results Teleconference and Webcast,#N/A, 5/02/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 2/21/2012 53220K50  BW   Ligand Licenses DARA Program to Retrophin,#N/A, 2/13/2014 45232710    BW   Novogene Acquires an Illumina HiSeq X Ten Sequencing System,"10/29/2012 SPPI-US   BW   Spectrum Pharmaceuticals Appoints Industry Veteran, Former Amgen Executive Joseph Turgeon, as Senior Vice President Sales & Commercial Operations",#N/A, 4/29/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 2/09/2012 53220K50  BW   Ligand to Present at the BIO CEO and Investor Conference on February 13,#N/A," 2/12/2014 45232710    BW   Illumina Launches the Illumina Accelerator Program, World’s First Genomics Incubator",10/15/2012 SPPI-US   BW   Spectrum Pharmaceuticals Named One of the Best Places to Work in Southern Nevada,#N/A, 4/24/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 2/07/2012 53220K50  BW   Ligand Reports Fourth Quarter and Full Year 2011 Financial Results,#N/A, 1/28/2014 45232710    BW   Illumina Reports Strong Finish to Fourth Quarter and Fiscal Year 2013,10/08/2012 SPPI-US   BW   Spectrum Pharmaceuticals Announces the USPTO Has Granted Five-Year Extension for FOLOTYN® Patent,#N/A, 4/24/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A
" 2/07/2012 0012X3-E  BW   Ligand Names Nishan de Silva, M.D., Vice President of Corporate Development",#N/A, 1/21/2014 45232710    BW   Illumina Signs Master Supply Agreement to Provide Next-Generation Sequencing Technologies to LabCorp®,10/02/2012 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the 11th Annual BIO Investor Forum in San Francisco on October 9th,#N/A, 3/25/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A
" 2/01/2012 53220K50  BW   Ligand Presents Full Data from Successful Phase II Trial of Captisol-Enabled®, Propylene Glycol-Free Melphalan at the BMT Tandem Meetings",#N/A, 1/16/2014 45232710    BW   Illumina Unveils Strategic Roadmap for Market Expansion, 9/24/2012 SPPI-US   BW   Spectrum Pharmaceuticals Provides Update on Belinostat Registrational Trial for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL),#N/A, 3/14/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 2/01/2012 53220K50  BW   Ligand to Report Fourth Quarter Results on February 7,#N/A, 1/15/2014 45232710    BW   Amgen and Illumina Enter Agreement to Develop Oncology Companion Diagnostic Test, 9/19/2012 SPPI-US   BW   Spectrum Pharmaceuticals Initiates Phase 3 Study of ZEVALIN® in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL); Most Common Form of Aggressive Non-Hodgkin’s Lymphoma,#N/A, 3/07/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 1/04/2012 53220K50  BW   Ligand to Present at the Biotech Showcase Conference on January 10th,#N/A," 1/15/2014 45232710    BW   Illumina to Announce Fourth Quarter and Fiscal Year 2013 Financial Results on Tuesday, January 28, 2014", 9/13/2012 SPPI-US   BW   Spectrum Pharmaceuticals to Present Corporate Update at UBS Global Life Sciences Conference in New York City on September 20th,#N/A, 2/28/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A
12/21/2011 LGND-US   BW   Ligand Enters into Platform Captisol® License and Supply Agreements with Lilly,#N/A, 1/14/2014 45232710    BW   Illumina Launches the NextSeq™ 500 Sequencing System," 9/11/2012 SPPI-US   BW   Spectrum Pharmaceuticals Appoints Industry Veteran and Former Senior Amgen Executive, Ken Keller, as Executive Vice President, Chief Operating Officer",#N/A, 2/26/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A
12/12/2011 53220K50  BW   Ligand Announces Positive Preclinical Data on Small-Molecule GCSF Receptor Agonist at the 53rd Annual Meeting of the American Society of Hematology,#N/A, 1/14/2014 45232710    BW   Illumina Introduces the HiSeq X™ Ten Sequencing System, 9/07/2012 SPPI-US   BW   Spectrum Pharmaceuticals to Present Corporate Update at Rodman & Renshaw Annual Global Investment Conference in New York City on September 10th and at Morgan Stanley Global Healthcare Conference in New York City on September 11th,#N/A, 2/13/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A
12/07/2011 53220K50  BW   Ligand to Present at the Oppenheimer Healthcare Conference on December 14,#N/A, 1/09/2014 45232710    BW   Illumina to Provide Next-Generation Sequencing (NGS) Technologies to Quest Diagnostics, 9/06/2012 ALTH-US   BW   Spectrum Pharmaceuticals Completes Acquisition of Allos Therapeutics; Effective and Swift Integration Expected to Result In Significant Synergies,#N/A, 2/06/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A
11/08/2011 53220K50  BW   Ligand Pharmaceuticals Announces Third Quarter Results,#N/A, 1/09/2014 45232710    BW   Illumina Announces Recipients of Agricultural Greater Good Initiative Grants, 9/04/2012 ALTH-US   BW   Spectrum Pharmaceuticals and Allos Therapeutics Announce Expiration of Offering Period and Final Completion of Tender Offer for Shares of Allos Therapeutics,#N/A, 2/01/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A
11/07/2011 53220K50  BW   Ligand Announces Positive Preclinical Data on IRAK4 Program at the 2011 American College of Rheumatology Annual Scientific Meeting,#N/A,12/23/2013 45232710    BW   Illumina to Webcast Live Presentations at Upcoming Events in January, 8/30/2012 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at Stifel Nicolaus Healthcare Conference in Boston on September 6th and at BioCentury NewsMakers Conference in New York City on September 7th,#N/A, 1/25/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A
11/02/2011 53220K50  BW   Ligand Announces Successful Phase II Results for Captisol®-Enabled Propylene Glycol-Free Melphalan,#N/A,11/19/2013 45232710    BW   Illumina’s MiSeqDxTM Receives FDA Premarket Clearance with Two Cystic Fibrosis Assays and Universal Kit for Open Use," 8/28/2012 84763A10  BW   Spectrum Pharmaceuticals and Allos Therapeutics Announce That FTC Clears Transaction; Tender Offer for Shares of Allos Common Stock To Expire at 5pm Eastern Time on September 4, 2012",#N/A, 1/24/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A
10/24/2011 53220K50  BW   Save-the-Date: Ligand Hosting Promacta Panel Discussion on November 7,#N/A,11/19/2013 45232710    BW   Illumina to Webcast Live Presentation at the Piper Jaffray Annual Healthcare Conference, 8/24/2012 84763A10  BW   Spectrum Pharmaceuticals Celebrates 10 Years of Delivering Better Treatment Options to Cancer Patients and Building Shareholder Value,#N/A,12/20/2012 04280A10 BW,#N/A,#N/A,#N/A,#N/A
10/19/2011 53220K50  BW   Ligand to Report Third Quarter Results on November 8,#N/A,"11/15/2013 00BDDM-E    BW   CORRECTING and REPLACING Oxford Nanopore Announces Secondary Placing, Divestment of Illumina", 8/23/2012 SPPI-US   BW   Spectrum Pharmaceuticals to Discuss Overall Business Strategy Including FUSILEV® Growth at the Southern California Investor Conference in Newport Beach,#N/A,12/18/2012 SHP-IE   BW   Arrowhead and Shire Enter into Collaboration and License Agreement to Develop Peptide-Targeted Therapeutics,#N/A,#N/A,#N/A,#N/A
10/19/2011 53220K50  BW   Ligand Enters into Platform Captisol® License Agreement with SAGE Therapeutics,#N/A,11/11/2013 45232710    BW   Illumina Names Francis deSouza as President, 8/17/2012 84763A10  BW   Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics,#N/A,12/14/2012 04280A10 BW,#N/A,#N/A,#N/A,#N/A
10/10/2011 53220K50  BW   Ligand Enters Into Global Licensing Agreement With Chiva Pharmaceuticals for Fablyn®,#N/A,11/01/2013 006KW9-E    BW   Verinata Health’s verifi® Prenatal Test Available through the California Prenatal Screening Program, 8/15/2012 SPPI-US   BW   Spectrum Pharmaceuticals Launches a Broad-based FUSILEV® Marketing Campaign; Increases Sales Force Footprint,#N/A,12/07/2012 ARWR-US  BW   Arrowhead Announces Pricing of a Public Offering of Common Stock and Warrants,#N/A,#N/A,#N/A,#N/A
10/07/2011 53220K50  BW   Ligand to Present at the BioCentury NewsMakers Conference on October 21,#N/A,"10/28/2013 006X4F-E    BW   Illumina Signs Agreement to Acquire NextBio, Leader in Analyzing and Aggregating Complex Genomic Data", 8/14/2012 SPPI-US   BW   Spectrum Pharmaceuticals Commences Patient Enrollment in Randomized Phase 2b Clinical Trial of Ozarelix for Hormone-Dependent Prostate Cancer,#N/A,12/06/2012 ARWR-US  BW   Arrowhead Research Corporation Announces Proposed Public Offering of Common Stock and Warrants,#N/A,#N/A,#N/A,#N/A
 8/26/2011 53220K50  BW   Ligand to Present at the Stifel Nicolaus Healthcare Conference on September 9,#N/A,10/22/2013 45232710    BW   Illumina Launches TruGenome Undiagnosed Disease Test, 8/10/2012 84763A10  BW   Spectrum Pharmaceuticals Announces Authorization Of Stock Repurchase Program up to $100 Million,#N/A,11/27/2012 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 8/08/2011 GSK-GB    BW   Ligand Pharmaceuticals Announces Second Quarter Results,#N/A,10/21/2013 45232710    BW   Illumina Reports Financial Results for Third Quarter of Fiscal Year 2013," 8/08/2012 SPPI-US   BW   Spectrum Pharmaceuticals Reports Record Revenues and Strong Profits for Second Quarter; Revenues of $68.7 Million up 51.5% over Last Year and Strong non-GAAP EPS of $0.37, up 48% over Last Year",#N/A,11/13/2012 ARWR-US  BW   Arrowhead Creates Hepatitis B Clinical Advisory Board and Names Dr. Robert Gish Chairman,#N/A,#N/A,#N/A,#N/A
 8/01/2011 53220K50  BW   Ligand to Report Second Quarter Results on August 8th,#N/A,"10/21/2013 45232710    BW   University of Cambridge, Genomics England Ltd., and Illumina Collaborate to Sequence 10,000 Whole Human Genomes for National Health Service Patients", 8/03/2012 84763A10  BW   Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics,#N/A,11/12/2012 ARWR-US  BW   Arrowhead Research to Present at BIO-Europe 2012,#N/A,#N/A,#N/A,#N/A
 7/26/2011 53220K50  BW   Ligand Partner GlaxoSmithKline Receives Positive Data from Promacta® PIII ENABLE1 Study in Hepatitis C-Related Thrombocytopenia,#N/A,10/14/2013 45232710    BW   Verinata Health’s verifi® Prenatal Test Expanded to Include Option to Test for Fetal Aneuploidy in Twin Pregnancies, 8/02/2012 84763A10  BW   Spectrum Pharmaceuticals Announces Publication in the Journal of Clinical Oncology of Encouraging ZEVALIN Data in Patients with Mantel-Cell Lymphoma,#N/A,10/29/2012 ARWR-US  BW   Arrowhead Presents Data Showing 99% Target Knockdown in Monkeys Without Toxicity Using Subcutaneous Formulation of Dynamic Polyconjugate siRNA Delivery System,#N/A,#N/A,#N/A,#N/A
" 6/29/2011 LGND-US   BW   Ligand Pharmaceuticals, Inc. Secures $10 Million from Square 1 Bank",#N/A,10/09/2013 45232710    BW   Illumina Launches Infinium® HTS-24 Arrays for Unparalleled Content and Sample Throughput Capacity, 8/01/2012 84763A10  BW   Spectrum Pharmaceuticals Announces Second Quarter 2012 Financial Results Teleconference and Webcast,#N/A,10/16/2012 04280A10 BW,#N/A,#N/A,#N/A,#N/A
" 6/22/2011 53220K50  BW   Ligand to Advance Clinical Development of Captisol-enabled®, Propylene Glycol-Free Melphalan for Multiple Myeloma",#N/A,"10/07/2013 45232710    BW   Illumina to Announce Third Quarter 2013 Financial Results on Monday, October 21, 2013", 7/30/2012 84763A10  BW   Spectrum Pharmaceuticals Named One of the Best Places to Work in Orange County,#N/A, 9/05/2012 ARWR-US  BW   Arrowhead to Present at Rodman and Renshaw Annual Global Investment Conference,#N/A,#N/A,#N/A,#N/A
 6/20/2011 53220K50  BW   Reminder: Ligand to Webcast Analyst and Investor Day on June 23 in New York City,#N/A,10/07/2013 45232710    BW   Illumina Launches TruSight One Sequencing Panel, 7/26/2012 84763A10  BW   Spectrum Pharmaceuticals Announces Publication Demonstrating Enhanced Survival with ZEVALIN in Premier Medical Journal Blood,#N/A, 8/30/2012 008759-E BW   Arrowhead Completes Enrollment in Phase 1b Trial of RNAi Drug Candidate CALAA-01,#N/A,#N/A,#N/A,#N/A
 6/20/2011 53220K50  BW   Ligand Enters into Captisol® Commercial Supply Agreement with Merck,#N/A, 9/25/2013 45232710    BW   Illumina Applies CE Mark to Expanded MiSeqDx™ System, 7/20/2012 84763A10  BW   Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics,#N/A, 8/14/2012 ARWR-US  BW   Arrowhead Enters into Antibody Candidate Evaluation Agreement with Merck,#N/A,#N/A,#N/A,#N/A
" 6/06/2011 53220K50  BW   Ligand Presents Phase IIa Data on Captisol®-Enabled, Propylene Glycol-Free Melphalan at ASCO 2011",#N/A, 9/23/2013 45232710    BW   Illumina Names Dr. Richard Klausner as Senior Vice President and Chief Medical Officer, 7/09/2012 SPPI-US   BW   Spectrum Pharmaceuticals to Present at the 2012 JMP Securities Healthcare Conference,#N/A, 8/13/2012 ARWR-US  BW   Arrowhead Reports Fiscal 2012 Third Quarter Financial Results,#N/A,#N/A,#N/A,#N/A
 6/06/2011 0786F6-E  BW   Ligand Presents Multi-Dose Phase I Data on Lead SARM Molecule LGD-4033 at the Endocrine Society Annual Meeting,#N/A, 9/19/2013 45232710    BW   Verinata Health Peer-Reviewed Publication Shows Circulating Cell-Free Fetal DNA Fractions Differ in Specific Aneuploidies, 7/06/2012 84763A10  BW   Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics,#N/A, 8/13/2012 ARWR-US  BW   Arrowhead Raises $6.2 Million Through Registered Direct Offering of Common Stock and Warrants,#N/A,#N/A,#N/A,#N/A
 6/03/2011 53220K50  BW   Ligand and The Medicines Company Agree to Worldwide License for Proprietary Captisol®-Enabled Intravenous Formulation of Clopidogrel,#N/A, 9/04/2013 45232710    BW   Illumina to Supply Natera with Sequencing Instruments and Consumables for Non-Invasive Prenatal Testing (NIPT), 7/03/2012 84763A10  BW   Spectrum Pharmaceuticals Launches Lucanthone Phase 2 Clinical Trial for the Treatment of Primary Glioblastoma Multiforme (GBM),#N/A, 8/09/2012 ARWR-US  BW   Arrowhead Research to Present at 2012 Wedbush PacGrow Life Sciences Management Access Conference,#N/A,#N/A,#N/A,#N/A
 5/11/2011 53220K50  BW   Ligand to Webcast Analyst and Investor Day on June 23 in New York City,#N/A, 8/27/2013 45232710    BW   Illumina to Webcast Live Presentation at the Morgan Stanley Global Healthcare Conference, 6/21/2012 84763A10  BW   Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics,#N/A, 8/07/2012 ARWR-US  BW   Arrowhead to Report Fiscal 2012 Third Quarter Financial Results,#N/A,#N/A,#N/A,#N/A
 5/10/2011 53220K50  BW   Ligand Pharmaceuticals Reports First Quarter Results,#N/A, 8/19/2013 45232710    BW   Illumina Launches New Reagent Kits for the MiSeq® System, 6/18/2012 SPPI-US   BW   Spectrum Pharmaceuticals Announces Outstanding ZEVALIN® Clinical Data In Aggressive Relapsed/Refratory Lymphoma; Presented at the 17th Congress of the European Hematology Association,#N/A, 8/06/2012 ALNY-US  BW   Alnylam Pharmaceuticals Reports Second Quarter 2012 Financial Results,#N/A,#N/A,#N/A,#N/A
 4/27/2011 53220K50  BW   Ligand to Report First Quarter Results on May 10th,#N/A, 8/01/2013 006KW9-E    BW   Verinata Health Receives New York State Laboratory Permit for verifi® Prenatal Test, 6/07/2012 84763A10  BW   Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics,#N/A, 7/11/2012 ARWR-US  BW   Arrowhead Announces Dosing of First Patient with Anti-Obesity Treatment Adipotide® in a Phase 1 Clinical Trial,#N/A,#N/A,#N/A,#N/A
 4/20/2011 006N55-E  BW   Ligand Partner Prism Pharmaceuticals to be Acquired by Baxter,#N/A, 7/23/2013 45232710    BW   Illumina Reports Financial Results for Second Quarter of Fiscal Year 2013, 6/05/2012 SPPI-US   BW   Spectrum Pharmaceuticals Announces Promising Clinical Data for ZEVALIN® and Belinostat at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting,#N/A," 6/26/2012 ARWR-US  BW   Arrowhead Announces New Study Demonstrating Rapid Improvement in Pro-Diabetic Metabolic Markers with Anti-Obesity Drug Candidate, Adipotide®",#N/A,#N/A,#N/A,#N/A
 4/18/2011 53220K50  BW   Ligand Names Matthew W. Foehr Chief Operating Officer,#N/A," 7/23/2013 45232710    BW   Illumina Acquires Advanced Liquid Logic, Leader in Digital Microfluidics Solutions"," 5/31/2012 SPPI-US   BW   Spectrum Pharmaceuticals Highlights Seven Abstracts of Clinical Data at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, June 1-5, 2012",#N/A, 6/06/2012 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 2/23/2011 53220K50  BW   Ligand to Present at the Citi 2011 Global Healthcare Conference on March 2,#N/A, 7/22/2013 45232710    BW   HistoGenetics Selects Illumina’s MiSeq® System as Next-Generation Sequencing Platform of Choice, 5/31/2012 SPPI-US   BW   Spectrum Pharmaceuticals to Present at the Jefferies 2012 Global Healthcare Conference,#N/A, 5/22/2012 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 2/15/2011 53220K50  BW   Ligand Announces Fourth Quarter and Full Year 2010 Consolidated Financial Results,#N/A, 7/18/2013 45232710    BW   Illumina Announces Phasing Analysis Service for Human Whole-Genome Sequencing, 5/29/2012 84763A10  BW   Spectrum Pharmaceuticals Announces Enrollment of First Group of Patients in Phase 1 Clinical Trial of RenaZorb®,#N/A, 5/09/2012 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 2/09/2011 53220K50  BW   Ligand Appoints John L. LaMattina to Board of Directors,#N/A," 7/09/2013 45232710    BW   Illumina to Announce Second Quarter 2013 Financial Results on Tuesday, July 23, 2013", 5/24/2012 84763A10  BW   Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics,#N/A, 5/08/2012 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 2/08/2011 53220K50  BW   Ligand to Report Fourth Quarter Results on February 15th,#N/A, 7/01/2013 45232710    BW   Illumina Applies CE Mark to MiSeqDx™ Cystic Fibrosis System, 5/17/2012 SPPI-US   BW   Spectrum Pharmaceuticals Commences Phase 2 Study of ZEVALIN® in Combination with the Redox Modulating Agent Motexafin Gadolinium (MGd),#N/A, 5/03/2012 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 2/07/2011 005Z10-E  BW   Cellerant Therapeutics Announces Key Additions to Sr. Management Team,#N/A, 7/01/2013 45232710    BW   Verinata Health Announces Agreement with Teva Pharmaceutical Industries in Collaboration with MOR Institute for Medical Data to Commercialize the verifi® Prenatal Test in Israel, 5/10/2012 84763A10  BW   Spectrum Pharmaceuticals and Allos Therapeutics Announce Extension of Previously Announced Tender Offer For Shares of Allos Therapeutics,#N/A, 5/01/2012 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 1/26/2011 LGND-US   BW   CyDex Pharmaceuticals Approves Merger with Ligand Pharmaceuticals,#N/A," 6/20/2013 ILMN-US     BW   Syntrix Biosystems Wins Final Judgment of $115 Million in Patent Case against Illumina, Inc.", 5/08/2012 SPPI-US   BW   Spectrum Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference,#N/A, 4/11/2012 0C6S52-E BW   Arrowhead Research Corporation Acquires Alvos Therapeutics and Proprietary Library of Targeting Peptides,#N/A,#N/A,#N/A,#N/A
 1/26/2011 53220K50  BW   Ligand Acquires CyDex Pharmaceuticals,#N/A, 5/29/2013 45232710    BW   Illumina to Webcast Live Presentation at the Goldman Sacks Global Healthcare Conference, 5/01/2012 84763A10  BW   Spectrum Pharmaceuticals to Present at the Deutsche Bank 37th Annual Health Care Conference,#N/A, 3/07/2012 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 1/06/2011 53220K50  BW   Ligand Forms Strategic Drug Development Alliance with Chiva Pharmaceuticals,#N/A, 5/16/2013 45232710    BW   Illumina Launches BaseSpace® Apps, 4/26/2012 84763A10  BW   Spectrum Pharmaceuticals Reports Record Revenues and Profits for First Quarter of 2012,#N/A, 3/05/2012 04280A10 BW,#N/A,#N/A,#N/A,#N/A
12/22/2010 53220K50  BW   Ligand Earns $1 Million Upfront Payment from Pfizer on Sublicensing of Tanaproget,#N/A, 5/15/2013 45232710    BW   Illumina Announces Partnerships to Automate TruSeq® and Nextera® Sample Preparation Kits, 4/23/2012 SPPI-US   BW   Spectrum Pharmaceuticals Expands Manufacturing Capacity and Builds Inventory Reserves for FUSILEV®,#N/A, 2/29/2012 ARWR-US  BW   Arrowhead Announces Patent Issuance Covering siRNA Inhibitors of HIF-2α (EPAS1),#N/A,#N/A,#N/A,#N/A
12/04/2010 53220K50  BW   Ligand Announces Positive Preclinical Data on Small Molecule Erythropoietin Receptor Agonists,#N/A, 5/01/2013 45232710    BW   Illumina to Webcast Live Presentation at Upcoming Investment Conferences in May, 4/20/2012 ALTH-US   BW   Allos Therapeutics Announces Outcome of Request for Re-examination of CHMP Opinion for FOLOTYN® in Europe,#N/A, 2/09/2012 ARWR-US  BW   Arrowhead Reports Fiscal 2012 First Quarter Financial Results,#N/A,#N/A,#N/A,#N/A
12/03/2010 53220K50  BW   Ligand Announces Presentation of Data from Multiple Studies of Dinaciclib by its Partner Merck at the ASH Annual Meeting,#N/A, 4/25/2013 45232710    BW   Verinata Health Publishes Clinical Laboratory Performance Data for verifi® Prenatal Test, 4/19/2012 84763A10  BW   Spectrum Pharmaceuticals to Be Added to the S&P SmallCap 600 Index,#N/A, 2/02/2012 04280A10 BW,#N/A,#N/A,#N/A,#N/A
11/19/2010 53220K50  BW   Ligand Reverse Stock Split Effective Today,#N/A, 4/22/2013 45232710    BW   Illumina Names Charles Dadswell as Senior Vice President and General Counsel, 4/17/2012 84763A10  BW   Spectrum Pharmaceuticals Announces First Quarter 2012 Financial Results Teleconference and Webcast,#N/A, 1/05/2012 04280A10 BW,#N/A,#N/A,#N/A,#N/A
11/09/2010 53220K50  BW   Ligand Pharmaceuticals Announces Third Quarter Results,#N/A, 4/22/2013 45232710    BW   Illumina Reports Strong Start to Fiscal Year 2013, 4/16/2012 84763A10  BW   Spectrum Pharmaceuticals Commences Tender Offer for All Outstanding Shares of Allos Therapeutics,#N/A, 1/04/2012 04280A10 BW,#N/A,#N/A,#N/A,#N/A
11/09/2010 53220K50  BW   Ligand Announces 1-for-6 Reverse Stock Split,#N/A, 4/18/2013 0BWZ9P-E    BW   Illumina and Kindstar Global Announce Strategic Collaboration to Facilitate Clinical Adoption of Illumina Technologies in Asia," 4/10/2012 SPPI-US   BW   PharmaVigilant Selected by Spectrum Pharmaceuticals, Inc. to Support 10 Studies",#N/A,12/20/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A
11/02/2010 53220K50  BW   Ligand Announces Approval for Revolade® in Japan,#N/A," 4/08/2013 45232710    BW   Illumina to Announce First Quarter 2013 Financial Results on Monday, April 22, 2013", 4/05/2012 84763A10  BW   Spectrum Pharmaceuticals to Acquire Allos Therapeutics: Acquisition Expected to Be Accretive on a Cash Basis in Q4 of 2012,#N/A,12/19/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A
11/02/2010 53220K50  BW   Ligand Awarded $2 Million from U.S. Government Under the Patient Protection and Affordable Care Act,#N/A, 4/04/2013 ILMN-US     BW   Illumina Launches TruSight™ Tumor Content Set, 4/05/2012 84763A10  BW   Spectrum Pharmaceuticals Announces Results of Apaziquone Phase 3 Clinical Trials,#N/A,12/15/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A
10/29/2010 53220K50  BW   Ligand to Report Third Quarter Results on November 9,#N/A, 3/27/2013 45232710    BW   Illumina Technology Enables Findings of the Collaborative Oncological Gene-Environment Study (COGS), 3/27/2012 84763A10  BW   Spectrum Announces Launch of New Patient-to-Patient Educational Campaign for ZEVALIN® on ZEVALIN.com,#N/A,11/28/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A
10/25/2010 53220K50  BW   Ligand to Present at the Oppenheimer 21st Annual Healthcare Conference on November 2,#N/A," 3/21/2013 45232710    BW   Illumina Announces Favorable Outcome of Its Patent Litigation Against Life Technologies, Inc.", 3/12/2012 84763A10  BW   Spectrum Pharmaceuticals to Present at the 24th Annual ROTH Conference,#N/A,11/23/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A
10/13/2010 53220K50  BW   Ligand Announces Market Launch of Bazedoxifene in Japan and Spain for the Treatment of Postmenopausal Osteoporosis,#N/A," 3/14/2013 45232710    BW   Illumina Announces Outcome of Its Patent Litigation Against Syntrix Biosystems, Inc."," 3/01/2012 84763A10  BW   Spectrum Pharmaceuticals Reports Record Revenues, Profits, and Cash Generated from Operations for the Twelve-Month Period Ended December 31, 2011",#N/A,11/16/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A
10/08/2010 53220K50  BW   Ligand Appoints Sunil Patel to Board of Directors,#N/A, 2/21/2013 45232710    BW   Illumina Completes Acquisition of Verinata Health, 2/24/2012 84763A10  BW   Spectrum Pharmaceuticals to Present at the Citi 2012 Global Health Care and the RBC Capital Markets Health Care Conferences,#N/A,11/14/2011 07J23G-E BW   Leonardo Biosystems Receives Second $1.25 Million Investment from the Texas Emerging Technology Fund,#N/A,#N/A,#N/A,#N/A
10/07/2010 53220K50  BW   Ligand to Divest Combinatorial Compound Library and Screening Technology for $1.8 Million,#N/A, 2/20/2013 45232710    BW   Illumina to Webcast Live Presentation at the Cowen and Company Annual Health Care Conference, 2/23/2012 84763A10  BW   Spectrum Pharmaceuticals Announces Date and Time for Its Fourth Quarter and Fiscal Year 2011 Financial Results Conference Call,#N/A,11/10/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 9/17/2010 53220K50  BW   Ligand Enters into Agreement with Proximagen for CXCR4 Target,#N/A," 2/01/2013 07G69B-E    BW   Research and Markets: Global Array Instruments Market 2012-2016 with Bio-Rad Laboratories Inc., Siemens and Illumina Inc. Dominating", 2/07/2012 84763A10  BW   Spectrum Pharmaceuticals to Present at the BIO CEO Investor Conference,#N/A,11/07/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 9/10/2010 53220K50  BW   Ligand to Present at the Stifel Nicolaus Healthcare Conference on September 17,#N/A," 1/31/2013 0CNWYH-E    BW   Research and Markets: Global DNA Sequencing Products Market 2012-2016 with Hoffmann-La Roche Ltd., Knome Inc. and RainDance Technologies Inc. Dominating"," 1/31/2012 128940-KR BW   Spectrum Pharmaceuticals In-Licenses a Novel, Long-Acting GCSF Drug in U.S. Clinical Trials from Hanmi Pharmaceuticals",#N/A,11/03/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 8/05/2010 53220K50  BW   Ligand Pharmaceuticals Announces Second Quarter Results,#N/A, 1/28/2013 45232710    BW   Illumina Reports Record Financial Results for Fourth Quarter and Fiscal Year 2012, 1/27/2012 84763A10  BW   Spectrum Pharmaceuticals Strengthens Commercial Operations,#N/A,11/02/2011 ARWR-US  BW   Vascular Research Further Validates the Drug Development Programs of Arrowhead Research Subsidiary Ablaris Therapeutics and Alvos Therapeutics,#N/A,#N/A,#N/A,#N/A
 7/26/2010 53220K50  BW   Ligand to Present at the BMO Capital Markets Healthcare Conference on August 5,#N/A, 1/15/2013 45232710    BW   Illumina Announces Recipients of Agricultural Greater Good Initiative Grants, 1/25/2012 84763A10  BW   Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN®,#N/A,10/27/2011 ARWR-US  BW   Arrowhead Research Appoints Bruce Given M.D. Chief Operating Officer,#N/A,#N/A,#N/A,#N/A
 7/22/2010 53220K50  BW   Ligand to Report Second Quarter Results on August 5th,#N/A," 1/15/2013 45232710    BW   Illumina to Announce Fourth Quarter and Fiscal Year 2012 Financial Results on Monday, January 28, 2013"," 1/23/2012 84763A10  BW   ZEVALIN Plus High Dose Chemotherapy (Z-BEAM) Highly Effective in Aggressive Lymphoma; Randomized Study Published in “CANCER”, the Journal of the American Cancer Society",#N/A,10/24/2011 ARWR-US  BW   Arrowhead Research Corporation Acquires Roche RNA Assets and Site,#N/A,#N/A,#N/A,#N/A
 7/15/2010 53220K50  BW   Ligand Launches New Corporate Web Site,#N/A, 1/08/2013 45232710    BW   Illumina Announces Sequencing Technology Innovations, 1/04/2012 84763A10  BW   Spectrum Pharmaceuticals to Present at the J. P. Morgan Healthcare Conference,#N/A,10/04/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 6/15/2010 53220K50  BW   Ligand Board Authorizes Reverse Stock Split and $10 Million Share Repurchase,#N/A, 1/07/2013 06V2JT-E    BW   Partners HealthCare and Illumina Announce Founding Members of GeneInsight Network,12/12/2011 84763A10  BW   Impressive ZEVALIN® Data Highlighted at 53rd Annual Meeting of the American Society of Hematology; Spectrum to Increase Clinical Efforts to Expand ZEVALIN Indications,#N/A, 9/15/2011 05TJN5-E BW   Elan Announces Board of Director Changes,#N/A,#N/A,#N/A,#N/A
 6/02/2010 53220K50  BW   Ligand to Present at the Jefferies Global Life Sciences Conference on June 9,#N/A," 1/07/2013 006KW9-E    BW   Illumina Strengthens Leadership Position in Reproductive Health with Agreement to Acquire Verinata Health, Inc.","12/12/2011 84763A10  BW   Multifaceted Repositioning Campaign for ZEVALIN® Unveiled at ASH 2011, Following Recent FDA Approval to Remove Bioscan Requirement",#N/A, 8/08/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 5/21/2010 53220K50  BW   Ligand Acquired Milestone and Royalty Interest in AstraZeneca IL-9 Program for Asthma,#N/A, 1/02/2013 ILMN-US     BW   Illumina to Webcast Live Presentation at the J.P. Morgan Healthcare Conference,"12/09/2011 84763A10  BW   Spectrum Pharmaceuticals Affirms Strong Patent Protection for FUSILEV® (levoleucovorin) Through December 31, 2019",#N/A, 8/01/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 5/06/2010 53220K50  BW   Ligand to Present at the MDB Capital Group Bright Lights Conference on May 11,#N/A,11/29/2012 ILMN-US     BW   Illumina Names Dr. Robert S. Epstein to its Board of Directors,"12/09/2011 84763A10  BW   Spectrum Pharmaceuticals Announces 19 ZEVALIN Presentations at the 53rd Annual Meeting of the American Society of Hematology (ASH) in San Diego, California, December 10-13, 2011",#N/A, 7/26/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 5/05/2010 53220K50  BW   Ligand Pharmaceuticals Announces First Quarter Results,#N/A,"11/26/2012 GNOM.XX2-US BW   Illumina Announces New Ruling in its Patent Litigation Against Complete Genomics, Inc.",12/07/2011 NVS-CH    BW   Decision Resources to Release Bladder Cancer Drug Market Forecast Through 2020,#N/A, 6/21/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 4/26/2010 53220K50  BW   Ligand to Report First Quarter Results on May 5th,#N/A,11/14/2012 ILMN-US     BW   Illumina to Webcast Live Presentation at Piper Jaffray Health Care Conference,12/07/2011 84763A10  BW   Spectrum Pharmaceuticals to Present at the Oppenheimer & Co. 22nd Annual Healthcare Conference,#N/A, 6/16/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 4/20/2010 53220K50  BW   Ligand Earns $6.5 Million Milestone Payment from Roche,#N/A,"11/12/2012 05WNSJ-E    BW   VWR International, LLC to Distribute Illumina’s qPCR Portfolio",12/05/2011 84763A10  BW   Spectrum Pharmaceuticals Files IND Application with U.S. FDA for SPI-014,#N/A, 6/09/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 3/29/2010 53220K50  BW   Ligand Presents First-in-Human Phase I Data on Lead SARM Molecule LGD-4033 at the International Congress of Endocrinology,#N/A,11/07/2012 ILMN-US     BW   Illumina Announces Winners of MiSeq® Grant Program,"11/28/2011 84763A10  BW   Spectrum Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell on Tuesday, November 29, 2011",#N/A, 5/12/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 3/12/2010 53220K50  BW   Ligand Announces Approval for Revolade® in Europe,#N/A,11/07/2012 45232710    BW   Caris Life Sciences Selects Illumina’s MiSeq® System to Enable Next-Generation Sequencing as Part of its Molecular Profiling Service,11/21/2011 84763A10  BW   FDA Approves the Removal of the Bioscan Requirement for ZEVALIN® Treatment,#N/A, 5/04/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 3/01/2010 53220K50  BW   Ligand to Present at the Cowen & Company 30th Annual Healthcare Conference on March 11,#N/A,11/06/2012 ILMN-US     BW   Biomatters’ Molecular Profiler Now Available in Illumina’s BaseSpace Apps,11/09/2011 84763A10  BW   Spectrum Pharmaceuticals to Present at the Lazard Capital Markets 8th Annual Healthcare Conference,#N/A, 5/03/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 2/19/2010 LGND-US   BW   A.P. Pharma Appoints Stephen R. Davis to Its Board of Directors,#N/A,10/23/2012 45232710    BW   Illumina Reports Financial Results for Third Quarter of Fiscal Year 2012,"10/28/2011 84763A10  BW   Spectrum Pharmaceuticals, Inc. Reports Strongest Financial Position in Company History: Record Revenues, Profits, and Cash Generated from Operations for the Three- and Nine-Month Periods Ended September 30, 2011",#N/A, 4/27/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 2/09/2010 53220K50  BW   Ligand Announces Fourth Quarter and Full Year 2009 Consolidated Financial Results,#N/A,"10/18/2012 45232710    BW   Illumina Comments on a Ruling in its Patent Litigation Against Complete Genomics, Inc.",10/24/2011 84763A10  BW   Spectrum Pharmaceuticals Announces Date and Time for Its Third Quarter and Nine-Month 2011 Financial Results Conference Call,#N/A, 4/06/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 2/01/2010 53220K50  BW   Ligand to Report Fourth Quarter Results on February 9th,#N/A,10/16/2012 ILMN-US     BW   Illumina Launches Infinium® HumanCore Arrays for Economical Large-Scale Genetic Studies,10/19/2011 84763A10  BW   LifeSci Advisors Publishes FUSILEV Survey Results,#N/A, 3/08/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A
 1/28/2010 53220K50  BW,#N/A,"10/15/2012 45232710    BW   Illumina to Announce Third Quarter 2012 Results on Tuesday, October 23, 2012"," 9/28/2011 84763A10  BW   Spectrum Pharmaceuticals Strengthens Commercial Operations with Appointment of Brian Holzer MD, MBA as Executive Director of Brand Management",#N/A, 2/10/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 9/19/2012 064CYH-E    BW   Illumina Acquires BlueGnome, Leading Provider of Cytogenetics and In Vitro Fertilization Screening Solutions", 9/26/2011 84763A10  BW   Spectrum Pharmaceuticals Completes Enrollment in the Belinostat Pivotal Trial for Relapsed/Refractory Peripheral T-Cell Lymphoma,#N/A, 2/09/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 9/18/2012 45232710    BW   Illumina Awarded FDA Contract for Next Generation Sequencing (NGS) Technology to Identify Foodborne Pathogens, 9/23/2011 84763A10  BW   Spectrum Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference,#N/A, 2/04/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 9/18/2012 ILMN-US     BW   Illumina Introduces TruSeq® Stranded mRNA and Total RNA Sequencing Sample Preparation Solutions, 9/20/2011 84763A10  BW   Spectrum Pharmaceuticals Receives Approximately $25 Million from Warrant Exercise,#N/A, 1/18/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 9/11/2012 06V2JT-E    BW   Illumina and Partners HealthCare Announce Alliance to Introduce Next-Generation Sequencing Clinical Interpretation and Reporting Tools, 9/19/2011 84763A10  BW   Spectrum Pharmaceuticals Announces Impressive Responses in Difficult to Treat Carcinomas with SPI-1620 in a Phase I Study,#N/A, 1/18/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 9/11/2012 ILMN-US     BW   Illumina Announces Expedited Individual Genome Sequencing Service (IGS), 9/16/2011 84763A10  BW   Spectrum Pharmaceuticals to Present at the UBS Global Life Sciences Conference,#N/A,12/22/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 9/11/2012 00CX0X-E    BW   Illumina Launches TruSightTM Targeted Sequencing Content Sets, 9/13/2011 84763A10  BW   Spectrum Pharmaceuticals Initiates Stock Repurchase Program,#N/A,12/20/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 9/10/2012 ILMN-US     BW   Illumina Names Paul Bianchi as Senior Vice President of Human Resources, 9/09/2011 84763A10  BW   Spectrum Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference,#N/A,"12/16/2010 06GVMY-E BW   Arrowhead Research to Report Fiscal 2010 Fourth Quarter and Year-End Financial Results and Host Conference Call on Wednesday, December 22, 2010",#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 9/04/2012 ILMN-US     BW   Illumina to Webcast Live Presentations at Upcoming Investment Conferences in September, 9/01/2011 84763A10  BW   Spectrum Pharmaceuticals to Present at the Stifel Nicolaus 2011 Healthcare Conference,#N/A,12/09/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 8/29/2012 HLCSQ-US    BW   Illumina Announces Favorable Outcome of its Patent Litigation Against Helicos BioSciences Corporation," 8/04/2011 84763A10  BW   Spectrum Pharmaceuticals Generates Cash from Operations, Reports Third Consecutive Profitable Quarter, and Record Revenue for the Three- and Six-Month Periods Ended June 30, 2011; Strongest Financial Position in Company History",#N/A,12/08/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 8/07/2012 065C1X-E    BW   NanoString Technologies Names Dale R. Levitzke Vice President of Global Sales for Life Sciences, 7/27/2011 84763A10  BW   Spectrum Pharmaceuticals Announces Date and Time for Its Second Quarter and Six-Month 2011 Financial Results Conference Call,#N/A,11/29/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 7/24/2012 ILMN-US     BW   Illumina Reports Financial Results for Second Quarter of Fiscal Year 2012, 6/21/2011 84763A10  BW   Spectrum Pharmaceuticals Has Ample Supplies of FUSILEV® to Meet the Growing Demand of Colorectal Cancer Patients in the U.S.,#N/A,11/23/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 7/24/2012 ILMN-US     BW   Illumina Announces BaseSpace® Pricing for Data Storage and Processing," 6/20/2011 84763A10  BW   Spectrum Pharmaceuticals’ ZEVALIN® Was Highlighted During Oral Presentations and Abstracts at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland",#N/A,11/04/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 7/23/2012 ILMN-US     BW   Illumina Introduces Universal Real-Time PCR Reagent Portfolio, 6/15/2011 84763A10  BW   Spectrum Pharmaceuticals Announces Authorization of Stock Repurchase Program up to $25 Million,#N/A,10/27/2010 ARWR-US  BW   NanoIntegris and Unidym Execute Global Distribution Agreement for HiPco Carbon Nanotubes,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 7/23/2012 008383-E    BW   Illumina Countersues IBS and Qiagen for Patent Infringement, 6/14/2011 84763A10  BW   Spectrum Pharmaceuticals Announces Results of Annual Meeting of Shareholders,#N/A,10/26/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 7/17/2012 ILMN-US     BW   Illumina Introduces Nextera® Exome and Custom Enrichment Sample Preparation Kits, 6/13/2011 09ZV3Y-E  BW   Spectrum Pharmaceuticals’ Chairman and Chief Executive Officer Named an Ernst & Young Orange County Region Entrepreneur of the Year® Award Winner,#N/A,10/18/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 7/13/2012 45232710    BW   Illumina to Announce Second Quarter 2012 Results on Tuesday, July 24, 2012"," 6/13/2011 84763A10  BW   Spectrum Pharmaceuticals Announces Promotions of Steven M. Fruchtman, MD, to Chief Medical Officer, Head of Medical & Regulatory Affairs, and Nozar Azarnia, PhD, to Head of Biostatistics and Data Management",#N/A, 9/29/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 7/03/2012 TSRX-US     BW   Corporate Directors Forum Hosts Open Breakfast Event: ‘Power and Politics Inside the Boardroom’, 5/31/2011 84763A10  BW   Spectrum Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference,#N/A, 9/28/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 6/20/2012 ILMN-US     BW   Illumina Announces RapidTrack Whole Genome Sequencing Service, 5/23/2011 84763A10  BW   Spectrum Pharmaceuticals Announces ZEVALIN® and Belinostat Abstracts to Be Presented at the American Society of Clinical Oncology Annual Meeting,#N/A, 9/23/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 6/18/2012 GNOM.XX2-US BW   Illumina Files Second Patent Infringement Suit Against Complete Genomics, Inc.", 5/12/2011 84763A10  BW   Spectrum Pharmaceuticals’ Chairman and Chief Executive Officer Named Ernst & Young Entrepreneur of the Year® Regional Award Finalist,#N/A, 9/09/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 6/04/2012 LIFE.XX5-US BW   Affymetrix, Illumina and Life Technologies Hold Entrenched Leadership Positions in Key Gene Expression Profiling Market Segments Revealed in New Report from Percepta Associates"," 5/04/2011 84763A10  BW   Spectrum Pharmaceuticals Reports Record Profit and Record Revenue for First Quarter 2011, a Four-Fold Revenue Increase over First Quarter 2010",#N/A, 8/19/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 5/31/2012 ILMN-US     BW   Illumina Introduces Nextera® XT DNA Sample Preparation Kits, 4/29/2011 84763A10  BW   FDA Approves FUSILEV® for Use in Patients with Colorectal Cancer,#N/A, 8/12/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 5/30/2012 ILMN-US     BW   Illumina to Webcast Live Presentations at Upcoming Investment Conferences in June, 4/27/2011 84763A10  BW   Spectrum Pharmaceuticals Announces Record Revenue and Record Profit in First Quarter 2011,#N/A, 8/10/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 5/29/2012 ILMN-US     BW   Queensland Centre for Medical Genomics Adopts Illumina Sequencing for Australian ICGC Program, 4/21/2011 84763A10  BW   Spectrum Pharmaceuticals Announces FDA Approval of FUSILEV®’s Ready-to-Use Formulation (RTU),#N/A, 8/05/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 5/23/2012 06NNTP-E    BW   Cold Spring Harbor Laboratory Joins the Illumina Genome Network, 3/28/2011 84763A10  BW   Independent Data Monitoring Committee Recommends Continuation of Spectrum Pharmaceuticals’ Pivotal Registrational Study of Belinostat in Peripheral T-Cell Lymphoma,#N/A, 6/23/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 5/22/2012 ILMN-US     BW   New York Genome Center Announces Formal Commencement of Collaborative Relationship with Illumina, 3/22/2011 84763A10  BW   FDA Accepts for Review Spectrum Pharmaceuticals’ ZEVALIN® Submission for the Removal of the Bioscan,#N/A, 6/17/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 5/02/2012 ILMN-US     BW   Illumina to Webcast Live Presentations at Upcoming Investment Conferences in May, 3/11/2011 84763A10  BW   Spectrum Pharmaceuticals to Present at the 23rd Annual ROTH OC Growth Stock Conference,#N/A, 6/15/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 4/25/2012 45232710    BW   Illumina Introduces BaseSpace Apps, Solutions for Genome Informatics", 3/10/2011 84763A10  BW   Spectrum Pharmaceuticals Reports Profitable Fourth Quarter and Record Revenue Growth for 2010,#N/A, 6/14/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/24/2012 45232710    BW   Illumina Launches MyGenome® App for iPad®, 3/07/2011 84763A10  BW   Spectrum Pharmaceuticals Announces Date and Time for Fourth Quarter and Fiscal 2010 Corporate Update Conference Call,#N/A, 6/07/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/23/2012 45232710    BW   Illumina Reports Financial Results for First Quarter of Fiscal Year 2012, 3/02/2011 84763A10  BW   Spectrum Pharmaceuticals to Present at the 31st Annual Cowen and Company Health Care Conference,#N/A, 6/04/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/18/2012 ILMN-US     BW   Illumina Announces Preliminary Voting Results for 2012 Annual Meeting of Stockholders, 2/25/2011 SPPI-US   BW   Spectrum Pharmaceuticals to Present at the RBC Capital Markets 2011 Health Care Investor Conference,#N/A, 6/01/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 4/18/2012 ROG-CH      BW   Roche decides not to extend its tender offer for Illumina, Inc."," 2/24/2011 84763A10  BW   Spectrum Pharmaceuticals Appoints Steven M. Fruchtman, MD, an Industry Veteran, as Vice President of Clinical Development",#N/A, 5/28/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 4/16/2012 45232710    BW   Illumina to Announce First Quarter 2012 Results on Monday, April 23, 2012", 2/23/2011 SPPI-US   BW   Spectrum Pharmaceuticals to Present at the Citi Investment Research 2011 Global Health Care Investor Conference,#N/A, 5/27/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/12/2012 ILMN-US     BW   Roche issues statement regarding Illumina offer," 2/15/2011 84763A10  BW   Spectrum Pharmaceuticals Announces Record Revenue Growth in Fourth Quarter and Fiscal Year 2010; Ends Year with $104 Million in Cash, Cash Equivalents and Investments",#N/A, 5/19/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/11/2012 ROG-CH      BW   Roche sends open letter to Illumina shareholders, 2/08/2011 84763A10  BW   Spectrum Pharmaceuticals to Present at the BIO CEO Investor Conference,#N/A, 5/13/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/10/2012 ILMN-US     BW   Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote for the Election of All Illumina Nominees Using Management’s WHITE Proxy Card, 1/24/2011 84763A10  BW   Spectrum Pharmaceuticals Submits Data to FDA in Support of Bioscan Removal for ZEVALIN®,#N/A, 5/07/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/09/2012 ILMN-US     BW   Illumina’s Board of Directors Sends Fourth Letter to Stockholders, 1/10/2011 076XLQ-E  BW   Spectrum Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference,#N/A, 4/26/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/06/2012 ROG-CH      BW   Roche disappointed with ISS recommendation, 1/06/2011 84763A10  BW   Spectrum Pharmaceuticals Announces Initiation of a Required Phase 1 Study of Apaziquone in Japan by Nippon Kayaku,#N/A, 4/20/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/06/2012 05LY6L-E    BW   Leading Proxy Advisory Firms Issue Reports in Strong Support of Illumina, 1/05/2011 84763A10  BW   Spectrum Pharmaceuticals to Develop Biosimilar Rituximab,#N/A, 4/15/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/04/2012 ROG-CH      BW   Roche sends second letter to Illumina shareholders, 1/04/2011 84763A10  BW   Spectrum Pharmaceuticals Submits Supplemental New Drug Application (sNDA) for Ready-to-Use Formulation of FUSILEV® in Colorectal Cancer,#N/A, 4/12/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 4/03/2012 00BMWM-E    BW   Knome Expands Executive Management Team, Positions Company for Growth",12/29/2010 84763A10  BW   Belinostat Plus Tarceva® Trial in Patients with Non-Small Cell Lung Cancer Enrolls First Patient,#N/A, 4/07/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/03/2012 ILMN-US     BW   Knome Selected as a Genome Interpretation Partner for Illumina Genome Network,"12/23/2010 84763A10  BW   Phase 2 Trial of Belinostat, a Novel HDAC Inhibitor, in the Treatment of Carcinoma of Unknown Primary (CUP) Meets Enrollment Target",#N/A, 3/22/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/03/2012 45232710    BW   Illumina’s Board of Directors Sends Third Letter to Stockholders,12/20/2010 84763A10  BW   Spectrum Pharmaceuticals Selected to Be Listed on NASDAQ Global Select MarketSM,#N/A, 3/18/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 4/03/2012 ROG-CH      BW   Roche disappointed by Illumina, Inc.’s Board of Directors’ rejection",12/07/2010 84763A10  BW   ZEVALIN Data as Preparatory Regimen Presented Prior to Autologous and Allogeneic Stem Cell Transplantation in the Treatment of Non-Hodgkin’s Lymphoma,#N/A, 2/11/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/02/2012 45232710    BW   Illumina’s Board Unanimously Rejects Roche’s Revised Unsolicited Offer,12/06/2010 84763A10  BW   ZEVALIN Demonstrates 35-Month Progression-Free Survival Benefit after Single Dose in Patients with Non-Hodgkin’s Lymphoma,#N/A, 2/08/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/02/2012 45232710    BW   Illumina Announces Preliminary Revenue for First Quarter 2012,12/06/2010 84763A10  BW   Single Dose ZEVALIN in First-Ever Phase 2 Monotherapy Trial for Non-Hodgkin’s Lymphoma Shows Significant and Durable Clinical Responses,#N/A, 2/08/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/29/2012 ILMN-US     BW   Illumina Advises Stockholders to Defer Taking Any Action in Response to Roche’s Increased Offer,11/30/2010 84763A10  BW   Spectrum Pharmaceuticals Board Approves Replacement of Stockholder Rights Agreement,#N/A, 2/03/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/29/2012 ROG-CH      BW   Roche increases offer price for Illumina shares to US$ 51.00 per share,"11/29/2010 84763A10  BW   FDA Accepts for Review Spectrum’s Response on FUSILEV® as a Class 2 Submission, and Establishes April 29, 2011 as PDUFA Action Date",#N/A, 2/02/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/26/2012 45232710    BW   Illumina’s Board of Directors Sends Second Letter to Stockholders,"11/18/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Presentation of Four Key Belinostat Abstracts at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida on December 4-7, 2010",#N/A, 2/01/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/26/2012 45232710    BW   Illumina Comments on Second Extension of Roche’s Unsolicited Tender Offer,"11/15/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Presentation of Eleven (11) Key ZEVALIN Abstracts & Papers at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida on December 4-7, 2010",#N/A, 1/20/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/26/2012 ILMN-US     BW   Roche extends tender offer for Illumina,11/12/2010 84763A10  BW   Spectrum Pharmaceuticals Ranked One of the Fastest Growing Companies in North America on Deloitte’s 2010 Technology Fast 500™,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 3/22/2012 45232710    BW   Macrogen, Inc. Increases Investment in Illumina’s Next-Generation Sequencing Technology",11/04/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Third Quarter 2010 Financial and Operating Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/20/2012 45232710    BW   Roche files definitive proxy statement,11/03/2010 84763A10  BW   Spectrum Pharmaceuticals Receives Nearly $1 Million in Grants for Qualifying Therapeutic Discovery Projects,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/19/2012 45232710    BW   Illumina Files Definitive Proxy Materials and Sends Letter to Stockholders,11/02/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Date and Time for Third Quarter 2010 Corporate Update Conference Call,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/07/2012 45232710    BW   Illumina Introduces TruSeq® Amplicon - Cancer Panel for MiSeq® System,11/01/2010 84763A10  BW   Spectrum Pharmaceuticals Submits Complete Response to FDA’s Complete Response Letter for FUSILEV in Colorectal Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/02/2012 45232710    BW   Illumina to Webcast Live Presentations at Upcoming Investment Conferences in March,10/12/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Appointment of Brett L. Scott as Senior Vice President and Acting Chief Financial Officer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 3/01/2012 45232710    BW   Illumina Announces Outcome of First Phase of Its Patent Litigation Against LadaTech, LLC",10/04/2010 84763A10  BW   Spectrum Pharmaceuticals to Present at the Jefferies 2010 Global Specialty Pharma & European Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/01/2012 GSK-GB      BW   LadaTech announces Illumina Found to Infringe Patent," 9/27/2010 84763A10  BW   Spectrum Pharmaceuticals to Ring the NASDAQ Stock Market Opening Bell on Tuesday, September 28, 2010",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 2/27/2012 45232710    BW   Illumina Comments on Roche’s Unsolicited Tender Offer Extension, 9/15/2010 84763A10  BW   Spectrum Pharmaceuticals to Present at the UBS Global Life Sciences Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 2/27/2012 ILMN-US     BW   Roche extends tender offer for Illumina, 9/09/2010 84763A10  BW   Spectrum Pharmaceuticals to Present at the Stifel Nicolaus 2010 Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 2/16/2012 06XD04-E    BW   New York Genome Center Launches Major Initiative with the Feinstein Institute for Medical Research to Sequence Whole Genomes of Alzheimer’s Patients," 9/08/2010 84763A10  BW   Spectrum Pharmaceuticals to Present at the Robert W. Baird & Co., Inc. 2010 Healthcare Conference",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 2/16/2012 45232710    BW   Illumina Launches Cancer Analysis Service, 9/07/2010 84763A10  BW   Spectrum Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 2/16/2012 GNOM.XX2-US BW   Illumina Announces Favorable Patent Claim Construction Ruling in Litigation Against Complete Genomics, Inc.", 8/11/2010 84763A10  BW   Spectrum Pharmaceuticals to Present at the 2010 Southern California Investor Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 2/15/2012 45232710    BW   The Broad Institute Joins the Illumina Genome Network, 8/09/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Second Quarter 2010 Corporate Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 2/08/2012 ILMN-US     BW   Faruqi & Faruqi, LLP Announces Investigation of Illumina, Inc.", 8/06/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Date and Time of Second Quarter 2010 Corporate Update Conference Call,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 2/08/2012 ROG-CH      BW   Roche disappointed by the actions of Illumina, Inc.’s Board of Directors"," 7/19/2010 84763A10  BW   Spectrum Pharmaceuticals Appoints George Tidmarsh, M.D., Ph.D, as Senior Vice President, Chief Scientific Officer",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 2/07/2012 45232710    BW   CORRECTING and REPLACING Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2011, 7/01/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Results of Annual Meeting of Shareholders,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 2/07/2012 45232710    BW   Illumina’s Board Unanimously Rejects Roche’s Unsolicited Tender Offer as Inadequate, 6/23/2010 84763A10  BW   Spectrum Pharmaceuticals Appoints James E. Shields as Chief Commercial Officer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/31/2012 ILMN-US     BW   Illumina Comments on Roche’s Director Nominees and Proposals," 6/18/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Adjournment of Annual Meeting of Shareholders until July 1, 2010",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/31/2012 ROG-CH      BW   Roche to nominate slate of independent directors for election at Illumina, Inc.’s 2012 annual meeting", 6/07/2010 84763A10  BW   Spectrum Pharmaceuticals to Present at Two (2) Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/27/2012 ILMN-US     BW   The Law Firm of Weiss & Lurie Investigates Illumina Inc.," 5/24/2010 84763A10  BW   Spectrum Pharmaceuticals to Present at the 2010 Citi Investment Research Global Healthcare Conference on Wednesday, May 26",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/27/2012 ILMN-US     BW   Roche commences tender offer for Illumina, Inc. for $44.50 per share in cash", 5/21/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Three Additional Belinostat Abstracts at the 2010 Annual Meeting of the American Society of Clinical Oncology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/27/2012 45232710    BW   Holzer Holzer & Fistel, LLC Announces Investigation into Potential Claims for Breaches of Fiduciary Duty by Illumina Inc’s Board of Directors", 5/21/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Belinostat PTCL Abstract at the 2010 Annual Meeting of the American Society of Clinical Oncology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/27/2012 45232710    BW   Johnson & Weaver, LLP Announces Investigation in Connection with the Possible Acquisition of Illumina, Inc. by Roche"," 5/14/2010 84763A10  BW   Spectrum Pharmaceuticals to Present at the 6th Annual Rodman & Renshaw Global Healthcare Conference on Tuesday, May 18th",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/27/2012 ILMN-US     BW   Illumina’s Board of Directors to Review Unsolicited Tender Offer from Roche, 5/10/2010 84763A10  BW   Spectrum Pharmaceuticals Announces First Quarter 2010 Corporate Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/26/2012 45232710    BW   Ryan & Maniskas, LLP Announces Investigation of Illumina, Inc.", 5/07/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Date for First Quarter 2010 Corporate Update and Pipeline Review Conference Call,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/26/2012 ROG-CH      BW   Roche responds to adoption of shareholder rights plan by Illumina Board of Directors," 5/03/2010 84763A10  BW   Spectrum Pharmaceuticals to Present at the 2010 BIO International Convention Business Forum on Wednesday, May 5, 2010",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/26/2012 ILMN-US     BW   San Diego Law Firm Robbins Umeda LLP Announces an Investigation of Illumina, Inc.", 4/21/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Belinostat Data Presentation at 101st Annual Meeting of the American Association for Cancer Research,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/26/2012 45232710    BW   The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Illumina, Inc. in Connection with a Merger Proposal from Roche", 4/05/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2009 Corporate Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/26/2012 ILMN-US     BW   Illumina Adopts Stockholder Rights Agreement, 4/01/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Delay in Filing 2009 Annual Report on Form 10-K,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/25/2012 ILMN-US     BW   Law Offices of Howard G. Smith Announces Investigation of Illumina, Inc.", 3/22/2010 84763A10  BW   Spectrum Pharmaceuticals Announces a National Cancer Institute-Sponsored Phase 1/2 Study of Belinostat in Thymic Malignancies,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/25/2012 45232710    BW   MURRAY FRANK LLP Announces Investigation of Illumina, Inc."," 3/11/2010 84763A10  BW   Spectrum Pharmaceuticals to Present at the 22nd Annual Roth Capital Markets Growth Conference on Monday, March 15",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/25/2012 45232710    BW   CORRECTING and REPLACING Glancy Binkow & Goldberg LLP Announces Investigation of Illumina, Inc."," 2/25/2010 84763A10  BW   Spectrum Pharmaceuticals to Participate at the RBC Capital Markets Healthcare Conference Panel on Wednesday, March 3rd in New York City",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/25/2012 45232710    BW   Law Firm Brower Piven Announces Investigation in Connection With the Possible Acquisition of Illumina, Inc. by Roche", 2/16/2010 SPPI-US   BW   Celldex Receives $3 Million Sublicense Income Payment from TopoTarget,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/25/2012 45232710    BW   Rigrodsky & Long, P.A. Investigates Illumina, Inc.’s Offer to Be Acquired by Roche"," 2/05/2010 84763A10  BW   Spectrum Pharmaceuticals to Present at the BIO CEO Investor Conference in New York City on Tuesday, February 9th",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/25/2012 45232710    BW   Bernstein Liebhard LLP Announces Investigation of Offer for Illumina, Inc."," 2/02/2010 84763A10  BW   Spectrum Pharmaceuticals Licenses Belinostat, a Novel Anticancer Drug in a Pivotal Registrational Trial",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/25/2012 ILMN-US     BW   Harwood Feffer LLP Announces Investigation of Illumina Inc., 1/29/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Receipt of $16 Million from Asian Partners Related to Apaziquone Collaboration Agreements Announced in November 2009,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/25/2012 ILMN-US     BW   Illumina Board of Directors to Review Unsolicited Acquisition Proposal from Roche, 1/27/2010 84763A10  BW   Spectrum Pharmaceuticals Terminates Ozarelix Development Program in Benign Prostate Hypertrophy (BPH) as It Continues to Prioritize Its Portfolio Strategy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/24/2012 ILMN-US     BW   Roche to host investor conference call regarding offer for Illumina, Inc.", 1/25/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Results of FDA Meeting Regarding FUSILEV® sNDA under Review for Advanced Metastatic Colorectal Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/24/2012 ROG-CH      BW   Roche offers to acquire all outstanding shares of Illumina, Inc. to further strengthen its leading role in diagnostics", 1/12/2010 84763A10  BW   Spectrum Pharmaceuticals Completes Enrollment in Second of Two Phase 3 Pivotal Trials for Apaziquone in Non-Muscle Invasive Bladder Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/17/2012 45232710    BW   Illumina to Announce Fourth Quarter and Fiscal Year 2011 Financial Results on Tuesday, January 31, 2012",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/10/2012 45232710    BW   Illumina Introduces the HiSeq 2500,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/09/2012 0BL1G4-E    BW   Aria Diagnostics Secures $52.7 Million in Oversubscribed Series C Financing,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/04/2012 ILMN-US     BW   Illumina Appoints Marc Stapley as Senior Vice President and Chief Financial Officer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/03/2012 45232710    BW   Illumina to Present at the J. P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,12/19/2011 45232710    BW   British Columbia Cancer Agency Joins the Illumina Genome Network,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,12/15/2011 45232710    BW   Illumina Hires Laura Lauman as Vice President of Marketing,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,11/30/2011 05M967-E    BW   Research and Markets: Strategic Analysis of the U.S. Next-Generation Sequencing Services. A Convergence of Favorable Market Dynamics,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,11/23/2011 45232710    BW   Illumina to Present at the Piper Jaffray Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,10/31/2011 05L5JM-E    BW   Illumina Names Dr. Daniel S. Grosu Chief Medical Officer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,10/25/2011 45232710    BW   Illumina Reports Financial Results for Third Quarter 2011,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,"10/18/2011 45232710    BW   Illumina to Announce Third Quarter 2011 Financial Results on Tuesday, October 25, 2011",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,10/12/2011 45232710    BW   Illumina Announces Novel Human Exome Content Available on Multiple BeadChip Formats,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,10/11/2011 45232710    BW   Illumina Introduces Revolutionary Workflow Enhancements for MiSeq™,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,10/06/2011 45232710    BW   Illumina Announces Preliminary Revenue for Third Quarter 2011,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,10/04/2011 45232710    BW   Illumina Enters Collaborative Research Agreement with UNTHSC for Next-Generation Sequencing in Forensic DNA Analysis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 9/29/2011 45232710    BW   Illumina Introduces Low-Cost Bovine BeadChip for Genotyping of Dairy Cattle,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 9/07/2011 45232710    BW   Illumina to Webcast Live Presentations at Upcoming Investment Conferences in September,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 8/03/2011 45232710    BW   Illumina Announces New $100 Million Share Repurchase Authorization,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 8/03/2011 05KQG6-E    BW   Illumina and University of Oxford to Sequence 500 Whole Human Genomes for Rare Disease Research,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 7/27/2011 45232710    BW   Illumina to Present at Leerink Swann Life Science Tools and Diagnostics Roundtable,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 7/26/2011 45232710    BW   Illumina Reports Financial Results for Second Quarter 2011,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 7/25/2011 45232710    BW   Illumina Announces First Customer Shipments of the Omni5 BeadChip,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 7/14/2011 06N7LQ-E    BW   Illumina Selected as a Preferred Service Provider for Cancer Research UK,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 7/13/2011 45232710    BW   Illumina Introduces TruSeq™ Custom Enrichment Kits for Next Generation Sequencing,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 7/12/2011 45232710    BW   Illumina to Announce Second Quarter 2011 Financial Results on Tuesday, July 26, 2011",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 6/29/2011 05H9L4-E    BW   University of Washington Department of Genome Sciences Joins Illumina Genome Network,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 6/08/2011 45232710    BW   Illumina Announces Bold Steps to Accelerate the Adoption of Individual Genome Sequencing,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 5/31/2011 45232710    BW   Illumina to Webcast Live Presentations at Upcoming Investment Conferences in June,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 5/09/2011 45232710    BW   Illumina Reduces Price of Whole Human Genome Sequencing Through Illumina Genome Network,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/26/2011 45232710    BW   Illumina Reports Financial Results for First Quarter 2011,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/26/2011 45232710    BW   Illumina to Present at Upcoming Investment Conferences in May,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/14/2011 05MK3P-E    BW   Camstar Enterprise PlatformTM Selected by Illumina to Accelerate New Product Introductions,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 4/12/2011 45232710    BW   Illumina to Announce First Quarter 2011 Financial Results on Tuesday, April 26, 2011",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/30/2011 ILMN-US     BW   Expression Analysis Announces Recipients of Its Annual GWAS and Data Analysis Grant Co-Sponsored by Illumina,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/18/2011 45232710    BW   Illumina Closes $800 Million Convertible Senior Notes,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/15/2011 45232710    BW   Illumina Prices $800 Million Convertible Senior Notes,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/14/2011 45232710    BW   Illumina to Offer $800 Million Convertible Senior Notes,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/02/2011 45232710    BW   Illumina to Present at Upcoming Investment Conferences in March,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 2/08/2011 45232710    BW   Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2010,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 2/01/2011 ILMN-US     BW   Expression Analysis Announces Research Acceleration Grant Focusing on Kinase Mutations and Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/25/2011 45232710    BW   Illumina to Announce Fourth Quarter and Fiscal Year 2010 Financial Results on Tuesday, February 8, 2011",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/18/2011 45232710    BW   Illumina to Open Latin America Office,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/18/2011 45232710    BW   Illumina Launches the Illumina Agricultural Greater Good Initiative to Help Reduce Global Hunger, Malnutrition and Poverty",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/11/2011 45232710    BW   Illumina Acquires Epicentre Biotechnologies, Leading Provider of Nucleic Acid Sample Preparation Reagents and Specialty Enzymes",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/11/2011 45232710    BW   Illumina Announces MiSeq™ Personal Sequencing System,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/11/2011 45232710    BW   Illumina Announces Preliminary Financial Results for Fourth Quarter 2010,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/10/2011 XGEN.XX1-US BW   Maven Semantic: Prostate Cancer Research Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/10/2011 45232710    BW   Illumina Introduces the Next Generation of iSelect® Custom Genotyping,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/04/2011 ILMN-US     BW   Illumina to Present at J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,12/15/2010 ILMN-US     BW   Affymetrix Announces Court Order Directing Dismissal of Illumina Patent Infringement Lawsuits,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,12/14/2010 WAT-US      BW   Maven Semantic: High Content Analysis Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,11/09/2010 45232710    BW   Illumina to Present at Upcoming Investment Conferences in November,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,11/03/2010 45232710    BW   Illumina Introduces TruSeq™ Sample Prep and Exome Enrichment Kits,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,11/02/2010 ILMN-US     BW   Expression Analysis and Illumina Fund GWAS and Data Analysis Grant Program to Support Cancer Research,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,10/26/2010 45232710    BW   Illumina Reports Financial Results for Third Quarter 2010,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,10/26/2010 45232710    BW   Illumina Announces HiSeq 1000 Sequencing System,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,10/22/2010 ILMN-US     BW   CORRECTING and REPLACING Sage Science Signs Co-Marketing Agreement with Illumina to Automate DNA Sizing Steps in Next-Gen Sequencing Sample Preparation,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,"10/12/2010 45232710    BW   Illumina to Announce Third Quarter 2010 Financial Results on Tuesday, October 26, 2010",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 9/15/2010 45232710    BW   Illumina and Wellcome Trust Sanger Institute Announce Completed Genome for Endangered Tasmanian Devil,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
